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ABSTRACT 
 
Linkage studies have implicated the 12q22-24 region in susceptibility to bipolar 
disorder. In this region alleles at the “Slynar” and Insulin Like Growth Factor 1 
(IGF1)  genes  showed  association  with  bipolar  disorder.  The  Slynar  gene  is 
contained within a region of 278 kb on chromosome 12q24 and expresses the 
sequence AY070435 in the human brain.  AY070435 has no known function. A 
Macaque  brain  expressed  cDNA  which  is  highly  homologous  to  human 
AY070435 has been cloned and sequenced. To further characterise the human 
Slynar gene and expressed mRNA transcript studies were carried out to identify 
Slynar in the mouse and in human neuroblastoma cell lines. Exhaustive efforts 
were taken to find a mouse homologue but these proved negative. Slynar shared 
no homology, or partial homology with any other gene in the human genome. 
The  other  12q24  bipolar  susceptibility  gene  IGF1  is  highly  expressed  in  the 
human brain and a well known for its neuromodulatory functions. IGF1 protein 
has been shown to have an antidepressant and anxiolytic-like effect in the mouse 
brain. On a genome wide association study (GWAS) with the UCL case control 
sample,  IGF1  was  found  to  be  associated  to  disease  with  5  SNPs  showing 
association  within  the  gene.  In  order  to  further  implicate  IGF1  and  find  the 
aetiological base pair changes responsible for disease, IGF1 was sequenced. New 
three new non database SNPs, three previously characterised polymorphisms and 
a CA repeat were found and genotyped in an extended UCL sample of 1,000 
cases and 1,000 controls. One of the novel SNPs and the CA repeat, both located 
in the promoter region, were associated with bipolar disorder. Haplotype analysis 
of the GWAS and new markers data confirmed association to bipolar disorder.   5 
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1  Introduction 
1.1  Bipolar Disorder 
Bipolar disorder is a lifelong mood disorder characterized by recurrent manic or 
hypomanic and depressive episodes. It can interfere with cognition and behavior, 
severely impacting relationships with family, friends, and employers. Social and 
marital conflict is common, including divorce, sexually transmitted diseases, and 
unwanted pregnancies, as well as job loss and financial difficulties (Miller 2006). 
 
Age of onset of bipolar disorder ranges from childhood to the late stages of life, 
but most commonly develops from late 20s to 30s in older studies and from late 
teens to early 20s in more recent reports. Bipolar disorder has been reported in 
children as young as 6 years old. Early onset correlates with a greater recurrence 
of affective disorder in families. Affected relatives have similar ages of onset and 
symptoms  to that of  the  proband.  (Hays  et  al.  1998;  O'Mahony  et  al.  2002; 
Emilien et al. 2007). 
 
1.1.1  Historical Background 
The origin of the concept of bipolar disorders has its roots in the work and views 
of the Greek the physicians of the classical period. In fact, the first systematic 
clinical descriptions of melancholia and mania were by Hippocrates (460-337 
BC). However, it was Aretaeus of Cappadocia (150-200 AD) who perceived a 
relationship  between  melancholia  and  mania,  recognizing  that  the  two  states 
could occur in the same individual (Angst et al. 2001).    12 
Aetiological theories for both melancholia and mania were developed within the 
theoretical framework of humoralism, established by physicians in the Classical 
period and remaining the dominant tradition in Europe throughout the Middle 
Ages. Simplistically stated, excess blood and yellow bile could lead to mania and 
excess  black  bile  to  melancholy.  The  treatments  of  blood  letting  and  diet  to 
balance  the  humors  were  thus  prescribed  in  accordance  with  the  model,  for 
instance by Robert Burton in his Anatomy of Melancholy in 1621 (Angst et al. 
2001).  
 
Although various writers continued to note the association of melancholia and 
mania during the 17
th and 18
th Centuries,  it  was  not until the middle of 19
th 
Century that a French psychiatrist identified a condition that he termed “folie 
circulaire”. He described a single condition constituting a continuous cycle of 
melancholy and mania with periods of wellness in between. It was possible that 
Falret was influenced by the views of German psychiatrist Griesinger, who in 
1845  had  used  the  image  of  a  circle  to  describe  the  relation  of  mania  and 
melancholy (Angst et al. 2001). 
 
In 1854, the same year that Falret published his theory in full, Jules Baillarger 
presented his own unitary concept of mania and melancholia, which he referred 
to as “folie a double forme”. Baillarger’s views differed from those of Falret, as 
he recognised that the symptoms alternated, but accorded no importance to the 
intervening  periods  of  wellness.  In  contrast,  these  intervals  were  central  to 
Falret’s concept of a circular disorder (Angst et al. 2001).  
   13 
It was Kraepelin in 1899 that coined the term “manic depressive insanity”. This 
concept unified the affective disorders, including both the circular and depressive 
types. A broader category was thus created. More importantly, Kraepelin also 
differentiated  manic  depressive  insanity  from  dementia  praecox.  This 
Kraepelinian  dichotomy  has  had  a  fundamental  impact  on  the  psychiatric 
community being called the “father of modern psychiatry” (Angst et al. 2001). 
 
Kraepelin’s unified view of the affective disorders faced considerable opposition, 
particularly in Germany. Karl Kleist (1953) challenged Kraepelin’s concept of 
manic-depressive disorders, believing that people who suffered from both manic 
and  depressive  episodes  were  suffering  from  a  different  illness  to  those  that 
experienced only one type of affective state. It is to Kleist that we owe current 
nomenclature of unipolar and bipolar disorder. Kleist’s ideas underwent further 
refinement by another of his colleagues, Karl Leonhard (Angst et al. 2001). 
 
Mania is the defining feature of bipolar disorder. Unipolar mania is classified as 
type of bipolar disorder and unipolar disorder now refers to depression. The work 
of Angst, Perris and Winkour in the 1960’s brought a genetic epidemiological 
approach to classification. Angst (1959-1963) and Perris (1963-1966) confirmed 
that unipolar mania was strongly related in genetic terms to “bipolar disorder” 
and should be included in that category (Angst et al. 2001). 
 
In 1881 Mendel used the term hypomania to describe a milder form of mania. 
This diagnosis category is widely used. (Angst et al. 2001).  
   14 
Accompanying this division of  bipolar disorder by  severity,  investigation  has 
taken place  into the relationship  between  bipolar disorder and schizoaffective 
disorders. It was Kahlbaum who first suggested that schizoaffective disorder was 
a separate group (1863). Subsequently Kraepelin was exercised by the problem 
of  defining  such  cases  and  he  thought  that  they  would  fit  into  one  of  his 
categories  of  manic  depressive  insanity  or  dementia  praecox  (1920). 
Schizoaffective psychosis was a term first used by Kasanin in 1933. Research 
since  the  1960s  has  indicated  a  strong  relationship  between  schizoaffective 
disorders  and  bipolar  affective  disorders.  Cadoret  (1974)  separated 
schizoaffective  disorders  into  schizoaffective  bipolar  and  schizoaffective 
unipolar. Based on data that relatives of bipolar probands are at elevated risk of 
schizoaffective bipolar disorder, Marneros (1999) has argued that schizoaffective 
bipolar should be included in the bipolar group (Angst et al. 2001). In addition, 
evidence from genetic epidemiology has been gradually accumulating
 over the 
past  two  decades.  Family  data  is  coherent  with  the  dichotomous
  view,  that 
schizophrenia
 and bipolar affective disorder are different entities (Craddock et al. 
2005).  Family  studies  have  shown  some  degree
  of  familial  coaggregation 
between schizophrenia and bipolar
 illness and between schizo-affective disorders 
and both bipolar
 disorder and schizophrenia (Craddock et al. 2005). That can be 
explained  by  the  fact  that  schizoaffective  disorders  are  mainly  bipolar  or 
schizophrenia and not a true in between state. Whole-genome linkage studies of 
schizophrenia  (Berrettini  2003;  Craddock  et  al.  2005)  and
  bipolar  disorder 
generally implicated different chromosomal regions with very few overlapping 
shared syndroms. When common susceptibility genes do exist it is likely to be 
different mutations in the gene that causes different syndroms.   15 
1.1.2  Bipolar Disorder Phenomenology and Classification 
1.1.2.1  Phenomenology 
Bipolar disorder can cause dramatic swings in mood from overly high and/or 
irritable to sad and hopeless, and then back again, often with periods of normal 
mood in between. The intensity of signs and symptoms varies from person to 
person.  The  periods  of  highs  and  lows  are  called  episodes  of  mania  and 
depression when they  meet criteria  for each respectively, and their  frequency 
varies greatly (Emilien et al. 2007). 
 
The  most  common  symptoms  exhibited  during  manic  episodes  include 
persistently elevated, expansive and/or irritable mood over a identified period of 
time. The mania is accompanied by feelings of high self-esteem, over optimism, 
grandiosity, pressure of speech, racing thoughts, distractibility, increased energy 
with  decreased  need  of  sleep,  increased  sexual  drive  and  overactivity  or 
agitation.  There  is  always  loss  of  inhibitions  sometimes  leading  to  reckless 
involvement in pleasurable, hazardous or embarrassing activities that may have 
serious marital, social, financial or judicial consequences. Mania symptoms may 
cause impairment in social and occupational functioning (Kupka et al. 2007). 
The symptoms of a hypomanic episode are similar to those of a mania episode, 
but they are milder than mania and last for shorter periods. These episodes do not 
cause a marked functional impairment or require hospitalization (Emilien et al. 
2007; Kupka et al. 2007).  
 
Depression as part of bipolar illness has symptoms very similar to those seen in 
unipolar  depression.  Atypical  depressive  symptoms  such  as  increased  sleep,   16 
increased appetite, rejection sensitivity, leaden paralysis and mood reactivity can 
be observed in a depressive episode in a bipolar patient and can also occur in a 
rare depressive disorder (El-Mallakh et al. 2006; Emilien et al. 2007; Kupka et 
al. 2007). In some cases patient recovery from mania can develop a mixed state 
of  depression  and  mania.  They  may  experience  rapidly  alternating  moods  of 
sadness, irritability, and dysphoria, which can last a week (Kupka et al. 2007). 
 
The most common first mood episode in BP appears to be major depression, 
however  bipolar  illness  can  also  present  first  mania,  hypomania  or  mixed 
symptoms. The disease has a variable course. There may be years between the 
first and second mood episodes. In addition, symptom fluctuation occurs in most 
patients with BP. A report from Judd et al, in  a 14.2 year  follow up of BPI 
patients, showed that patients were symptomatic 50% of the time, with episodes 
of depression three times more often than mania. Patients with BPI showed week 
to week changes both in severity and polarity on average six times per year (El-
Mallakh et al. 2006; Miller 2006). 
  
1.1.2.2  Classification of Bipolar Disorder 
For diagnostic purposes the current classifications used are those  in DSM-IV 
(2000) and ICD-10 (1992) (Kupka et al. 2007). The Diagnostic and Statistical 
Manual  of  Mental  Disorders  (DSM),  published  by  the  American  Psychiatric 
Association,  is the standard classification of  mental disorders used by  mental 
health professionals in the United States. It describes mood disorders in three 
parts:  (a)  mood  episodes;  (b)  mood  disorders;  (c)  characteristics  of  the  most 
recent episode or the longitudinal course of recurrent illness. The International   17 
Classification  of  Diseases  was  developed  by  the  World  Health  Organization 
(WHO). The ICD has become the world wide standard diagnostic classification 
for all diseases. 
 
In the DSM-IV classification bipolar illness can be classified into four subtypes: 
(a)  Bipolar  Disorder  I;  (b)  Bipolar  Disorder  II;  (c)  cyclothymic  disorder;  (d) 
Bipolar Disorder not otherwise specified. To be classified as a Bipolar Disorder I 
patient, the individual needs to have at least one episode of mania and previous 
episodes of depression. Most patients with  bipolar disorder 1 will experience 
subsequent manic or depressive episodes. They can also experience hypomanic 
and  mixed  episodes,  as  well  as  a  lower  threshold  of  mood  changes  between 
episodes. Patients with bipolar disorder 2 have a history of only hypomania and 
major depressive episodes. Patients with cyclothymic disorder sometimes only 
experience manic mild mood changes that do not reach bipolar 1 or bipolar 2 
levels. By definition they have symptoms depression and elevated mood for at 
least 2 years, with no symptom-free period greater than 2 months (Miller 2006). 
 
1.1.3  Diagnosis and Treatment 
1.1.3.1  Diagnosis 
Diagnostic  assessment  of  bipolar  disorder  has  several  aspects:  a  life  time 
diagnosis according to DSM-IV or/and ICD-10; a diagnosis of the current mood 
episode or a state of interepisodic remission, rating the severity of the current 
mood disturbance, and describing the longitudinal course of illness (Kupka et al. 
2007).   18 
A diagnosis of bipolar disorder is commonly obtained by applying one of the 
semi-structured interviews by trained clinicians. Many other assessment scales 
have  been  developed  to  use  in  conjunction  with  the  standard  methods  of 
diagnosis (Miller 2006; Kupka et al. 2007). 
  
Assessment of bipolar disorder requires a good history of episodic variation over 
the patients’ entire life time. Numerous clinical studies have shown that about 
40% of persons who eventually develop bipolar symptoms are initially diagnosed 
with unipolar depression. There are also studies that show that it takes an average 
of a decade from the time a patient seeks help from mental health professionals 
for  bipolar  disorder  and  to  be  confirmed  diagnosis.  This  high  percentage  of 
uncertainty can be explained by several factors. Around one half of patients do 
not know they are experiencing manic episodes. In fact, patients mainly seek 
help  when  suffering  from  depressive  episodes.  This  leads  to  a  general 
underestimate of the extent of manic symptoms leading to an underdiagnosis of 
bipolar  disorder.  One  approach  to  overcome  this  problem  is  to  access  the 
patient’s  behavior  patterns  from  family  and  friends  (El-Mallakh  et  al.  2006; 
Miller 2006).  
 
1.1.3.2  Treatment 
Treatment of bipolar disorder requires use of antimanic and antidepressant drugs. 
About 50% of bipolar disorder patients respond to lithium and lamotrigine. Often 
patients feel better they may abandon their medication, which may result in a 
relapse.  
   19 
Mood stabilization with lithium is a key treatment in all phases of the illness. It 
has been used in some patients for 30 to 40 years and can be very successful. The 
second most important drug is lamotrigine and has been shown repeatedly to be 
better than valproic acid. Carbamezine and other anti-epileptic drugs have also 
been widely used but with less success (Miller 2006; Emilien et al. 2007). 
 
Antipsychotics drugs such as  haloperidol and chlorpromazine  are also widely 
used in clinical treatment of mania. Haloperidol and chlorpromazine seem to be 
good sedatives for manic patients but are not truly antimanic. A recent meta-
analysis  of  atypical  antipsychotics  -  including  aripiprazole,  olanzapine, 
quetiapine, resperidone and ziprasidone - concluded that they were all superior to 
a placebo, but only small differences in efficacy were observed between them. 
Benzodiazepines  are  widely  used  as  an  adjunct  treatment  for  behavioral 
disturbance, although they carry the risk of disinhibition and dependence. ECT is 
sometimes  used  as  an  effective  treatment  for  both  mania  and  depression  but 
nowadays is rarely used for mania (Perlis et al. 2006; Emilien et al. 2007). 
 
On  the  whole,  antidepressants  are  an  effective  treatment  for  BP  depressive 
episodes.  There  are  now  three  main  classes  of  anti-depressant:  tricyclic 
antidepressants  (TCA),  monoamine  oxidase  inhibitors  (MAOI),  and  selective 
serotonin reuptake inhibitors (SSRI), plus other miscellaneous antidepressants. 
Efficacy  is  similar  for  different  antidepressants,  although  there  are  notable 
differences in the side effect profiles. SSRIs are generally used as first line agents 
for depression because of their higher tolerability and safety in overdose (Malhi 
et al. 2003; El-Mallakh et al. 2006).   20 
Psychotherapy  can  be  used  in  the  management  of  mild  depression 
Psychotherapeutic support may also improve functioning between episodes and 
reduce distress (Miller 2006).  
 
1.1.3.3  Hospitalization 
A  severe  episode  of  depression  or  mania,  during  which  an  individual  may 
become a danger to himself/herself or others, requires inpatient hospitalization. 
Certain  patients  admit  themselves  to  hospital  voluntarily  while  others  need 
compulsory.  
In the first stage of hospitalization, the first priority is to maintain safety and 
ensure adequate food and liquid intake.  
When the patient’s condition improves, attempts can be to teach the patient to 
recognize  the  symptoms  that  led  to  the  hospitalization  with  the  hope  of 
preventing future hospitalization. At this point, families should be involved and 
also learn about the signs and symptoms.  
As the time  for discharge approaches, the patient begins to spend  more time 
away from the hospital, during the day or even overnight. This time is used to 
reorganize life out of hospital, to start getting re-involved with family and other 
activities. It also serves as a time to assess readiness for discharge. Discharge 
planning should include the patient and family reviewing their perceptions of the 
onset of the episode, the reasons for hospitalization, and agreeing to a plan for 
dealing  with  symptoms  should  they  recur.  Liaison  with  community  support 
services should be made at this time.    21 
The frequency and intensity of follow up care depends on the patient's individual 
needs.  An  individual  may  go  for  outpatient  therapy  to  a  psychiatrist,  a 
community mental health centre or a family doctor. The patient may also attend 
group  sessions  to  learn  how  to  deal  with  the  disease  and  to  increase  self 
confidence. 
 
1.1.4  Impact of Bipolar on Society 
It  was  believed  that  no  more  than  1%  of  the  general  population  has  bipolar 
disorder.  However,  new  data  provided  converging  evidence  for  a  higher 
prevalence of up to 5%, when including severe unipolar depression (Akiskal et 
al. 2000).  
 
An epidemiological study of a sample of 112 persons with an ICD-10 diagnosis 
of  bipolar  disorder  showed  that  69.9%  of  the  patients  reported  a  recurrent 
episodic illness; 25% had a chronic course without clear remissions and 5.4% 
had a single episode of mania. Moreover, assessed on a lifetime basis, suicidal 
ideas were common (78.6%) and levels of drug and alcohol abuse/dependence 
were  high  (32.1%).  The  majority  (84.8%)  had  had  at  least  one  contact  with 
inpatient, outpatient or emergency services in the previous year (Morgan et al. 
2005). 
  
The World Health Organization has determined that bipolar disorder is the eighth 
most  important  public  health  problem  worldwide  (Emilien  et  al.  2007).  The 
Global Burden of Disease Study used Disability Adjusted Life Years (DALYs) 
to measure disease burden for many conditions (Murray et al. 1997). DALYs are   22 
a composite measure of the sum of life years lost to premature death and years 
lived with disability adjusted for severity. Out of the 107 disorders considered, 
bipolar  disorder  ranked  in  22
nd.  According  to  this  study,  bipolar  disorder 
accounted for the loss of 1.43×10
7 DALYs in 1990. It has been estimated that the 
total cost of bipolar disorder in the UK is two billion pounds per year (Das Gupta 
et al. 2002). 
 
In terms of the individual, the disease involves prolonged periods of illness and is 
likely to recur and worsen. Although virtually all patients recover from acute 
episodes, only around 20% have prolonged periods of occupational and social 
stability. This is reflected in a number of measures of reduced social functioning. 
Bipolar sufferers  have  higher rates of unemployment, increased use of  health 
services  and  increased  marital  dysfunction  (Sajatovic  2005).  Furthermore,  in 
some  bipolar  disorder  patients,  diminished  neurocognitive  function  may  exist 
across  all  clinical  stages,  most  notably  in  the  neuropsychological  domain  of 
executive function, verbal learning, memory and attention (Watson et al. 2006). 
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1.2  Neurobiology of Bipolar Disorder 
Numerous  theories  that  attempt  to  explain  bipolar  disorder  aetiology  have 
evolved in the last few decades. Evidence from family, twin and adoption studies 
have  strongly  suggested  heritable,  genetic  factors  for  bipolar  disorder. 
Biochemical and pharmacological studies led to various hypotheses implicating 
neurotransmitters,  enzymes  and  neuropeptides,  as  well  as  the  endocrine  and 
immune systems. Neuroanatomical and neuroimaging techniques have permitted 
the  study  of  brain  neurology  and  functional  effects  associated  with  mood 
symptoms and disease. However, prior to molecular genetic studies very little 
was known about the causes of bipolar disorder. Genetic investigation followed 
by neurobiology has begun to make great advances in aetiological understanding. 
 
1.2.1  Neurotransmitter systems  
Many  investigators  assumed  that  monoamine  transmitters,  such  as 
norepinephrine,  dopamine  and  serotonin  were  implicated  in  the  aetiology  of 
bipolar disorder. More recently, the glutamatergic, cholinergic and GABAergic 
neurotransmitter systems have been implicated (Newberg et al. 2008).  
 
1.2.1.1  Noradrenergic System 
The  noradrenergic  system  is  involved  in  both  modulating  brain  function  and 
producing the body’s response to emotions. Data has shown that this system is 
altered in bipolar affective disorders (Bunney et al. 1965; Coppen 1969; Coppen 
1969).  Increased  noradrenergic  function  has  been  consistently  observed  in 
patients  with  mania.  Moreover,  the  mood  stabilizers  lithium,  valproate  and   24 
carbamazepine have been shown to exert effects on the noradrenergic system 
and/or on its downstream molecular targets, via distinct mechanisms (Nutt 2002; 
Berton et al. 2006). 
 
1.2.1.2  Dopaminergic System  
The midbrain dopamine system regulates motor activity, motivation and reward 
pathways. In addition, the mesolimbic dopamine system plays a critical role in 
goal-directed behaviour. All of these functions are disrupted in both poles of the 
disorder (Soares et al. 2007; Newberg et al. 2008). 
 
Pharmacologic studies show that some medications, such as antipsychotic drugs 
act on dopamine receptors (Diehl et al. 1992; Kapur et al. 1992; Gao et al. 2005). 
However,  data  does  not  support  primary  dopaminergic  alterations  in  bipolar 
patients, even if this system is strongly implicated in the process of hypomania 
and mania. Rather, the primary abnormality in bipolar disorder seems to be a 
genetically determined dysregulation of multiple neurotransmitter systems (Nutt 
2006; Brugue et al. 2007; Dunlop et al. 2007; Gershon et al. 2007). 
 
1.2.1.3  Serotonergic System 
Serotonin  has  a  wide  range  of  effects,  including  cardiovascular  regulation, 
intestinal  motility  and  modulation  of  respiration,  thermoregulation,  circadian 
rhythm  entrainment,  sleep-wake  cycle,  appetite,  aggression,  mood,  sexual 
behaviour, sensorimotor reactivity, pain sensitivity and learning. Dysfunction of 
the  serotonergic  system  is  thought  to  be  involved  in  a  variety  of  psychiatric 
disorders, including mood disorders (Soares et al. 2007). Substantial evidence for   25 
the role of serotonin in patients with bipolar disorder comes from alterations in 
the  serotonergic  system  cause  by SSRI  medication  (Nutt  2002;  Berton  et  al. 
2006). In addition, data from many different studies, including imaging studies, 
suggest that abnormalities of the serotonergic system are present in depression 
and in bipolar disorder (Craddock et al. 2001; Higgs et al. 2006; Lesch et al. 
2006; Cannon et al. 2007). 
 
1.2.1.4  Cholinergic System 
The cholinergic system uses acetylcholine as its neurotransmitter. Acetylcholine 
(ACh)  has  functions  both  in the peripheral  nervous system (PNS) and  in the 
central  nervous  system  (CNS).  In the  central  nervous  system,  ACh  acts  as  a 
neuromodulator, acting on brain plasticity, CNS excitability and in the reward 
system (Soares et al. 2007). 
   
The  cholinergic-aminergic  balance  hypothesis,  supported  by  pharmacological 
data,  proposes  that  an  increased  ratio  of  cholinergic  to  adrenergic  activity 
underlies the pathophysiology of depression, whereas the reverse occurs in mania 
(Davidson 1972; Janowsky et al. 1972). In addition, multiple studies have shown 
that chronic in vivo lithium treatment increases ACh synthesis and its release in 
the rat brain (Jope 1979). In behavioural studies, chronic lithium at clinically 
relevant  doses  is  reported  to  enhance  a  number  of  cholinergically  mediated 
reponses, including catalepsy and hypothermia (Lerer et al. 1985). 
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1.2.1.5  GABAergic System 
γ-aminobutyric acid (GABA) is the major inhibitory nerotransmitter in the CNS, 
diminuishing the activity of its many target neurons, and thought to be involved 
in many disorders (Soares et al. 2007; Newberg et al. 2008). 
 
Not  all  GABA  studies  have  given  consistent  results.  However,  recent 
postmortem  and  clinical  studies  gave  a  new  insight  of  the  potential  role  of 
GABA  in  bipolar  disorder  (Dean  2004).  A  study  has  found  that  there  is  an 
increase in GABA(A) receptors containing alpha5 subunit in the hippocampus 
from  subjects  with  bipolar  I  disorder  (Dean  et  al.  2005).  In  addition, 
abnormalities  of  GABA  synthetic  enzymes  and  GABAergic  system  related 
molecules have been found in many studies with bipolar patients (Brambilla et 
al. 2003). There is also an hypothesis that suggests that valproate increases the 
availability of GABA in synapses. Various studies have shown that GABA does 
increase  in  rodent  brain  after  valproate  administration.  In  fact,  it  seems  that 
valproate  increases  GABA  release  and  interacts  with  its  transporters.  Also, 
antidepressants, mood stabilizers, electroconvulsive therapy, and GABA agonists 
have been shown to reverse the depression-like behaviour in animal models and 
to be effective in unipolar and bipolar patients by increasing brain GABAergic 
activity (Brambilla et al. 2003). 
   
1.2.1.6  Glutamergic System 
Glutamate is the major excitatory neurotransmitter in the CNS, and it is known to 
play  a  role  in  regulating  the  threshold  for  excitation  of  most  other 
neurotransmitter systems (Soares et al. 2007; Newberg et al. 2008).   27 
The strongest direct evidence for a role for glutamate in mood disorders comes 
from  pharmacological  and  imaging  data.  Magnetic  resonance  spectroscopy 
(MRS)  studies  in  bipolar  disorder  patients  have  shown  abnormalities  of 
glutamine/glutamate basal levels in brain regions such as prefrontal and anterior 
cingulate cortices and hippocampus (Yildiz-Yesiloglu et al. 2006). In addition, a 
second  study  reported  that  the  mean  occipital  cortex  glutamate  levels  were 
increased in subjects with depression compared to controls, suggesting that an 
excess  of  glutamate  in  synapses  contributes  to  neuronal  atrophy  and  loss 
(Sanacora et al. 2004). Moreover, drugs used for bipolar disorder treatments such 
as  lithium,  lamotrigine  and  Riluzole,  have  been  shown  to  act  by  decreasing 
glutamate levels, using different pathways (Newberg et al. 2008). 
 
AMPA-type  glutamate  receptors  are  ionotropic  transmembrane  receptors  for 
glutamate that mediates fast synaptic transmission in the CNS. AMPA receptors 
are the most commonly found receptor in the nervous system. They are involved 
in plasticity and they seem to be a target of mood stabilizers. Chronic lithium and 
valproate treatment have both been shown to downregulate synaptic expression 
of an AMPA receptor subunit (GluR1) in the hippocampus, in vitro and in vivo 
(Du et al. 2004). Interestingly, the antidepressant imipramine has the opposite 
effect of upregulating the AMPA synaptic strengh in the hippocampus (Du et al. 
2003).  Furthermore,  recent  studies  indicate  that  AMPA  receptor  antagonists 
attenuate several ‘manic-like’ behaviours in rodents produced by amphetamine 
administration (Ossowska et al. 2004). 
   28 
The NMDA receptor is an ionotropic glutamate receptor. Activation of NMDA 
receptors results in the opening of an ion channel that is nonselective to cations. 
This allows flow of Na
+ and small amounts of Ca
2+ ions into the cell and K
+ out 
of the cell. Calcium flux through NMDARs is thought to play a critical role in 
synaptic plasticity, a cellular mechanism for learning and memory (Newberg et 
al.  2008).  Valproate  seems  to  block  synaptic  responses  mediated  by  NMDA 
receptors (Basselin et al. 2008). Also, ketamine, an NMDA receptors antagonist 
seems to have a antidepressant action (Engin et al. 2009; Phelps et al. 2009). 
  
1.2.2  Neuroendocrine Systems 
The relationship  between endocrine dysfunction  and pathological  mood states 
was  one  of  the  earliest  considerations  of  biological  psychiatry.  Of  all  the 
endocrine  systems  hypothesized  to  be  linked  to  affective  disorder,  the 
hypothalamic-pituitary-adrenal (HPA) was one of the most consistent findings. 
The HPA axis consists of the hypothalamus, pituitary and adrenal glands, various 
hormones and releasing factors, and it regulates body’s acute response to stress 
(Soares et al. 2007). Increased  HPA activity  has  been  associated with  mixed 
manic states, depression and less consistently, with classical manic states (Manji 
et al. 2003). 
 
1.2.3  Signalling Networks  
Lately, research on pathophysiology and treatment of mood disorders has moved 
from  a  focus  on  neurotransmitters  to  intracellular  cascades.  Following 
neurotransmitter release and binding at the post-synaptic membrane, a second   29 
messenger signalling cascade occurs that ultimately induces a cellular response. 
This  is  an  extremely  complex  pathway  and  dysfunctions  on  the  second 
messenger  mechanisms  have  also  been  implicated  in  the  etiology  of  bipolar 
disorder.  
 
1.2.3.1  Gαs/cAMP-generating signalling pathway 
Gα is a subunit of the major heterotrimeric G protein complex, which is also 
constituted  by  the  γ  and  β  subunits.  These  trimeric  complexes  are  loosely 
associated with G-protein-coupled-receptors (GPCR). Upon receptor stimulation, 
receptors  and  G  proteins  undergo  conformational  changes  that  lead  to  the 
stimulation of the effector proteins, such as adenylyl cyclase (AC). Cyclic AMP 
(cAMP) is a second messenger generated by AC, under cell stimulation. When 
the levels of intracellular cAMP increase, cAMP binds to the cAMP-dependent-
protein kinase (PKC) regulatory subunits, leaving the catalytic subunits free to 
phosphorylate its substrates (Soares et al. 2007). 
 
In  studies  of  Gα  in  peripheral  cells  and  post-mortem  brain  tissue,  Gα 
predominant species were consistently elevated (Young et al. 1991; Young et al. 
1994). In addition, the cAMP/PKA system has been studied in post-mortem brain 
of bipolar disorder patients. Data shows that levels of PKA regulatory subunits 
were significantly lower in cytosolic fractions of frontal, temporal, occipital and 
parietal cortices, and in the cerebellum and thalamus of bipolar disorder subjects 
when  compared  to  controls  (Chang  et  al.  2003).  In  addition,  lithium, 
carbamazepine and haloperidol seem to affect the G/cAMP system (Jakobsen et 
al. 1998; Karege et al. 1999; Chen et al. 2000; Karege et al. 2000).    30 
1.2.3.2  Phosphoinositide/Protein Kinase C Signalling Pathway 
Protein kinase C (PKC) exists as a family of closely related subspecies, that have 
a heterogeneous distribution in the brain, and together with other kinases, appear 
to play a crucial role in the regulation of synaptic plasticity and various forms of 
learning and memory. PKC is one of the major intracellular mediators of signals 
generated by neurotransmitter receptors (Manji et al. 2003). Allison and Stewart 
implicated this system in the aetiology of mood disorders when they observed 
that lithium reduces brain levels of inositol (Allison et al. 1971). More recent 
postmortem and animal data supports a role for PI/PKC signalling system in the 
pathophysiology of bipolar disorder (Newberg et al. 2008). Furthermore, whole-
genome association and lithium studies have implicated genes from this pathway 
in lithium treatment and genetic liability to bipolar disorder (McQuillin et al. 
2007; Baum et al. 2008). 
 
Inositol  deplection  has  been  suggested  to  be  a  molecular  mechanism  of  the 
therapeutic effect of lithium (Berridge 1985). Furthermore, some genes of these 
pathway seem to be downregulated by lithium such as PKC (Bitran et al. 1995; 
Manji et al. 1996; Wang et al. 2001) and myristoylated, alanin rich C-kinase 
substrate  (MARCKS),  a  major  PKC  substrate  and  a  protein  involved  in 
regulating  long  term  neuroplastic  events  (Wang  et  al.  2001).  In  addition, 
valproate seems to produce a similar effect to lithium acting by depleting inositol 
(Shaltiel et al. 2004). Nonetheless, these drugs seem to exert they effects through 
different mechanisms (Newberg et al. 2008). 
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1.2.3.3  GSK-3 Signalling Pathway 
Glycogen  synthase  kinase-3  (GSK-3)  plays  a  critical  role  in  the  survival  of 
neurons and it is involved in many pathways implicated in mental illness, such as 
the dopamine signalling pathway (Beaulieu et al. 2005). In addition, new data on 
DISC1, a previously implicated gene in both schizophrenia and bipolar disorder, 
shows that DISC1 mediates neural progenitor proliferation by regulating the -
catenin/GSK3 signalling pathway (Mao et al. 2009). The results showed that 
DISC1 stabilises -catenin by inhibiting GSK3 trough direct action, similarly to 
lithium action (Figure 1.1) (Harwood 2005; Beaulieu et al. 2008; Mao et al. 
2009).  
  
 
Figure   1.1 GSK3 signalling pathway. The figure shows that GSK3 inhibits -catenin 
activity by phosphorylation. When -catenin is active will act in the expression regulation of 
other genes and ultimately results in normal progenitor cell proliferation. GSK3 function 
seems to be regulated by direct interaction with both Lithium and DISC1 (Harwood 2005; 
Beaulieu et al. 2008; Mao et al. 2009). Figure adapted from (Coyle 2007). 
 
Recent  animal  behavioural  data  have  shown  that  manipulation  of  the  GSK-3 
signalling cascade produces both antidepressant and anti-manic effects (Leng et 
al.  2008).  It  has  been  shown  that  inhibition  of  GSK3  has  decreased 
amphetamine-induced hyperactivity in mice, in a model of mania (Beaulieu et al.   32 
2004) and the overexpression of -catenin in mouse brain mimics the effects of 
lithium in the amphetamine mania model (Gould et al. 2007).   
 
1.2.3.4  Neurotrophic Signalling Cascades 
Neurotrophic  factors  are  a  family  of  regulatory  factors  that  mediate  the 
differentiation and survival of neurons, as well as the modulation of synaptic 
transmission  and  synaptic  plasticity.  Increasing  evidence  suggests  that 
neurotrophic factors inhibit cell death cascades by activating the ERK/MAPK 
signalling  pathway  and  upregulating  the  expression  of  anti-apoptotic  proteins 
such as BCL-2 (Newberg et al. 2008). Many of these survival pathways converge 
at the level of mitochondrial function, and recent findings provide evidence for 
neurotrophic signalling-mediated mitochondrial dysfunction in bipolar disorder 
(Kato 2001).  
 
Dysregulation  of  calcium  homeostasis  is  an  essential  component  of  the 
pathophysiology  of  classic  mitochondriopathies,  and  impaired  regulation  of 
calcium cascades has been found to be the most reproducible biological measure 
of  intracellular  alterations  described  in  research  on  bipolar  disorder.  Data 
suggests that the mitochondrial endoplasma reticulum calcium regulation system 
contributes to the calcium variations seen in bipolar disorder (Kato et al. 2003). 
In addition, a number of microarray studies on postmortem human brain found 
that  mRNAs  coding  for  mitochondrial  proteins  were  decreased  in  bipolar 
disorder  (Iwamoto  et  al.  2005).  All  together,  there  is  evidence  of  a  role  for   33 
mitochondrial calcium sequestration in the modulation of synaptic plasticity, and 
as a possible cause of bipolar and related affective disorders.    
 
Pharmacological  studies  of  valproate  and  lithium  showed  that  the  use  of 
therapeutically relevant concentrations of the drugs activate secondary messenger 
cascades  such  as  the  ERK/MAPK  survival  pathway,  which  may  mediate  the 
antimanic effect of mood disorder (Bielecka et al. 2008). Chronic treatment of 
rats with therapeutic doses of valproate and lithium doubled Bcl-2 levels in the 
cingulate cortex, dentate gyrus and striatum (Bielecka et al. 2008).  
 
1.2.4  Histone Deacetylase 
Valproate acts directly on histone deacetylase (HDAC) (Gottlicher et al. 2001). 
HDACs  are  enzymes  that  regulate  the  acetylation/deacetylation  of  histones, 
thereby  affecting  gene  expression.  Loss  of  histone  acetylases  (HATs)  and 
HDACs regulation has been shown to be involved in neuronal dysfunction and 
degeneration  (Selvi  et  al.  2009).  Valproate  is  a  HDAC  inhibitor,  and  likely 
regulates gene expression through its effects on HDAC. 
 
1.2.5  Neuroanatomy Studies 
Neuroimaging  studies  of  bipolar  disorder  have  tried  to  give  new  insights. 
Structural imaging suggests abnormalities in prefrontal cortical areas, striatum 
and amygdala that appear to exist early in the course of illness and, potentially, 
be present before illness onset (Nugent et al. 2006; Terry et al. 2009). Other   34 
changes  in  midline  cerebellum,  lateral  ventricles  and  other  prefrontal  regions 
appear to develop with repeated episodes (Strakowski et al. 2005). Spectroscopic 
studies identify abnormalities of membrane and second messenger metabolism, 
as  well  as  bioenergetics,  in  striatum  and  prefrontal  cortex  as  well,  further 
establishing striatal-thalamic-prefrontal circuits as an integral part of expression 
of bipolar disorder (Strakowski et al. 2005). Finally, functional imaging studies 
show activation differences between bipolar disorder and controls in these same 
anterior limbic regions (Robinson et al. 2008). Together, neuroimaging studies 
support a model of bipolar disorder that involves dysfuntions within sub-cortical-
prefrontal  networks  and  the  associated  limbic  modulating  regions  in  the 
amygdale as well as in the midline cerebellum (Strakowski et al. 2005).   
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1.3  Genetics and Bipolar Disorder    
1.3.1  Family Studies 
One characteristic of a genetic disorder is that it aggregates, or clusters within 
families. In  family  studies a proband  is the  index case ascertained through  a 
systematic catchment procedure and the risk of disease in the relatives of the 
affected proband subject is investigated. The first and second degree relatives are 
screened not only for bipolar disorder but also for other psychiatric illnesses. The 
family morbid risk can therefore be calculated in the families of probands and the 
families  of  controls  and  then  compared  to the  risk  in  the general  population 
(Ashley-Kosh 2006). 
 
One problem associated with this method is that it is difficult to know if the 
relative  risk  observed  is  due  to  genetic  or  family  environmental  factors. 
Therefore  the  observed  familial  clustering  needs  to  be  investigated  using 
adoption studies where genes and environment are better separated (Ashley-Kosh 
2006). 
 
Early  family  studies  made  no  differentiation  between  bipolar  disorder  and 
depression  and  did  not  routinely  assess  psychiatric  comorbity  (Althoff  et  al. 
2005). Therefore little can be inferred about familial risk of bipolar disorder from 
these studies. Nowadays, many studies from independent groups and different 
geographical regions have shown a convincing  familiality  in  bipolar disorder. 
One example is a meta-analysis of eight family studies, that yielded an odds ratio   36 
of 7 for bipolar disorder in first-degree relatives of bipolar disorder probands 
(Craddock et al. 1999).  
 
Investigators have questioned whether bipolar disorder 1 and bipolar disorder 2 
represent  genetically  distinct  entities.  It  was  found  that  the  risk  of  bipolar 
disorder 1 was similarly elevated in relatives of bipolar disorder 1 probands and 
bipolar disorder 2 probands. However, the risk of bipolar disorder 2 was much 
greater  in  relatives  of  bipolar  disorder  2  probands  than  bipolar  disorder  1 
probands (Heun et al. 1993). This finding argues for at least some commonality 
in susceptibility to bipolar disorder 1 and bipolar disorder 2.  
 
There has also been interest in the effect of gender (of proband or relative) and 
the effect of the nature of relationship (i.e. sibling, parent or offspring) on the 
risk of bipolar disorder. No clear sex-related effect on risk has been shown and 
no clear consensus was reached about the nature of the relationship. However, 
reliable data is only available for risk in first-degree relatives (Craddock et al. 
1999). 
 
Family  studies  in  bipolar  disorder  raise  a  few  problems  such  as  the  difficult 
phenotypic definition and possible birth cohort effects and variable age of onset. 
Other problems relate to the conduct of the studies, e.g. lack of direct interviews 
(Faraone et al. 1990). Nevertheless, studies do exist that indicate familiality in 
BP.   37 
1.3.2  Segregation Analysis 
Segregation analysis is a genetic method that is used to examine the recurrence 
of an  illness within  families to determine  if the patterns are  indicative of an 
autosomal dominant, X-linked, autossomal recessive, polygenic or mixed genetic 
and  environmental  model.  Modern  methods  use  likelihood  statistics  to  fit  a 
particular inheritance model to the observed data. By comparing the likelihood of 
several models, one can determine which model provides the best fit to the data. 
Segregation analysis does not prove that a particular inheritance model is correct 
but will determine if the data is consistent with that inheritance model (Ashley-
Kosh  2006).  All  segregation  analysis  must  be  carried  using  strict  rules  of 
ascertainment of proband and secondary cases in families. 
 
Segregation analyses on  systematically  ascertained pedigrees produced results 
consistent with single gene models, in which a single gene plays a major role in 
determining disease susceptibility, as well as multigenic multifactorial models. 
However, these results need to be viewed with caution due to the limited power 
of the studies in the face of the known extensive degree of genetic heterogeneity 
found in bipolar disorder (Craddock 2007). 
  
The data from classical genetic epidemiological studies is consistent with models 
of inheritance that include major gene effects as well as epistatic and polygenic 
transmission is the favoured transmission in less than 50% of studies (Gurling et 
al.  1991).  Nevertheless,  the  multifactorial  polygenic  model,  where  multiple 
genes  interact  with  each  other  and  with  multiple  environmental  factors  to 
influence susceptibility to disease, is often quoted (Craddock 2007). However   38 
linkage studies using large multiply affective families suggest that major genes 
have a role on bipolar disorder (Curtis et al. 2003).  
 
Other  genetic/molecular  mechanisms,  such  as  mitochondrial  inheritance, 
dynamic mutation, anticipation and epigenetic effects, have been suggested to 
induce complex patterns of inheritance in BP (McInnis et al. 1993; McMahon et 
al. 1995; Kornberg et al. 2000; Craddock 2007). Moreover, many linkage studies 
have  reported  cosegregation  of  X-linked  markers  with  bipolar  disorder.  An 
association study of the linked region implicated the G-Protein coupled receptor 
50 (GPR50) gene for the X chromosome (Thomson et al. 2005).  
 
1.3.3  Twin Studies 
Twin  and  adoption  studies  are  used  to  differentiate  the  role  of  genetics  and 
environment in the aetiological variance of a trait. The premise of twin studies is 
the  comparison  of  the  disease  concordance  in  monozygotic  twins  (MZ)  and 
dizygotic twins (DZ). Since MZ twins share 100% of their DNA and DZ twins 
only  share  50%,  a  greater  disease  concordance  in  MZ  compared  with  DZ  is 
consistent with the involvement of genetics. The ratio of MZ concordance to DZ 
concordance is estimated. The ratio is reported as either ‘proband-wise’ or ‘pair-
wise’.  The  proband-wise  ratio  is  defined  as  the  proportion  of  affected  twin 
partners  of  probands.  In  other  words,  it  is  the  probability  that  an  affected 
proband’s  twin  will  have  the  disease.  The  pair-wise  method  expresses 
concordance as the proportion of all twin pairs that are concordant (Ashley-Kosh 
2006), regardless of whether a twin proband from the same pair was ascertained 
twice.   39 
An  advantage  of  this  method  is  that  generally  twins  share  the  same  family 
environment, at least during childhood. However, MZ twins share more similar 
intrauterine and extrauterine environments than DZ twins. This may lead to a 
higher concordance among MZ twins. Later in life twins will often not share the 
same  environment,  which  will  increase  differences  between  twins. 
Misclassification  of  MZ twins  can  also  occur  and  affect  twins’  concordance. 
However with DNA screening very high certainty can be achieved (Ashley-Kosh 
2006).   
 
Twin studies of bipolar disorder have found consistently higher concordance for 
MZ  twins  than  DZ  twins  (Rafaelsen  1981).  The  estimated  MZ  twins’ 
concordance for narrowly defined bipolar disorder was found to be 50% from 
pooled data of six available studies (Craddock et al. 1999). Recent studies have 
given very high heritability estimates for bipolar disorder. Thirty MZ and 37 DZ 
twins from the Maudsley twin register were studied and additive genetic variance 
was estimated at 85% using a narrow definition of affection (McGuffin et al. 
2003). Meanwhile, a population  based twin study of 26 twin pairs showed  a 
heritability  estimate  of  93%  (Kieseppa  et  al.  2004).  Non-shared  rather  than 
family  environment  was  implicated  in  explaining  the  remaining  non  genetic 
variance in these studies. 
  
Discordant MZ twins have been studied in bipolar disorder in order to identify 
environmental  risk  or  protective  factors  (Allen  1976).  Investigators  have 
generally  measured  various  biological  features  in  the  affected  and  unaffected 
twin  and  normal  controls.  For  example,  affected  twins  were  found  to  be   40 
significantly impaired on some measures of visual-spatial functioning and verbal 
memory  compared  with  the  unaffected  twin  (Gourovitch  et  al.  1999). 
Furthermore,  the  right  hippocampus  was  identified  as  smaller  and  less 
asymmetric in the affected co-twin compared to the unaffected co-twin (Noga et 
al. 2001). However, both these studies found significant differences between the 
unaffected co-twin and normal controls. This raises the spectre that while the BP 
phenotype  is  not  expressed  in  the  unaffected  co-twin  the  genotype  is  being 
expressed  sub-clinically  -  in  these  cases  in  terms  of  brain  morphology  and 
neuropsychological  function.  These  ‘hidden’  effects  are  referred  to  as 
endophenotypes.  Discordant  MZ  twins  have  also  been  used  to  identify  risk 
factors at a molecular level by investigating gene expression differences. These 
differences have also been used to try and identify aetiological genes (Kakiuchi 
et al. 2003). 
 
1.3.4  Adoption Studies 
Adoption studies can also be used to examine the evidence for genetic versus 
common familial environmental factors. In this approach, cases are ascertained 
and then the frequency of the disease in biological parents is compared to the 
frequency in adoptive parents. Higher frequencies in biological parents indicate a 
strong genetic influence, while higher frequencies in adoptive parents argues in 
favour of common familial environmental factors (Ashley-Kosh 2006). 
 
Adoption  studies  of  bipolar  disorder  are  rare  and  only  two  are  reported. 
Biological  parents  of  the  cases  are  difficult  to  find.  In  addition,  sometimes 
children  are  placed  in  similar  environments  to  the  families  of  the  biological   41 
parents, which may make it less certain that the method can distinguish between 
genetics and environmental factors. However, when these problems are solved, 
this approach can provide critical information regarding the etiology of complex 
traits (Ashley-Kosh 2006). 
  
Two bipolar disorder adoption studies have been published, indicating the strong 
genetic component that this disease has. A higher risk of BP was found in the 
biological parents of BP adoptees than in their adoptive parents (Mendlewicz et 
al.  1977).  A  subsequent  study  supported  this  finding,  although  only  ten  BP 
probands were included (Wender et al. 1986).  
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1.4  Mapping Bipolar Disorder 
1.4.1  Genetic and Phenotypic Heterogeneity 
Locus heterogeneity exists when two or more genes act independently to cause 
an identical trait. Thus, clinically identical forms of the same disease phenotype 
can be caused by different genetic etiologies. This is an important consideration 
in genetic studies  because heterogeneity can confound linkage analyses. With 
more genetic diseases there may also be locus heterogeneity and it is certain that 
a  common  disease  like  bipolar  disorder  will  be  heterogenic.  Cases  of 
pleiotropism  have  also  been  described.  Pleiotropism  causes  phenotypic 
heterogeneity  and  means  that  several  disease  phenotypes  can  result  from  the 
same mutations (Pericak-Vance 1998). 
 
Heterogeneity causes difficulties in the search for genes involved in the etiology 
of complex diseases. In linkage studies, locus heterogeneity has been one of the 
greatest  problems  in  identifying  chromosomal  regions  of  importance  within 
families. If homogeneity had been assumed and linkage analysis carried out on a 
collection of families containing a mixture of two autosomal forms, the results 
could  have  been  misleading  and  linkage  might  have  been  overlooked.  Locus 
heterogeneity  also  affects  association  studies,  since  the  power  of  association 
studies decreases as soon as there is more than one susceptibility locus affecting 
a  disease.  Generally,  to  overcome  heterogeneity  problems,  more  families  are 
needed to detect a significant result (Pericak-Vance 1998).      
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1.4.2  Power Analysis 
Before undertaken linkage analysis, it is critical to know whether the available 
pedigree information is sufficient to allow detection of the genes undertaking the 
trait  of  interest.  Similarly,  for  allelic  and  haplotypic  association  analysis  on 
adequate sample size is essential. Power calculations show that sample sizes of 
600 can detect allelic association between a concordant marker allele when only 
a  case  allele  frequency  differs  by  4  to  5%  in  cases  compared  to  controls, 
assuming complete linkage disequilibrium (LD). Estimates can be obtained prior 
to collection of samples to develop sampling strategies that will ensure adequate 
power to detect genetic effects. The interpretation of power studies is based on 
fundamental statistical concepts such as having complete LD between a marker 
and  a  disease  allele.  The  less  the  LD  the  greater  the  sample  size  is  needed 
(Haines et al. 2006). 
 
1.4.3  Genetic Markers 
For any disease gene mapping study it is essential to choose informative genetic 
markers that will be used to test for linkage or association. Markers used for 
genotyping  are  restriction  fragment  length  polymorphisms  (RFLPs),  variable 
number  of  tandem  repeats  (VNTRs),  short  tandem  repeats  (STRs)  or 
microsatellite repeats, and single nucleotide polymorphisms (SNPs). 
 
RFLPs were introduced in 1978 and in 1982 became the first modern genotyping 
markers to be used in a successful linkage study, of Huntington disease (Gusella 
et  al.  1983).  RFLPs  are  based  on  a  single  base  pair  change  that  creates  or   44 
eliminates a cleavage site for a restriction enzyme. RFLPs are inherited as simple 
Mendelian codominant markers, which can be useful in family studies. However 
they have low heterozygosity (usually < 0.4), which is a severe disadvantage for 
use in family linkage studies. 
 
The main disadvantage was RFLPs was greatly improved by the identification of 
VNTRs in 1987 (Nakamura et al. 1987). These new markers are made up of 
specific sets of consensus repetitive sequences that can vary between hundreds of 
base pairs in length. VNTRs and minisatellites are highly polymorphic and have 
a high heterozygosity rate.  
 
STRs are widely and evenly distributed in the genome and are relatively easy to 
score. The number of repeat motifs  may  vary,  however the  most useful ones 
consist of a repeated sequence motif of two (dinucleotide), three (trinucleotide) 
and four (tetranucleotide) (Litt et al. 1989; Weber et al. 1989).  
 
SNPs consist of a polymorphism at a single base pair location. In the past SNPs 
were  analysed  with  restriction  enzymes  to  produce  RFLPs.  SNPs  occur  very 
frequently  in the  human genome (Wang et al. 1998). This  high  frequency of 
SNPs  made  them  very  useful  for  association  studies,  where  the  power  of 
association is strongest over small distances (Hacia et al. 1996). One of their 
drawbacks  is  the  low  heterozygosity,  however  they  can  be  clustered  into 
haplotypes, which can significantly increase their information content. More than 
6 million SNPs have been identified all over the genome due to the effort of the 
SNP  Consortium,  the  HapMap  Project  and  the  Human  Genome  Sequencing   45 
Project. These can be visualised using internet genome browsers such as NCBI 
(http://www.ncbi.nlm.nih.gov/),  UCSC  (genome.ucsc.edu/)  and  Ensembl 
(www.ensembl.org/). 
  
1.4.4  Linkage Analysis 
Linkage analysis is one of the many methods that can be used to map genes. In 
fact,  the  application  of  molecular  biology  techniques  in  combination  with 
statistical linkage analysis has led to rapid localization of genetic loci for many 
disorders. 
 
In linkage analysis, cosegregation of two or more loci, one of which can be a 
disease allele, is examined in a family to determine if the two loci demarked by 
differing  alleles  segregate  independently  following  Mendelian  ratio  (alleles 
observed and compared against random segregation – 50%). Disease alleles will 
segregate with a marker allele if they are close on the same chromosome.   
 
The  measure  of  genetic  distance  is  the  recombination  fraction,  which  is  the 
probability  that  a  recombination  will  occur  in  a  defined  distance  along  a 
chromosome  in  relation  to  the  genetic  marker.  Recombination  occurs  when 
homologous chromosomes cross over.  A  non-recombinant offspring  is one  in 
which  the  parental  type  remains  intact.  Multiple  crossing-overs  may  occur 
between two loci if they are in opposite ends of large chromosomes. However, 
recombinants between closely linked marker alleles will rarely suffer crossing 
over events maintaining that region more conserved. The recombination fraction 
is referred as ө. ө ranges from 0 to 0.5:   46 
ө = 0 when two genes are completely linked 
ө = 0.5 when two genes segregate independently  
 
1.4.4.1  Parametric Linkage Analysis 
Haldane  and  Smith,  in  1947,  developed  a  method  for  linkage  analysis.  They 
proposed the probability ratio test for linkage. This ratio is the probability of the 
data at some given value of ө divided by the probability of non linkage (ө = 0.5) 
(Haldane  et  al.  1947).  Morton  et  al  further  developed  Haldane  and  Smith 
methodology and first defined logarithm of the odds (LOD) score as the log10 of 
the odds for linkage (Morton 1955).  
 
The  parametric  LOD  score  is  a  likelihood-based  statistical  measure  which 
computes the likelihood of the observed markers in a family sample showing 
linkage as opposed to the null hypothesis of non linkage. It can only be inferred 
from  observed  phenotypes  of  family  members  and  for  that  requires  the 
assumption of certain parameters  in a genetic  model. That  is the reason why 
these studies are named parametric or model-based linkage analysis. There are 
four major advantages of model-based linkage analysis: (a) statistically, it is a 
more powerful approach than any nonparametric method if the genetic model 
assumed is approximately correct; (b) it uses every family member’s phenotypic 
and  genotypic  information;  (c)  It  provides  an  estimate  of  the  recombination 
fraction between marker and disease locus; (d) It provides a statistical test for 
linkage and for genetic (locus) heterogeneity. 
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The genetic model used in parametric linkage analysis includes (a) the mode of 
inheritance  of  the  trait;  (b)  the  trait  and  marker  allele  frequencies;  (c)  the 
penetrance values for each possible disease genotype, that is, the probabilities of 
expressing  the  disease  phenotype  given  the  genotype;  (d)  sex  specificity  of 
recombination fractions (Terwilliger et al. 1993). 
 
The model is mostly used assuming a mutation rate of zero and using a sex-
averaged  recombination  fraction.  When  the  genetic  model  is  unknown  LOD 
scores  may  still  be  calculated. However, analysis still  has to assume that the 
penetrance  and  recombination  fraction  have  been  estimated  correctly.  If  they 
have  not,  this  can  lead  to  false  negatives.  Though,  LOD  score  has  been 
successfully used in many complex traits. It has been used to find single-gene 
effects in subset of families and also has been applied in conjunction with non-
parametric models in more complex linkage signals. 
 
1.4.4.1.1  Two-Point Analysis 
The likelihood (L) of observing the cosegregation of disease allele and a marker 
allele is calculated with variable values of ө (that range between 0 and 0.5) and 
compared to the likelihood when ө =0.5, which is the null hypothesis (H0). H0 
assumes no linkage and the alternate hypothesis (HA) assumes that the disease 
and the marker locus are linked. ө is the recombination fraction, R the number of 
recombinants, and NR the  number of  non recombinants. The total  number of 
offspring of that family (N) will be R+NR.  
L= ө
 R(1- ө)
NR 
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Log10 of the ratio of these likelihoods is then determined for each value of ө 
within the range, and each of the resulting numbers is referred to as the LOD 
score,  z(x),  where  x  represents  a  particular  value  of   ө    within  the  range  of 
recombination fractions (ө =0 to ө =0.5): 
z(x) = log10 [L(pedigree given ө =x)/L(pedigree given ө =0.5)] 
 
The value z(x) is referred to as a two point LOD score, since it involves linkage 
between two loci. It is the value of the log10 likelihood at a specific value of ө. 
To  demonstrate  linkage,  there  must  be  evidence  of  cosegregation  that  allows 
rejection of the H0. LOD scores of 3 or more (1000:1 odds in favour of linkage) 
are indicative of linkage. Values under 3 and above 2 are useful for replication. A 
LOD of 2 on the X chromosome is considered sufficient to show linkage because 
of the high prior probability of observing ahead father to sun transmission.   
 
Since diseases rarely accord to perfect Mendelian ratios, LOD score analysis has 
undergone many revisions in an attempt to improve its ability to model traits 
whose  inheritance  shows  such  deviation.  Morton  realised  that  locus 
heterogeneity could reduce the power of the LOD score method to detect linkage 
and developed a test for linkage heterogeneity, the K-test (Morton 1956). Other 
tests  of  heterogeneity  have  subsequently  been  developed,  including  the 
Admixture or A test (Smith et al. 1963) and the B test (Risch 1988). It can be 
readily appreciated that the phenomenon of incomplete penetrance could have a 
great  effect  on  likelihood  calculations.  Hence,  a  penetrance  function  was 
introduced in an attempt to account for this (Ott 1974).   49 
1.4.4.2  Non-Parametric Models 
When the underlying genetic model cannot be specified with any confidence, as 
happens with majority of complex traits, parametric LOD score analysis looses 
much of its power, and results can be misleading. The solution to this problem 
was to develop methods that would rely less on the genetic model specifications. 
These analytical procedures offer a robust approach when model parameters are 
less  certain,  but  they  all  have  the  weakness  of  being  unable  to  detect  locus 
heterogeneity.  The  term  non  parametric  linkage  analysis  is  used  to  describe 
methods  that  do  not  take  into  account  the  recombination  fractions  and  the 
penetrance. 
 
Methods for non parametric linkage analysis can be distinguished based on four 
key features: (a) which members of the family are included in the analysis; (b) 
how  phenotypic  similarity  and  estimates  of  trait  locus  genetic  effect  are 
incorporated; (c) how genotypic similarity at the marker locus is measured and 
estimated (by identity by state or identity by descent); (d) whether the analysis 
includes identity by state estimates at single or multiple markers. The greatest 
variability in study design occurs in deciding which members of the family are 
included in the analysis and how many markers can be analysed. 
 
Model-free analysis can be performed on affected sib-pairs or more extended 
pedigrees.  Sib-pair  analysis,  where  no  recombination  fraction  is  specified, 
requires the genotypes of two affected siblings with or without their parents. For 
any given locus the probabilities that the siblings share 0, 1 or 2 alleles identical 
by descent, on score are 0.25, 0.5 and 0.25 respectively. Evidence that these   50 
probabilities do not hold implies that the marker allele is linked to the disease 
locus. In extended pedigrees other family members such as cousins and affected 
individuals  across several generations can  be used. These  additional  affective 
relatives add more useful information to the sample, but do not contribute to 
within  family  information  since  they  must  be  cleared  as  independent  sibling 
pairs. The Affected Pedigree Member Method (Weeks et al. 1988; Weeks et al. 
1992) and the Nonparametric Linkage Score (NPL) method, as implemented in 
the program GENEHUNTER, can be used to look for excess allele sharing in 
extended pedigrees.  
 
1.4.4.3  Two-Locus Linkage 
Linkage analysis has traditionally considered loci individually in relation to the 
disease.  However,  complex  inheritance  may  arise  through  gene  interaction. 
Attempts have been made to perform two-locus linkage analysis. The first report 
of a two-locus linkage analysis was applied to Multiple Sclerosis families and 
provided evidence for two unlinked loci (Tienari et al. 1994). More recently, a 
systemic two-dimensional genome scan of essential hypertension was performed 
and was able to identify novel epistatic loci (Bell et al. 2006). In BP, two-locus 
admixture  linkage analysis was employed, with evidence that it increased the 
power to detect linkage when loci on chromosome 21q and 11p were both taken 
into account and assumed to be acting independently (Smyth et al. 1997). 
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1.4.5  Allelic and Haplotypic Association Studies 
Association studies look for a significantly increased or decreased frequency of a 
marker  allele,  genotype  or  haplotypes,  with  a  disease  trait  than  would  be 
expected  by  chance  if  there  was  no  association  between  marker(s)  and 
phenotype.  
 
Allelic association can occur between linked or unlinked loci. The term linkage 
disequilibrium often is used to refer to allelic association between linked loci. 
Conceptually,  this  is  the  same  as  standard  linkage  analysis,  however  the 
recombination distances being analysed are very small, generally smaller than 
1cM, and the recombination events can only be inferred based on the level of 
sharing the same allele.  
 
There are several events that may be responsible for allelic association, namely 
mutation, migration, selection and genetic drift. After an initial event generates 
an allelic association, the association begins to decay. The rate of decay is related 
to  the  recombination  rate  and  is  higher  in  unlinked  loci  than  linked  loci.  In 
general, the closest the marker is to the disease, the longer the marker allele-
disease association will persist through the generations. Variations within and 
between populations may occur, especially due to phenomenon such as regional 
selection pressure or recent population admixture. Population stratification may 
be a problem that affects case-control association studies, and must be kept in 
mind when selecting the individuals that will be used in the population sample 
for the study, since they should be closely matched for ancestry. 
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1.4.5.1  Measures of Allelic Association 
There  are  many  methods  to  calculate  linkage  disequilibrium  and  all  measure 
deviation  from  independent  assortment  of  alleles  at  different  loci.  The  three 
measures  mentioned  are  disequilibrium  coefficient,  correlation  coefficient (r
2) 
and Lewontin’s D’. 
 
The  disequilibrium  coefficient  (D)  directly  measures  the  deviation  of  the 
haplotype frequency from the product of the allele frequencies. The coefficient is 
zero when there is no association.  
D = Pr(AB)-Pr(A)Pr(B)  
 
where P(A)  is  frequency of allele  A  and P(B) the  frequency of  allele B and 
P(AB) the  frequency of  AB  haplotype. This  method can give results that are 
difficult to interpret since its maximum value depends on the allelic frequencies. 
So alternative standardized methods where developed, being the most commonly 
used the correlation coefficient and Lewontin’s D’. The correlation coefficient 
(r
2) is based on D being proportional to the covariance of the allele counts at two 
loci: 
r
2=D/{P(A)[1-Pr(A)]Pr(B)[1-Pr(B)]}   
  
This is a standard statistical measure with well known properties. When r
2 is zero 
there is no allelic association. 
Lewontin’s D’  is the disequilibrium coefficient standardized by its maximum 
value: 
D’= D/min{Pr(A)[1-Pr(B)], Pr(B)[1-Pr(A)] } if D>0   53 
D’=D/min {-Pr(A)Pr(B),-[1-Pr(A)][1-Pr(B)]} if D<0 
 
Again, when D’ equals to zero there is no association. 
Both correlation coefficient and Lewontin’s D’ values fall in between -1 and 1, 
being  the  maximum  values  independent  of  allelic  frequencies.  However  the 
measures  themselves  are  dependent  on  the  allele  frequencies  and  their 
evolutionary histories. 
 
1.4.5.2  Tests for Association 
There are two types of association studies, dependent on the type of sample used. 
The  case-control  tests  use  unrelated  individuals  who  are  affected  (cases)  and 
unaffected  (controls).  Case  control  studies  compare  allele  or  genotype 
frequencies in the cases to the frequency in a set of matched controls. Family-
based  tests  of  association  use  affected  individuals  and  their  relatives.  Allele 
frequencies  in  affected  individuals  are  compared  to  family-based  controls, 
typically parental controls or unaffected siblings. 
 
1.4.5.2.1  Case-control Test  
The  case-control  test  is  a  standard  test  for  the  differences  between  allele  or 
genotype  frequencies  in  the  two  samples.  For  balanced  data  where  the  same 
number of cases and controls is compared, the test used is: 
Tcc=[∑
m(ai-ui)]
2/∑
m(ai-ui)
2 , being i=1 
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Where m is the number of marker alleles and ai and ui are the number of times 
the ith allele is found in the cases and controls, respectively. The statistics can be 
compared to a chi-square test with m-1 degrees of freedom. Following a 2x2 
contingency  (Table    1.1),  the  chi-squared  calculation  for  the  case-control  test, 
with one degree of freedom, would be: 
Tcc = [(ad-bc)
2(a+b+c+d)]/[(a+b)(c+d)(b+d)(a+c)] 
 
Table   1.1 2x2 Contingency table for case/control analysis 
Marker  Cases  Controls 
Present  A  B 
Absent  C  D 
Total 
a+b 
c+d 
            Total                             a+c                             b+d                        a+b+c+d 
 
 
Odds ratio (OR) can also be used to measure association between genetic marker 
and disease in case-control studies. The OR is calculated using the following 
formula: 
OR = (a/b)/(b/d) = ad/bc 
 
Confidence intervals (CI) which specify the range of true values for the OR can 
be  derived  by  estimating  the  variance  and  are  calculated  from  the  following 
equation: 
CI = (OR)expz[±(var(lnOR)]
1/2 
var(lnOR)=(1/a)+(1/b)+(1/c)+(1/d) 
 
where, for a 95% confidence limit or a significance level of 0.05, z=1.96. 
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1.4.5.3  Haplotype Analysis  
Haplotype  analysis  looks  for  association  between  disease  and  a  particular 
combination of alleles at adjacent loci on the same chromosome. The strongest 
associations are found when a particular allele or haplotype has a low frequency 
in the population and is increased in cases. Thus, there is potential for a stronger 
association when examining haplotypes, because many haplotypes will have a 
low population frequency. In fact, Daly et al observed in their association studies 
in the 5q31 region, that a creation of a comprehensive haplotypic map facilitates 
mapping approaches based on haplotypes within LD blocks (Daly et al. 2001). 
 
However, haplotypic analysis has some difficulties. Haplotypes are not generally 
observed  directly.  Instead,  they  are  typically  inferred  from  the  individual’s 
genotypes. Some haplotypes can be predicted with some certainty, but when the 
individual  is  heterozygous  at  more  than  a  locus, the  haplotype  assignment  is 
ambiguous.  To  overcome  this  problem  the  EM  algorithm  was  developed  to 
estimate haplotypes frequencies (Ott 1977). Since then, many association tests 
have been created to test for haplotypic association in case-control and family 
studies. The one adopted in the UCL research  group was GENECOUNTING 
(Curtis  et  al.  2006).  In  addition,  haplotype  analysis  is  very  sensitive  to 
genotyping  error  (Moskvina  et  al.  2006).  This  may  lead  to  a  highly  inflated 
significance  value  for  haplotypes  in  the  absence  of  any  single  marker 
associations. Various tests can be preformed to try to identify genotyping error, 
including testing  for Hardy  Weinberg Equilibrium (HWE). HWE can also  be 
used to check for aberrant haplotypic association due to sample mismatches.  
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1.5  Linkage and Association Results in Bipolar Disorder 
1.5.1  Linkage 
Many  linkage  studies  have  been  carried  out  to  find  susceptibility  regions  to 
bipolar  disorder  (Table    1.2).  Two  meta-analyses  of  bipolar  disorder  genome 
scans have been conducted. The first study examined seven published genome 
scans for bipolar disorder, and found the strongest evidence for susceptibility loci 
on 13q and 22q (Badner et al. 2002). A more recent meta-analysis (Segurado et 
al. 2003) of thirteen genome scans of bipolar disorder, including the UCL bipolar 
linkage study (Curtis et al. 2003), was carried out using non parametric rank 
order statistics to test the randomness of the distribution of positive lods across 
the genome. The rank order of positive lods showed that several loci, linked to 
bipolar disorder on chromosomes 1p32.1, 1q31-q32, 11p13 -p13.3 and 21q21.3-
qter were non random with p values of less than 0.05. The study also provided 
some support for regions on chromosome 9p22.3-21.1, 10q11.21-22.1, 14q24.1-
32.12 and regions of chromosome 18.  
 
However,  many  other  chromosomal  regions  have  been  implicated  in  bipolar 
disorder linkage studies (Hayden et al. 2006). In the UCL whole genome linkage 
study  where  large  families  containing  many  cases  of  bipolar  and  unipolar 
disorder were used, linkage was found on chromosomes 1q32, 11p15, 12q24, 
21q21 and Xq26-28 (Curtis et al. 2003). An NIMH Genetics Initiative showed 
significant linkage signals at 10q25, 10p12, 16q24, 16p13 and 16p12 (Cheng et 
al. 2006). Linkage at loci on 9q31.1-34, 6q23-24 and 2q33-36 were reported in a   57 
Swedish study on an isolated population (Venken et al. 2005). A linkage study in 
Quebec implicated the 12q24 region (Shink et al. 2005).    
 
In  addition,  several  consortia  have  combined  data to  strengthen  evidence  for 
valid linkages. The Wellcome Trust UK-Irish bipolar affective disorder sibling 
pair genome scan study gave further support on regions 6q16-21, 4q12-21, 9p21, 
10p14-21 and 18q22 (Lambert et al. 2005). A study of four European family 
samples of bipolar disorder provided more evidence on chromosome 4q31 and 
6q24 (Schumacher et al. 2005). One of the largest studies, where data from 11 
bipolar disorder genome wide linkage scan studies involving 5179 individuals 
from 1067 families was used, established significant linkage on chromosome 6q 
and 8q (McQueen et al. 2005).    
 
Table   1.2 Summary of the main studies done for linkage analysis on bipolar disorder.  
Chromosomal region  Study 
1p32.1  (Segurado et al. 2003) 
1q31-32  (Curtis et al. 2003; Segurado et al. 2003) 
2q33-36  (Venken et al. 2005) 
4p  (Le Hellard et al. 2007) 
4q  (Lambert et al. 2005; Schumacher et al. 2005) 
4q21  (Cassidy et al. 2007) 
5q33  (Herzberg et al. 2006; Jasinska et al. 2009) 
6q  (Lambert et al. 2005; McQueen et al. 2005; Schumacher et al. 
2005; Venken et al. 2005) 
7q36  (Cassidy et al. 2007) 
8q  (McQueen et al. 2005) 
8p23.1  (Walss-Bass et al. 2006) 
8q13.3  (Walss-Bass et al. 2006) 
9p22-21  (Segurado et al. 2003; Lambert et al. 2005; Cassidy et al. 2007) 
9q  (Venken et al. 2005) 
10p  (Lambert et al. 2005; Cheng et al. 2006) 
10p14  (Joo et al. 2009) 
10q  (Segurado et al. 2003, Venken, 2008 #390; Cheng et al. 2006) 
11p  (Curtis et al. 2003; Segurado et al. 2003) 
12q23-24  (Dawson et al. 1995; Ewald et al. 1998; Morissette et al. 1999; 
Degn et al. 2001; Ewald et al. 2002; Abkevich et al. 2003; Curtis 
et al. 2003; Shink et al. 2005; Cassidy et al. 2007) 
13q  (Badner et al. 2002, Wigg, 2009 #396) 
13q13-q14  (Maziade et al. 2009)   58 
14q24  (Cassidy et al. 2007) 
15q26  (Vazza et al. 2007; McAuley et al. 2009) 
16q24  (Cheng et al. 2006) 
16p  (Ross et al. 2008) 
16p13-12  (Cheng  et  al.  2006;  Cassidy  et  al.  2007,  Jones,  2007  #391; 
Merette et al. 2008) 
18q  (Segurado et al. 2003; Lambert et al. 2005) 
20  (Ross et al. 2008) 
21q21  (Curtis et al. 2003; Segurado et al. 2003) 
22q  (Badner et al. 2002) 
22q11  (Savitz et al. 2007) 
Xq26-28  (Curtis et al. 2003, Wigg, 2009 #396) 
 
1.5.2  Association 
Fine mapping of linkage regions has given rise to the detection of possible genes 
implicated  on  bipolar  disorder  aetiology.  There  are  many  studies  implicating 
many different genes in bipolar disorder. To have an overall idea of the genes so 
far implicated, data from many association studies have been compiled on Table 
  1.3. These data prove locus heterogeneity and point to the need for large sample 
sizes.   
  
Table   1.3 Compilation of different studies implicating genes in bipolar disorder. This table 
was created using the Genetic Association Database (http://geneticassociationdb.nih.gov). 
The p-values mentioned were selected for being the most positive ones. 
Gene Symbol  Gene Name  Chromosome  P-values  Publication 
ALOX12  Arachidonate  12-
lipoxygenase 
17 p13.1  0.010  (Fridman  et  al. 
2003) 
ANK3  Ankyrin 3  10q21    (Ferreira  et  al. 
2008;  Schulze  et 
al. 2009) 
ARNTL  Aryl  Hydrocarbon 
Receptor  Nuclear 
Translocator-like  
11p15  0.025  (Nievergelt  et  al. 
2006) 
BCR  Breakpoint cluster region  22q11  0.0054  (Hashimoto  et  al. 
2005) 
BDNF  Brain-derived 
neurotrophic fac 
11p13  0.000394  (Neves-Pereira  et 
al.  2002; 
Rybakowski  et  al. 
2003; Lohoff et al. 
2005; Green et al. 
2006; Kremeyer et 
al. 2006; Muller et 
al. 2006; Okada et 
al. 2006; Vincze et   59 
al. 2008; Petryshen 
et  al.  2009;  Xu et 
al. 2009) 
CACNA1C 
 
calcium channel, voltage-
dependent,  L  type,  alpha 
1C subunit 
12p13.3    (Ferreira  et  al. 
2008) 
CLOCK  Clock homolog (mouse)  4q12  0.026  (Benedetti  et  al. 
2003) 
COMT  Catechol-O-
methyltransferase 
22q11.21-
q11.23 
0.002  (Kirov et al. 1998; 
Mynett-Johnson  et 
al.  1998;  Papolos 
et  al.  1998; 
Burdick  et  al. 
2007; Zhang et al. 
2009) 
DAOA  D-amino  acid  oxidase 
activator 
13q33.2  0.01  (Williams  et  al. 
2006;  Prata  et  al. 
2008;  Bass  et  al. 
2009) 
DGKH  Diacylglycerol kinase, eta  13q14.11  1.5 x 10
-8  (Baum et al. 2008) 
DISC1  Disrupted  In 
Schizophrenia 1 
1q42.1  0.00026  (Hodgkinson et al. 
2004;  Thomson  et 
al.  2005;  Schosser 
et al. 2009) 
DRD1  Dopamine receptor D1  5q35.1  0.016  (Severino  et  al. 
2005;  Dmitrzak-
Weglarz  et  al. 
2006;  Del  Zompo 
et al. 2007) 
DRD2  Dopamine receptor D2  11q23  0.029  (Perez de Castro et 
al. 1995; Massat et 
al. 2002) 
DRD4  Dopamine receptor D4  11p15.5  0.001  (Muglia  et  al. 
2002;  Lopez  Leon 
et al. 2005) 
DTNBP1  Dystrobrevin  binding 
protein 1 
6p22.3  0.014  (Fallin et al. 2005; 
Breen  et  al.  2006; 
Joo  et  al.  2007; 
Gaysina  et  al. 
2008) 
GABRA1  Gamma-aminobutyric 
acid (GABA) 1 
5q34-q35  0.0008  (Horiuchi  et  al. 
2004) 
GABRA3  Gamma-aminobutyric 
acid (GABA) 3 
Xq28  0.0004  (Massat  et  al. 
2002; Craddock et 
al. 2008) 
GABRA4  Gamma-aminobutyric 
acid (GABA) 4 
4p14-q12  -  (Craddock  et  al. 
2008) 
GABRA5  Gamma-aminobutyric 
acid (GABA) 5 
15q11.2-q12  0.024  (Papadimitriou  et 
al.  1998;  Otani  et 
al. 2005; Craddock 
et al. 2008) 
GSK3B  Glycogen synthase kinase 
3 bet 
3q13.3  0.0047  (Benedetti  et  al. 
2004; 
Szczepankiewicz 
et al. 2006) 
GRP50  G receptor protein 50  Xq27  0.007  (Thomson  et  al. 
2005) 
HTR2A  5-hydroxytryptamine 
(serotonin) 2A receptor 
13q14-q21  0.007  (Chee  et  al.  2001; 
Bonnier  et  al.   60 
2002;  Ranade  et 
al. 2003) 
HTR3A  5-hydroxytryptamine 
(serotonin) 3A receptor 
11q23.1  0.00016  (Niesler  et  al. 
2001) 
HTR4  5-hydroxytryptamine 
(serotonin) 4 receptor 
5q31-q33  0.002  (Ohtsuki  et  al. 
2002) 
MAOA  Monoamine oxidase A  Xp11.4-p11.3  0.037  (Lim  et  al.  1995; 
Lin  et  al.  2000; 
Preisig et al. 2000; 
Gutierrez  et  al. 
2004; Muller et al. 
2007) 
MLC1  Megalencephalic 
leukoencephalopathy with 
subcortical cysts 1 
22q13.33  0.002  (Verma  et  al. 
2005;  Selch  et  al. 
2007) 
MTHFD1  5,10-
methylenetetrahydrofolate 
dehydrogenase 
14q24  0.0054  (Kempisty  et  al. 
2007) 
MTR  Methionine synthase  1q43  0.0172  (Kempisty  et  al. 
2007) 
NAPG  N-ethylmaleimide-
sensitive  fusion  (NSF)-
attachment protein 
18p11  0.027  (Weller  et  al. 
2006;  Li  et  al. 
2009) 
NCAM1  Neural  cell  adhesion 
molecule 1 
11q23.1  0.004  (Arai et al. 2004) 
NDUFV2  Nicotinamide  adenine 
dinucleotide 
(NADH)ubiquinone 
oxidoreductase 
18p11  0.009  (Washizuka  et  al. 
2004; Zhang et al. 
2009) 
NOS3  Nitric oxide synthase 3  7q36  0.021  (Reif et al. 2006) 
OTX2  Orthodenticle  homeobox 
2 
14q21-q22  0.003  (Sabunciyan  et  al. 
2007) 
PER3  Period  homolog  3 
(Drosophila) 
1p36.23  0.008  (Nievergelt  et  al. 
2006) 
S100B  Glial  cell-derived 
neurotrophic factor 
21q22  0.009  (Roche et al. 2007) 
SLC6A4  Serotonin transporter  17q11.1-q12  0.001  (Mynett-Johnson 
et  al.  2000; 
Mellerup  et  al. 
2001;  Bellivier  et 
al. 2002; Serretti et 
al. 2004; Lasky-Su 
et  al.  2005; 
Masoliver  et  al. 
2006) 
SYNGR1  Synaptogyrin 1  22q13.1  0.00007  (Verma  et  al. 
2005) 
TAAR6  Trace  amine  associated 
receptor 6 
6q23.2  0.00002  (Pae et al. 2008) 
TPH2  Tryptophan hydroxylase 2  12q21.1  0.004  (Van  Den  Bogaert 
et al. 2006; Harvey 
et al. 2007; Lin et 
al. 2007; Lopez et 
al.  2007; 
Grigoroiu-
Serbanescu  et  al. 
2008) 
TRPM2  Transient  receptor 
potential  protein 
21q22.3  0.008  (McQuillin  et  al. 
2006;  Xu  et  al.   61 
melastatin type 2  2006;  Xu  et  al. 
2009) 
VMAT1  Vesicular  monoamine 
transporter 1 
8p21.3  0.003  (Lohoff  et  al. 
2006) 
WFS1  Wolframin  4p16  0.03  (Koido et al. 2005) 
XBP1  X-box binding protein 1  22q12.1  0.01  (Masui et al. 2006) 
 
 
Table   1.3 shows that there are some genes that have been consistently implicated 
in bipolar disorder, for example BDNF (Neves-Pereira et al. 2002; Rybakowski 
et al. 2003; Lohoff et al. 2005; Muller et al. 2006; Okada et al. 2006) and COMT 
(Kirov et al. 1998; Mynett-Johnson et al. 1998; Papolos et al. 1998). Members of 
the GABA receptors family have also shown to be associated to bipolar disorder 
(GABRA1, P= 0.0008; GABRA5, P=0.024) (Papadimitriou et al. 1998; Horiuchi 
et al. 2004; Otani et al. 2005). 
 
Interestingly, genes encoding proteins belonging to pathways of the monoamine 
transmitters,  dopamine  and  serotonin  have  not  shown  consistently  positive 
results.  However,  the  serotonin  transporter  (Mynett-Johnson  et  al.  2000; 
Mellerup et al. 2001; Bellivier et al. 2002; Serretti et al. 2004; Lasky-Su et al. 
2005; Masoliver et al. 2006), Tryptophan hydroxylase 2 (Van Den Bogaert et al. 
2006; Harvey et al. 2007; Lopez et al. 2007) and the serotonin receptors 2A 
(Chee et al. 2001; Bonnier et al. 2002; Ranade et al. 2003), 3A (Niesler et al. 
2001) and 4 (Ohtsuki et al. 2002), all belonging to the serotonin pathway have 
been  implicated  on  bipolar  disorder.  In  fact,  recently  has  been  shown  that 
missense  mutations  in  Tryptophan  hydroxylase  2  have  functional  properties 
(McKinney et al. 2009). In addition, the Dopamine receptor D1 (Severino et al. 
2005; Dmitrzak-Weglarz et al. 2006), D2 (Perez de Castro et al. 1995) and D4 
(Lopez Leon et al. 2005) might also be associated with bipolar disorder.    62 
It  is  also  of  notice  that  the  DISC1,  the  gene  famous  for  its  implication  in 
schizophrenia it has been associated to bipolar disorder (Hodgkinson et al. 2004; 
Thomson et al. 2005; Hennah et al. 2008). It is possible that DISC1 mutations 
cause both schizophrenia and bipolar disorder but no actual mutations have been 
found.  
 
1.5.2.1  Association studies on Chromosome 12 
 
Linkage disequilibrium mapping was carried out on the linkage region of 12q23-
24 in a UK Caucasian case-control sample of 347 cases and 374 controls (Glaser 
et al. 2005). Two SNPs (rs3847953 and rs933399) and an insertion/deletion with 
putative functional relevance (which are in high LD with each other and with the 
microsatellite marker) showed significant or nearly significant association with 
bipolar disorder after Bonferroni-correction (reaching nominal p values from p = 
0.002 to p = 0.005). In addition, a significant signal (p = 0.0016) was identified 
for  one  microsatellite  marker.  Haplotypic  analysis  gave  evidence  of  the 
involvement of CUX2 and the hypothetical protein FLJ32356.  
 
Association studies on the chromosomal region 12q24.31 in a population from 
Saguenay-Lac-St-Jean  (Quebec),  revealed  significant  allelic  associations 
between the bipolar phenotype and markers NBG6 (P = 0.008) and NBG12 (P < 
10
-3).  The  authors  looked  for  candidate  genes  in  the  NBG12  area  and  found 
KIAA1595 and FLJ22471, both hypothetical proteins (Shink et al. 2005).  
Further  fine  mapping  on  chromosome  12  highlighted  the  purinergic  receptor 
P2X, ligand-gated ion channel, 7 (P2RX7) as a candidate gene. However P2RX7 
has been delivering conflicting data. A French Canadian population sample was   63 
studied and the presence of two susceptibility loci, the P2RX7 and CaMKK2 
genes was detected (Barden et al. 2006). The strongest association with bipolar 
disorder  was  with  the  non-synonymous  SNP  P2RX7-E13A  (rs2230912)  ( 
p=0.000708). However a study done in a large UK case-control sample, neither 
rs2230912 nor any of 8 other SNPs genotyped across P2RX7 were found to be 
associated with bipolar disorder (Green et al. 2009).  
 
In a UCL and Danish collaboration, a region of 298 kb on chromosomal region 
12q24  was  found  to  be  associated  with  BP.  Fine  mapping  of  the  region 
implicated an unknown gene, Slynar (Kalsi et al. 2006). Slynar gene is discussed 
in more detail in section 1.6.1. 
 
In  the  12q21  region,  Tryptophan  hydroxylase  (TPH2)  has  be  found  to  be 
associated to bipolar disorder, with the strongest pValue being 0.004 (Table   1.3). 
TPH2 is the rate-limiting enzyme in the serotonin (5-HT) biosynthetic pathway 
responsible for the regulation of serotonin levels (Van Den Bogaert et al. 2006; 
Harvey et al. 2007; Lopez et al. 2007). 
 
1.5.3  Genome Wide Association Studies (GWAS) 
The principle of GWAS is similar to locus specific tests of association. However 
instead of the starting point being a specific gene or chromosomal region, the 
variants  that  may  confer  risk  to  disease  are  analysed  in  the  whole  genome 
(Hennah et al. 2008; Porteous 2008). Advances which  made GWAS possible 
where: the development of the HapMap resource that facilitates the design and 
genotyping of SNPs for the association studies; the development of microarrays   64 
enables to up to 1 million SNPs to be genotyped in a single DNA sample; the 
existence of large clinical sample collections has helped overcome the problem 
of heterogeneity (WTCCC 2007; Baum et al. 2008; Ferreira et al. 2008; Sklar et 
al. 2008). 
 
The Wellcome Trust Case Control Consortium (WTCCC) (WTCCC 2007) used 
a sample of 2000 individuals for each of 7 major diseases and a shared set of 
3000  controls.  The  group  used  the  GeneChip  500k  Mapping  Array  Set 
(Affimetrix chip) that comprises 500,568 SNPs. The strongest signal in bipolar 
disorder was with the marker rs420259 at chromosome 16p12 (P=6.3 X 10
-8). At 
this locus there are very interesting genes such as PALB2 (Partner and Localizer 
of  BRCA2)  which  is  involved  in  the  stability  of  key  nuclear  structures; 
NDUFAB1 (NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1) 
which encodes a subunit of complex I of the mitochondrial respiratory chain; and 
DCTN5 (dynactin 5) which encodes a protein involved in cellular transport and 
that  interacts  with  DISC1.  Association  was  also  detected  with  the  SNP 
rs1526805 with p=2,2 X10
-7, which is close to KCNC2, a Shaw-related voltage-
gated potassium channel. Other highly ranked genes include GABRB1 (GABA 
A Receptor Beta 1) encoding a ligand-gated ion channel (rs7680321 P=6.2 X10
-
5), GRM7 (Glutamate Receptor Metabotropic 7, rs1485171 P=9.7 X 10-5) and 
SYN3 (Synapsin III, rs11089599, P=7.2 X10
-5).  
 
Baum et al carried out a GWAS in two case control samples of European origin 
(461 bipolar disorder 1 cases and 563 matching controls from NIMH and 772 
bipolar disorder 1 cases and 876 control from a German sample) (Baum et al.   65 
2008). They pooled the DNA and ran the samples in the Illumina-Hap550 chip. 
A  total  of  88  SNPs  covering  80  genes  were  replicated  in  both  samples.  The 
strongest  association  came  from  a  marker  on  the  first  intron  of  DGKH 
(Diacylglycerol kinase eta, P=1.5 X 10
-8). This gene encodes a protein involved 
in the lithium-sensitive phosphatidyl inositol pathway. Other replicated signals 
were  in  the  gene  NXN  (combined  P=0.0003,  which  encodes  a  protein 
neuroredoxin;  VGCNL1,  a  voltage-gated  ion  channel  highly  expressed  in  the 
brain  (combined  P=  8.1  X10
-5),  DFNB3  gene  that  encodes  the  neuronally 
expressed protein whirlin (combined P=0.0001) and SORC2, which encode a 
VPS10 domain containing receptor, expressed in the developing brain (combined 
P from 0.0005 to 1.4 X 10
-5). The authors also argue that the results detected 
markers that had a weak but reproducible association. That none of the replicated 
genes  confer  a  large  population  risk  of  disease.  And  that  these  results  are 
compatible with either heterogeneity or a polygenic threshold model.  
 
Sklar et al performed a genome wide scan in 1461 patients with bipolar disorder 
1 and 2008 controls from the Systematic Treatment Enhancement Program for 
Bipolar Disorder (STEP-BD) and the UCL collection (Sklar et al. 2008). They 
used  the  GeneChip  Human  Mapping  500K  Array  Set  from  Affimetrix  and 
successfully  genotyped  372,193  SNPs.  The  strongest  single  SNPs  where  in 
MYO5B (Myosin 5B, p=1.66 X10
-7) and TSPAN8 (tetraspanin-8, p=6.11 X10
-7). 
Haplotypic  analysis  supported  the  single  markers  results  highlighting  again 
MYO5B and TSPAN8 and also EGFR (Epidermal Growth Factor Receptor, p= 
8.36  X  10
-8).  Replications  were  carried  out  on  two  samples,  the  NIMH  trio 
family sample (n=409 trios) and the Edinburgh case control sample (365 cases   66 
and 351 controls). The three strongest markers were not successfully replicated. 
However,  replicated  pValues  below  0.05  in  a  53Kb  region  of  18q22  were 
observed.. The SNPs were approximately 146 Kb from CDH7, a brain expressed 
cell to cell adhesion protein. Similarly, rs10491113 was found near TMEM132E, 
an uncharacterized transmembrane protein. Also, two SNPs near MBP (Myelin 
Basic Protein) and GRM3 (Glutamate Receptor Metabotropic 3) showed positive 
allelic association. 
 
A analysis of Sklar et al , WTCCC and the Ferreira GWAS results showed that a 
SNP was consistently associated to disease in all studies, with p>0.05. The SNP 
is  located on the third  intron of CACNA1C, the alpha  subunit of the  L-type 
voltage-gated calcium channel. Within this gene there are other associated SNPs 
in both WTCCC and Sklar et al. Additionally, Sklar et al also compared their 
results to Baum study. The strongest result in the Baum study, for the DGKH, 
was  not  positive  on  the  STEP-BD/UCL  study.  However,  Baum’s  fifth  most 
positive marker, near the gene DFNB31 even not being represented on Sklar’s 
platform, there were other markers for the same gene that showed to be positive 
with p of approximately 0.0003. Interestingly, the WTCCC study also showed 
positive association with markers at this locus with p < 10
-4. The authors argue 
that the results obtained show that the disease common variant hypothesis does 
not fit for bipolar disorder. However, if common variants do exist for the disease 
they  may  be  of  very  small  effect  and  thus  require  very  large  samples  to  be 
reliably detected. 
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Ferreira  et  al  used  the  same  data  and  platform  as  the  WTCCC  and  STEP-
BD/UCL and genotyped more 1,098 individuals with bipolar disorder and 1,267 
from the ED-DUB-STEP2 dataset, which included additional samples from the 
STEP-BD study as well as bipolar cases and controls  from the University of 
Edinburgh  and  Trinity  College  Dublin  (Ferreira  et  al.  2008).  The  combined 
results of the new sample with the STEP-BD/UCL and WTCCC data identified 
many  susceptibility  loci  for  bipolar  disorder.  Using  the  genotyped  data  and 
imputation, 1.8 million variants were tested in 4,387 cases and 6,209 controls. 
This study identified a region of strong association (rs10994336, p = 9.1 x 10(-
9))  in  ANK3  (ankyrin  G).  Ferreira  et  al  also  found  further  support  for  the 
previously reported CACNA1C (alpha 1C subunit of the L-type voltage-gated 
calcium  channel;  combined  P  =  7.0  x  10(-8),  rs1006737).  To  conclude,  the 
authors suggest that ion channelopathies may be involved in the pathogenesis of 
bipolar disorder. 
 
A  meta analysis of data from the Baum et al and  WTCCC GWAS data was 
preformed (Baum et al. 2008). Markers in genes like ZIP3 (combined P=5 X10
-
6), a zinc transporter with roles in synaptic transmission and JAM3 (junctional 
adhesion  molecule  3,  p=1  x  10
-6)  a  cell  to  cell  adhesion  molecule,  show 
consistently positive results in each of the studies and in a combined analysis. 
The DGKH gene also seems to show consistent association. The most significant 
marker  of  Baum’s  study  (rs1012053  p=1.5  X  10
-8)  showed  little  evidence  of 
association in the WTCCC study. However, in the latter there are six markers 
within 2Kb of DGKH that show evidence of association with P-values as low as   68 
0.0006. The authors justify this result has reflect of allelic heterogeneity at the 
same risk locus.  
 
GWAS has allowed to powerful studies of association across the genome with no 
prior hypotheses. The results so  far point to heterogeneity as  being the  main 
complication  of  genetic  studies  of  bipolar  disorder.  Ferreira  et  al  tested  for 
polygenic transmission in the largest sample so far and could find no evidence 
for interaction between any associated genes (Ferreira et al. 2008). This suggests 
that  bipolar  disorder  may  be  caused  by  multiple  rare  variations  that  have  an 
addictive effect on the phenotype rather than a polygenic effect.  
 
It seems that the complexity of the genetics of bipolar disorder, which involves 
trait,  locus  and  allelic  heterogeneity  will  require  many  new  samples  before 
consensus is revealed. Researchers are using GWAS data to do pathway analysis 
(Askland  et  al.  2008;  Torkamani  et  al.  2008)  and/or  to  converge  functional 
genomics with association data (Le-Niculescu et al. 2008). Le-Niculescu et al 
proposes the use of convergent functional genomics in human and animal models 
to highlight genes that may not have been highlighted in a genetic study (Le-
Niculescu et al. 2008). They have integrated data from WTCCC, Baum and Sklar 
GWAS data with human post mortem brain gene expression data, blood gene 
expression data as well as relevant animal model data. Genes were prioritized 
according to a score of  multiple  independent  lines of evidence. The top four 
candidate genes were ARNTL, a transcription factor involved in the circadian 
rhythms; BDNF; ALDH1A1 that has been implicated in brain development; and 
KLF12, a transcription factor that represses a zinc finger transcription factor. The   69 
direct pathway analysis using the WTCCC data (Torkamani et al. 2008) showed 
that  the  enriched  signalling  pathways  were:  heparin  sulphate  and  heparin 
metabolism (p=0.01), a pathway  involved  in the  inactivation of dopamine  by 
sulfation;  Cytoskeleton  remodelling-Alpha-1A  adrenergic  receptor-dependent 
inhibition of PI3K (p=0.01); niacin-HDL metabolism (p=0.03); and glutamate 
regulation  of  dopamine  D1A  receptor  signalling  (p=0.04).  Another  study  has 
done  a  pathway-based  analysis  using  the  NIMH  and  WTCCC  GWAS  data 
(Askland  et  al.  2008).  Their  findings  suggest  involvement  of  ion  channel 
structural  and  regulatory  genes,  including  voltage-gated  ion  channels  and  the 
broader  ion  channel  group  that  comprises  both  voltage  and  ligand-gated 
channels.    
 
1.5.4  Copy Number Variations 
 
Recent studies have brought to attention to copy number variations (CNVs) as a 
source  of  genetic  variation  and  a  possible  factor  contributing  to  disease 
(Stankiewicz  et  al.  2002;  Iafrate  et  al.  2004;  Sebat  et  al.  2004).  CNVs  are 
segments of DNA ranging from one kilobase to several megabases, for which 
copy-number differences occur due to duplication, insertional  transposition or 
deletion events (Feuk et al. 2006; Redon et al. 2006). CNVs can disrupt a gene’s 
function by occuring within the gene or in regulatory regions. CNVs may also 
generate  novel  fusion  proteins,  create  new  imprinting  patterns  and  create 
differential allelic expression (Lupski et al. 2005).  
 
Rare  CNVs  have  been  associated  with  mental  retardation,  autism  and 
schizophrenia (de Vries et al. 2005; Stefansson et al. 2008; Weiss et al. 2008). In   70 
addition, recent data has been published implicating CNVs in BP. A study done 
on 46  individuals  in a three-generation Old Order Amish pedigree, using the 
Illumina HumanHap550 BeadChip, has identified 50 CNV regions that ranged in 
size from 12 to 885 kb (Yang et al. 2009). 19 of these CNVs regions were well 
characterized regions and were compared with expression data and 11 (58%) 
were associated with expression changes of genes within, partially within or near 
these CNV regions  in  fibroblasts or lymphoblastoid cell  lines at a nominal P 
value <0.05. A set a set four CNVs, located at 6q27, 9q21.11, 12p13.31 and 
15q11, were more present in cases than controls. The variants were affecting the 
expression of neuronal genes within or near the CNVs. A second study on a 
small sample of 35 control, 35 schizophrenia and 35 BP patients was carried out 
using  the  bacterial  artificial  chromosome  (BAC)  array  comparative  genome 
hybridization  (aCGH)  (Wilson  et  al.  2006).  The  CNV  analysis  showed 
aberrations  in  BAC  clones  containing  regions  1p34.3,  14q23.3  and  22q12.3. 
These three clones were found to contain brain-expressed genes GLUR7, GRM7 
AKAP5  and  CACNG2.  These  genes  are  involved  in  glutamate  signalling  on 
bipolar and schizophrenia patients.    
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1.6  Mouse as an animal model 
` 
Genes  cannot  be  manipulated  in  humans,  therefore  scientists  turn  to  other 
organisms to investigate gene  function. Animals such as the  fruit  fly and the 
nematode worm have been used in the past. However, over the past century, the 
mouse has developed into the premier animal model system for genetic research.  
 
Analysis of the mammalian lineage indicate that mice and humans diverged 75 
million  years ago, which  is a recent evolutionary event (Madsen et al. 2001; 
Murphy et al. 2001). Both groups share similar body plans, organ systems and 
mechanisms  of  physiological  regulation.  Mice  and  humans  genomes  are  also 
arranged in a similar pattern. Their genomes share roughly the same size, contain 
the  same  number  of  genes  and  a  large  proportion  of  the  mouse  and  human 
genomes are syntenic, which means that they possess chromosomal regions with 
the same order of genes. In addition, approximately 99% of mouse genes have 
human counterparts. Conversely, mouse orthologs can be identified for 99% of 
human genes (Tecott 2003).  
 
The existence of a cortex and other evolutionary adaptations in humans make the 
human  brain  and  behaviour  much  more  complex than  in  mice. However, the 
brains  of  vertebrates  share  a  common  structural  organization  and  the  brain 
structure is well conserved among mammals.  This means that even though there 
are differences, the extensive neuroatomical and genetic homologies give rise to 
a  wide  variety  of  behavioural  processes  that  are  conserved  between  species 
(Tecott  2003),  such  as  hunger,  fear,  aggression,  sleep,  circadian  rhythms, 
classical  and  operand  conditioning  and  sexual  behaviour.  Also,  there  are   72 
behavioural  responses  to  drugs  that  are  common  among  humans  and  mice. 
Looking at the genetic perturbations and behaviour, there are mutated genes that 
have similar effects in both species. An example is a behavioural disturbance 
caused  by the  monoamine oxidase  A gene, where both species  become  more 
aggressive and display impulsive sexual behaviours towards females (Brunner et 
al. 1993; Cases et al. 1995). In addition, the hypothalamic neuropeptide orexin 
gene  when  mutated  in  both  humans  and  mice  cause  sudden  episodes  of 
inactivity.  This  syndrome  is  denominated  narcolepsy  (Chemelli  et  al.  1999; 
Nishino  et  al.  2000;  Peyron  et  al.  2000).  We  must  remember  that  not  all 
mutations  will  result  in  similar  phenotypes  in  the  two  species,  which  is  a 
consequence  of  the  evolutionary  differences  between  them.  Despite  these 
discrepancies, mice still are a valuable tool on the study of genes and behaviour.  
 
One of the key events that turned the mice into a successful tool in science was 
the development and application of new molecular technologies. Strategies, such 
as  transgenic  and  gene  targeting,  are  used  to  generate  lines  of  mice  with 
enhanced, reduced or altered gene expression. This allows precise engineering of 
genetic alterations to study the neuronal basis of behaviour (Tecott 2003; Holmes 
et al. 2004). Also the capacity of create homozygous populations of mice through 
inbreeding  techniques  permitted  minimization  of  the  extent  to  which  genetic 
factors contribute to variability in response to experimental manipulations. This 
is an advantage since the strains possess a unique set of alleles and these results 
in distinct biological properties such as size, cancer susceptibility or behavioural 
traits (Tecott 2003).   73 
In addition to all the advantages mentioned before, there are also economical and 
practical issues that make mice popular in labs. Mice are small, easy to maintain 
in the laboratory and (compared to most mammals) have a short breeding cycle 
(about  2  months).  They  can  produce  4  to  15  offspring  per  litter  and 
approximately one litter every month (Wolfensohn et al. 2003).  
All of these reasons  make  mice  very useful  in  the study of genes, and  more 
specifically in the study of behavioural disorders. Mouse models are beginning to 
be developed for bipolar disorder. Since bipolar disorder is a complex disease 
with heterogeneous type of behaviours, an endophenotype based research that 
focuses specific behaviours in transgenic or normal mice have been carried out. 
There are models that focus on features of depression and others that have been 
used to assess manic behaviours (Cryan et al. 2007). An example of a mouse 
mania model was developed by manipulating hippocampal GluR1 and GluR2 
receptors resulting in manic-like behaviour (Du et al. 2008). There is also a study 
with  lamotrigine  where  researchers  study  its  antidepressant-like  effect  in  the 
mouse and also the involvement of the noradrenergic system (Kaster et al. 2007).  
Kato et al used the mouse as a model to study the effect of mitocondrial DNA 
mutations in the mouse brain. They produced a mouse with mitochondrial DNA 
deletions that presented bipolar-like behaviours (Kato 2006). 
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1.7  Slynar and IGF1  
1.7.1  Slynar 
A maximum lod score of 2.11 to bipolar disorder was found on chromosome 
12q23-q24.1 (Dawson et al. 1995). Later a lod score of 3.67 and sib pair linkage 
p value of 0.00003 at 12q23-24 was published (Ewald et al. 1998; Ewald et al. 
2002). A haplotype sharing study of 12q24 in a genetic isolate also confirmed 
this  region  being  linked  to  bipolar  disorder  (Degn  et  al.  2001).  In  Canada, 
(Morissette et al. 1999; Shink et al. 2005) a kindred showed linkage to bipolar 
affective disorder at 12q23-12q24 with a lod of 3.35.  Multiply affected families 
with  just unipolar affective disorder have also shown  very good evidence  for 
linkage  at  C12q22-24  with  a  multipoint  heterogeneity  LOD  score  of  6.1 
(p=0.0000007) (Abkevich et al. 2003). A genome wide scan in a sample of 60 
affected  sibling  pairs  (ASP)  in  Irish  families  gave  suggestive  evidence  for 
linkage at 12q24. The p values for the results of the multipoint linkage analysis 
were  p=0.0146  and  with  the  pairwise  linkage  analysis  gave  a  p=0.043892 
(Cassidy et al. 2007).  
 
The UCL linkage study of 12q22-24 gave a lod of 2.7 (Curtis et al. 2003). The 
region was investigated by fine mapping to find the exact position of a bipolar 
susceptibility locus on 12q24 in two case-control association samples originating 
from Denmark and the UK. In a sample of 681 bipolar cases and 550 controls 
statistically  significant  allelic  association  with  bipolar  disorder  was  found  for 
twelve markers (Kalsi et al. 2006). The region covered in represented in Figure 
1.2. The pattern of allelic association was similar in the Danish and UK samples.   75 
In the Danish sample the most significant single marker association was with the 
microsatellite  307CA2  (p  =  0.0014).  The  most  significant  single  marker 
association  in  the  UK  sample  was  with  D12SDK1  (p  =  0.0002).  Tests  of 
haplotype  association  in  the  UK  sample  with  the  markers  29818insT  and 
307CA1 gave a permutation test pValue of 0.0013. A three marker haplotype 
was also significantly associated with bipolar disorder in the UK sample with 
permutation test p value of 0.0079. The results validate the earlier linkage studies 
and strongly implicate a 300kb region on 12q24 that contributes to the aetiology 
of affective disorders.  
 
 
Figure 1.2 Schematic of the 2Mb region on chromosome 12q24 that surrounds Slynar gene. 
The  genes  Skoynar,  Slynar  and LOC121296  are  transcribed  from  the  sense  strand  and 
LOC338825, Pufu, Slanar and LOC440117 are transcribed from the antisense strand. Fine 
mapping in the UCL and Danish samples had implicated a 300 Kb region (indicated by the 
red square) in which Slynar was the most promising candidate gene (Kalsi et al. 2006). The 
genetic  distance  was  obtained  from  UCSC  genome  browser,  version  May  2004.  Figure 
adapted from (Kalsi et al. 2006).  
 
   
Within  the  300  Kb  region,  using  RT-PCR  on  brain  mRNA  several  CNS 
expressed sequences in this region were identified (Figure 1.2). The identified 
genes were Slynar, Pufu and Slanar. The most promising candidate gene in this 
300  kb  region  is  denoted  Slynar  in  the  Aceview  database  (Unigene  cluster 
Hs.369455)  or  AY070435  in  the  UCSC  genome  browser,  since  Slynar  bears 
homology to a macaque brain-expressed cDNA and to a chimpanzee genomic 
sequence (Kalsi et al. 2006). The region is not well characterised in terms of 
125,878,922  125,673,105 
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transcription, alternative splicing and protein translation and no known function 
has been attributed to this gene. So far, four alternative splice variants have been 
found  in  mRNA  samples  from GeneBank (Figure 1.3): AY070435 or Slynar, 
which is the hypothetical protein, and the cDNA was found in a brain sample 
(Guo  et  al.  2001);  AK091521  is  a  foetal  brain  cDNA  (Ota  et  al.  2004); 
BC039096 is a IMAGE clone found in testis (Strausberg et al. 2002); CR615184 
is  a  clone  found  in  human  foetal  brain  (Li  et  al.  2004).  Slynar  has  been 
sequenced  to  identify  aetiological  base  pair  changes,  however  up  to  now  no 
changes  were  found  to  be  associated  with  disease.  On  the  reverse  strand  of 
Slynar another brain expressed cDNA was detected. This gene is denominated 
Slanar or LOC387895 by ACEVIEW and BC069215 by UCSC browser (Figure 
1.2). However, due to the stronger homology to primates, Slynar was chosen for 
functional studies in this region and not Slanar.     
 
The study of early onset forms of a disorder has proved a successful strategy in 
the  mapping  of  genetic  traits.  It  has  been  found  that  the  risk  to  first  degree 
relatives  is  elevated  in the  families of  bipolar probands with early onset. An 
analysis of the UCL bipolar sample data was done grouping people with an early 
onset, <21 yrs, using OPCRIT and SADS-L data (n=313). Allelic association 
was  tested  by  comparing  this  group  against  controls  (n=644)  for  30  markers 
between 1634tet and D12SDK1. Chi squared and CLUMP tests were used where 
appropriate.  Haplotype  analysis  using  GENECOUNTING  was  performed.  As 
previously reported seven 12q24 markers were associated with bipolar disorder 
the full UCL sample (Kalsi et al. 2006). Increased evidence for allelic association 
was observed in the early onset group. A total of ten markers were found to be   77 
associated, generally at increased levels of significance. Haplotype analysis also 
yielded increased evidence for association with pValues ranging from <0.0001 to 
0.02. Reference to HapMap data indicates that a relatively common haplotype 
containing the minor (A) allele of the SNP rs7133178 may harbour aetiological 
changes. This SNP is in the intron of Slynar however is in the exon of BC069215 
(LOC387895), the gene that is located on the negative strand.  
 
 
Figure 1.3 Alignment of Slynar (AY070435) and its alternative splicing transcripts with the 
genomic DNA (figure taken from UCSC genomic database, assembly March 2006). On the 
top,  the  continuous  grey  bar  represents  the  chromosome  band  demarking  the  relative 
location. Below are represented all the human  mRNAs found to be expressed from this 
region. The sequence is represented by small black boxes and thinner line with arrows. The 
black boxes correspond to exons and the thinner line represents the introns. The arrows 
show the direction of the gene’s transcription. The red arrows (on the left of the legend) 
indicate  four  transcripts  correspondent  to  Slynar  and  the  alternative  splicing  products: 
AY070435, BC039096, AK091521 and CR615184. The remaining transcripts do not refer to 
Slynar, as they are transcribed from the antisense strand. In exon 3 and 4 of AY070435 
sequence, the orange bands correspond to a difference in the sequence between the genome 
and the mRNA found.  
 
1.7.2  IGF1 
Insulin Growth Factor 1 (IGF1) is a 70 amino acid peptide that shares homology 
with  insulin  (Rotwein  1991).  IGF1  actions  are  mediated  by  a  cell  surface 
receptor called the Type 1 IGF Receptor (IGF1R). IGF1R is widely expressed in 
the brain, being concentrated in neuron rich structures such as hippocampus and 
the  olfactory  bulb  (Aberg  et  al.  2006).  These  receptors  are  receptor tyrosine 
kinases. After IGF1 binds IGF1R, it induces autophosphorylation of the insulin 
Chromosome location on 12q24 (bp) 
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receptor substrate (IRS) adaptor proteins. These IRS proteins bind to tyrosine 
phosphate  docking  sites  on  the  activated  receptors,  undergo  phosphorylation 
themselves,  and  then  recruit  additional  signalling  proteins  to transduce  IGF1 
actions (Bondy et al. 2004). Additionally, actions of IGF1 are modulated by a 
group of cystine-rich IGF-binding proteins (IGFBPs). Six different IGFBPs have 
been  characterized  to  date,  and  they  prolong  IGF1  half  life  by  impending 
proteolysis and modulate the peptide’s interaction with IGF1R (Duan 2002). 
 
Apart from regulating somatic growth and metabolic processes, IGF1 has many 
functions in the brain. The best established activity of IGF1 is its crucial role in 
brain development (Russo et al. 2005). In the adult, IGF1 is a pleiotropic peptide 
involved  in  numerous  processes  to  maintain  brain  homeostasis.  At  a 
cellular/molecular level, IGF1 acts in basic energy regulatory loops, cell sorting 
and cell to cell communication, among others, making this peptide essential for 
normal  brain  function  (Trejo  et  al.  2004).  At  a  system  level,  IGF1  acts  on 
neuronal specific traits such as synaptic plasticity and neurotransmission. IGF1 
also has an extensive neuroprotective activity (Fernandez et al. 2007). IGF1 is 
expressed in the brain, especially during brain development and in response to 
injury (Bondy et al. 1991; Lee et al. 1993). IGF1 can also be transported to the 
brain  through  the  blood  brain  barrier  (Reinhardt  et  al.  1994).  It  has  been 
suggested  that  IGFBP,  which  is  abundantly  expressed  along  the  blood-brain 
barrier, may help IGF1 be transported into the brain (Lee et al. 1993; Reinhardt 
et al. 1994).  
Indirect evidence suggests that stress and depression inhibit neurogenesis in the 
adult hippocampus, which leads to the notion that hippocampus cell proliferation   79 
and neurogenesis may be a target for the treatment of depression (Kempermann 
et  al.  2003;  Santarelli  et  al.  2003).  IGF1  is  present  in  the  adult  brain  in  the 
hippocampus  and  the  olfactory  bulb  (Kar  et  al.  1993).  Repeated  systemic  or 
central administration of IGF1 has been shown to increase neurogenesis in the 
dentate gyrus of the hippocampus (Aberg et al. 2000). It has also been shown 
that increase of neurogenesis by exercise may be mediated by IGF1 (Trejo et al. 
2001).  In  addition,  it  was  reported  that  chronic  administration  of  the 
antidepressants venlafaxine and fluoxetine increased the protein levels of IGF1 in 
the hippocampus (Khawaja et al. 2004). In a recent paper, central administration 
of IGF1 in mice has shown to have an antidepressant-like effect (Hoshaw et al. 
2005). A recent review has linked antipsychotic drug mechanisms, the insulin 
signalling  pathway  and  possible  abnormalities  in  this  pathway  with 
schizophrenia (Girgis et al. 2008). 
 
1.7.2.1  IGF1 GWAS results 
A GWAS study was carried out on 506 UCL bipolar cases and 510 controls, 
together with an American STEP-BD sample (Sklar et al. 2008).  
In this study, 10 out of 37 SNPs covering the IGF1 region were found to be 
associated with BP (Table 1. Table   8.7). Five of the associated SNPs (rs5742688, 
rs2072592, rs12423791, rs4764698, rs5742615) are located within the gene in 
the intronic regions with p values ranging from 0.0057 to 0.000037. The other 
five markers are located upstream IGF1, in the putative promoter region of IGF1. 
These markers span a region of approximately 3000 bp. However, it is known 
that promoter control regions can be as far as 14.5 kb (Ho et al. 2006).   80 
Assessing  Hardy-Weinberg  equilibrium  (HWE)  is  often  employed  as  an 
important  initial  step  for  genotype  data  quality  checking  in  genetics  studies 
(Nielsen et al. 1999). All the UCL data was checked for HWE. The only SNP 
that was out of HWE was rs5742615. This is the most significantly associated 
SNP (p=0.000037). Analysis of all data was done in the presence and absence of 
this SNP, and it had no effect on pValues. 
Table 1.4 Tests of association  of SNPs in IGF1 region in the UCL GWAS data. UCSC 
March 2004 assembly positions. * SNP out of Hardy-Weinberg Equilibrium. 
Marker Marker Location χ2 P value
rs5742688 G A
Controls 101314993 13 0.013 1001 0.987 7.637 0.0057
Cases 31 0.031 977 0.969
rs2072592 G A
Controls 101316099 992 0.973 28 0.027 11.152 0.00080
Cases 1004 0.992 8 0.008
rs12423791 C G
Controls 101361295 989 0.973 27 0.027 13.334 0.00030
Cases 998 0.994 6 0.006
rs4764698 G C
Controls 101362527 987 0.973 27 0.027 13.375 0.00030
Cases 998 0.994 6 0.006
rs5742615* G T
Controls 101373268 1002 0.969 31 0.031 17.006 0.000037
Cases 1002 0.994 6 0.006
rs35765 C A
Controls 101384163 85 0.083 935 0.917 5.257 0.0219
Cases 115 0.114 897 0.886
rs2607983 A G
Controls 101402171 114 0.112 904 0.888 7.153 0.0075
Cases 154 0.152 858 0.848
rs12309723 A C
Controls 101425980 975 0.956 45 0.044 3.969 0.0464
Cases 984 0.972 28 0.028
rs703542 G C
Controls 101443545 135 0.133 881 0.867 4.975 0.0257
Cases 170 0.168 840 0.832
rs703548 G A
Controls 101447140 139 0.137 879 0.863 4.04 0.0444
Cases 170 0.169 838 0.831
Alleles and Observed AlleleFrequencies
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2  Aims of the Project 
The objective of the project was to study two susceptibility genes for bipolar 
disorder that are located in the linkage to bipolar disorder region 12q23-24.  
 
My aim was to characterize Slynar and to attempt to find out what function it has 
in the human brain. In order to achieve that, studies were done in a mouse model 
and in human cell lines. The first step of this project was to find a homologous 
RNA  transcript  of  Slynar  in  the  mouse.  To  detect  the  gene  and  confirm  its 
sequence,  techniques  such  as  RT-PCR,  qPCR,  cloning  and  sequencing  were 
used. Once confirmed Slynar expression in the mouse, attempts to obtain a full 
cDNA clone of Slynar through RACE and cDNA library screening were done. In 
addition, a northern blot was done to evaluate where Slynar was expressed in the 
mouse, how many alternative transcripts can be found and what are the sizes of 
the different transcripts. Similarly to what it was described for the mouse project, 
studies  to  detect  and  characterise  Slynar  in  the  human  were  carried  out  in 
neuroblastoma SH-SY5Y cells, differentiated and non-differentiated into mature 
neurons, and in human brain RNA. In addition to detection of the gene by RT-
PCR and qPCR and detection of a Slynar cDNA clone by RACE and cDNA 
library screening, knock out assays of Slynar in SH-SY5Y cells were also done 
to try to analyse the effect of the gene silencing in the cells.    
 
As showed in section 1.6.2 of this thesis, through the analysis of GWAS data 
IGF1 was implicated in bipolar disorder. My aim was to sequence IGF1 to find 
possible aetiological base pair changes and to understand how these changes may 
affect  the  gene’s  function  and  its  pathways.  Any  SNPs  or  polymorphic   82 
microsatellites  found  by  sequencing  were  genotyped  using  Kaspar,  Melting 
Curve analysis or Polyacrilamide gels methodologies. Association analysis was 
carried out using Chi square tests, with the exeption of the microsatellites that 
were analysed using the statistical software CLUMP. All haplotypic analysis was 
carried out using GENECOUNTING and whole genome significance analysis 
was done by COMBASSOC.  
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3  Methodology 
3.1.1  DNA Extraction 
3.1.1.1  DNA Extraction from Whole Blood Cells 
Genomic DNA was extracted from whole blood samples using a standard cell 
lysis, proteinase K digestion, phenol/chloroform ethanol precipitation method. It 
is a two day method. In the first day the leukocytes are isolated and then lysed to 
release the genomic material, followed by overnight digestion of proteins with 
proteinase K. The second day involves the isolation and extraction of genomic 
DNA. The DNA was extracted from fresh blood if it was practical to do so. 
Otherwise the blood was stored at -80
0C. 
On day one… 
If the blood was stored at -80
 oC, it was allowed to gently thaw out in a water 
bath at 30-35
oC. This was done to prevent the cells from lysing from shock and 
the release of damaging enzymes such as DNase. 
The  fully thawed blood was then transferred to 50ml  centrifuge tubes, which 
were then topped to 50ml with 1x lysis buffer. The tube was inverted several 
times to ensure mixing. This allowed the lysis buffer to break up the whole red 
blood cells (erythrocytes) whilst leaving the DNA containing white blood cells 
(leukocytes) intact. The lysate was then spun in a balanced centrifuge at 3000rpm 
(2000g) at 4
oC for 15 minutes to pellet and isolate the white blood cells. The 
pellet was re-suspended in 50ml of 1x lysis buffer to remove any remaining red 
blood cells and again centrifuged at 3000 rpm for 15 minutes.    84 
The cleaned white blood cell pellet was re-suspended in 500µl of 10% sodium 
dodecyl sulfate (SDS), which would break open the cells by disrupting the lipid 
membrane,  hence  releasing  its  contents  including  the  genomic  DNA  into  the 
solution.  In  addition,  10ml  proteinase  K  buffer  was  added  to  provide  stable 
optimum conditions for the proteinase K enzyme. To the lysate, 50µl of 20mg/ml 
proteinase  K  was  mixed  in.  The  presence  of  the  enzyme  would  break  down 
complex protein allowing for their efficient removal and also to deactivate any 
damaging enzymes such as DNAase. This lysate was incubated in a water bath at 
55
oC (just below the optimum temperature of proteinase K at 65
 oC) on a shaking 
platform overnight, to allow for the reaction to occur as far as possible. 
On day two… 
5ml of buffered phenol along with 5ml of chloroform (1:24 Isoamyl alcohol: 
chloroform) was mixed with the cell lysate. The phenol-chloroform mixture is 
used to dissolve the lipids and agglomerate the proteins. After centrifugation, 
layers  do  appear.  The  nucleic  acids  will  be  on  the  top  aqueous  layer  while 
agglomerated protein would be lower down.  
The mixture was then centrifuged at room temperature for 15 min at 3000rpm 
which  allow  the  mixture  to  separate  out  into  the  organic  solvent  (phenol-
chloroform) layer at the bottom (containing lipids), the protein interphase, and on 
top  the  aqueous  layer  containing  the  nucleic  acid.  This  aqueous  layer  was 
transferred into a fresh labelled 50ml centrifuge tube for DNA precipitation. The 
organic solvents are disposed of safely according to UCL’s  health and safety 
disposal of hazardous solvents protocol.   85 
It is difficult to extract the aqueous layer up to the interphase without disturbing 
the layer itself. So we used 1 gram of PVPP (Polyvinylpolypyrrolidine) mixed 
with 5ml of TE to improve the separation of layers. Once centrifuged with the 
organic  mixture,  PVPP  will  hold  down  the  protein  interphase  along  with  the 
organic solvents allowing one to remove the maximum amount of the aqueous 
layer without contamination. 
From this aqueous layer, DNA was precipitated by adding 1500µl of 3M Sodium 
Acetate. 30ml of absolute ethanol are added to the tube and then the tube was 
inverted gently until the DNA precipitated out of solution into a condensed white 
clump.  
The DNA clump was removed with a plastic rod and then washed in 70% ethanol 
to remove as much sodium acetate as possible, in order not to interfere with the 
Polymerase Chain Reaction (PCR). The DNA clump was then transferred into a 
labelled 1.5ml micro screw tube containing 500µl of TE. The DNA samples were 
stored away from light at room temperature for about a week. This was to allow 
the DNA to dissolve into solution before quantification. 
 
3.1.1.2  DNA Extraction from Saliva Samples 
The Oragene DNA Self-Collection Kit (Oragene) is a non invasive method of 
collecting  DNA  samples  from  patients.  This  is  an  all-in-one  system  for  the 
collection, preservation, transportation and purification of DNA from saliva.   86 
Donor  patients  give  a  saliva  sample  into  the  base  of  an  Oragene  sample 
collection kit. The lid of the container has a preservative which stabilizes the 
DNA, and allows the samples to be kept up to 5 years at room temperature. The 
preservative in the lid is released when the lid is tightened immediately after the 
saliva collection.  
Next step was the incubation of the container with the sample in a water bath at 
50C  for 1  hour. 160µL of Oragene DNA Purifier  it was added to 4  mL of 
sample and this was incubated in ice for 10 minutes. Then, the samples were 
centrifuged at high speed for 10 minutes at room temperature. The pellet was 
discarded and an equal volume of room temperature absolute ethanol was added. 
The samples were well mixed until a DNA precipitate could be seen, and the 
sample was left standing at room temperature for 10 minutes to allow the DNA 
to  fully  precipitate.  The  samples  were  then  centrifuged  at  high  speed  for  10 
minutes at room temperature. The supernatant was discarded and the DNA pellet 
was left to dry. The DNA was rehydrated in 500µL of TE and stored at room 
temperature, protected from light, for a week. This allowed the DNA to dissolve 
completely. 
 
3.1.2  DNA Quantification 
3.1.2.1  Quantification of Saliva and Whole Blood DNA Samples 
All DNA samples were quantified with Picogreen (Molecular Probes), in a Light 
Cycler480 (Roche).   87 
The DNA samples were quantified  by transferring 2µl of each sample  into a 
fresh labelled 2ml microcentrifuge tube containing 78µl of TE. These tubes were 
thoroughly mixed and 2µl of each of these samples were transferred to 96 well 
plate, containing 18µl of TE. Along side the samples to be quantified was  a 
series  of  wells  containing  known  concentrations  of  DNA  derived  from  calf 
thymus. This was diluted to produce samples at 0, 1, 10, 20, 50, 75 and 100ng/µl. 
This was done in order to produce standard curve from which the concentration 
of the samples could be derived from. 
The  DNA  samples  were  mixed  with  20µl  of  Picogreen  (150µl  Picogreen 
dissolved in 30ml of TE) which is a fluorescent dye which specifically binds to 
double stranded DNA. The fluorescence is directly proportional to the quantity of 
DNA  present.  From  the  results,  some  of  the  DNA  was  diluted  into  a 
concentration of 25ng/µl for direct use. The rest was labelled as stock with its 
known concentration. All DNA is stored below 5
0C in a dark place to maintain 
its quality. 
 
3.1.2.2  Quantification of cDNA and plasmid DNA 
For the quantification of DNA samples, such as cDNA or plasmid DNA that 
resulted  from  bacterial  purification,  was  used  a  NanoDrop
®  ND-1000 
Spectrophotometer (Thermo Scientific). This spectrophotometer measures DNA 
samples  up  to  3200  ng/mL  without  dilution  and  with  high  accuracy  and 
reproducibility. It uses a spectrum range from 220 to 750 nm. A 1 µl sample was 
pipetted onto the end of a fiber optic cable (the receiving fiber). A second fiber 
optic  cable  (the  source  fiber)  was  then  brought  into  contact  with  the  liquid   88 
sample causing the liquid to bridge the gap between the fiber optic ends. The gap 
was  controlled  to  both  1mm  and  0.2  mm  paths.  A  pulsed  xenon  flash  lamp 
provides the light source and a spectrometer utilizing a linear CCD array was 
used to analyze the light after passing through the sample. The data was then 
analyzed by the ND-1000 PC software. 
 
3.1.3  RNA Extraction 
3.1.3.1  RNA Extraction from Tissue 
Different  body  tissues  (brain,  cerebellum,  liver,  lungs,  heart  and  testis)  were 
extracted  from  adult  mice.  The  animals  were  killed  under  the  Schedule  1, 
appropriate  methods  of  human  killing,  which  came  to  effect  in  1997.  The 
sacrifice  was  done  by  exposure  to  carbon  dioxide  in  a  rising  concentration, 
followed by the dislocation of the neck, to ensure that the killing process was 
completed (Wolfensohn et al. 2003). 
 
1 ml of TRIZOL Reagent (Invitrogen) was added to each 50 to 100 mg of mouse 
tissue. The tissue was homogenized with the homogenizer DIAX 900 (Heidolph), 
and samples were incubated at room temperature for 5 minutes. After adding 200 
µL  of  chloroform  to  each  sample,  the  tubes  were  shaken  vigorously  for  15 
seconds and stored at room temperature for 15 minutes. The samples were spun 
down  in a  microcentrifuge (centrifuge 5417R, Eppendorf) at 12,000 g for 15 
minutes  at  4  C  to  phase  separate  the  sample.  To  precipitate  the  RNA,  the 
aqueous phase was transferred to a fresh tube and 500 µL of isopropanol was 
added.  The  samples  were  stored  at  room  temperature  for  10  minutes  and   89 
centrifuged at 12,000 g for 10 min at 4 C. The supernatant was removed and the 
pellet was washed by vortexing in 1mL 75% ethanol. This was centrifuged at 
7,500 g for 5 min and 4 C. In the end, the pellet was air-dried for 3 to 5 minutes 
and ressuspended in 100 µL of RNAse free water. 
 
3.1.3.2  RNA Extraction from Cells 
Cells were grown  in a 75 cm
2 T-Flask  following the  normal growth routine. 
When the 100% confluency was reached, 1 mL per 10 cm
2 (area based on the 
culture dish) of TRIZOL Reagent (Invitrogen) was added to lyse the cells. The 
subsequent  procedure  is  similar  to  what  it  is  done  with  homogeneized  tissue 
samples (see section 3.1.3.1). A chloroform and isopropanol RNA extraction was 
done, followed by rehydration of RNA in RNAse free water.  
 
3.1.3.3  Total and PolyA
+ RNA Purification 
To purify total RNA the RNeasy
® Mini Kit (Qiagen) was used. This technology 
combines the selective binding properties of a silica-gel-based membrane with 
the speed of microspin technology. The protocol followed was the RNeasy
® Mini 
Protocol for RNA cleanup from the RNeasy
® Mini Handbook (June 2001). These 
samples were subjected to DNaseI treatment, as described in the same handbook. 
 
Two different kits were used for the purification of poly A
+ RNA. The Oligotex
® 
mRNA  Kit  (Qiagen)  is  based  on  spin  columns  purification  and  the  mRNA 
Isolation Kit (Roche) uses magnetic separation. In the Oligotex
® mRNA Kit spin 
columns are used which have an affinity reagent, oligotex suspension, for the   90 
detection,  isolation  and  purification  of  nucleic  acids  containing  a  poly  A
+ 
sequence. The protocol followed was the Oligotex mRNA Spin-Column Protocol 
from the Oligotex
® Handbook (May 2002). In the mRNA Isolation Kit (Roche), 
a biotin-labeled oligo(dT)20 probe and streptavidin magnetic particles are added 
to total RNA. The biotin probe will bind to the poly A
+ sequence which has high 
affinity  to  bind  streptavidin  particles.  With  a  magnetic  separator  streptavidin 
magnetic particles are captured and with them the mRNA. The protocol used was 
from the kit’s instruction manual (Roche, June 2005). 
 
With the Oligotex
® mRNA Kit the poly A
+ RNA samples were cleaner, however 
with mRNA Isolation Kit the obtained yields were higher.  
 
3.1.4  RNA Quantification and Quality Assessment 
The Agilent 2100 bioanalyzer (Agilent Technologies) is an analytical instrument 
based on lab-on-a-chip technology. The system uses a miniature glass chip that 
contains a network of interconnected channels and reservoirs. The channels are 
filled with a gel matrix, composed by a sieving polymer and a fluorescence dye, 
and  there  are  wells  for  buffer  and  the  sample.  Sample  components  are 
electrophoretically  separated  and  detected  by  the  emission  of  fluorescence. 
Analysis is done on gel images and electropherograms (Figure   3.1). These allow 
total RNA and mRNA quantification and accurate quality evaluation.    
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Figure    3.1  An  example  of  a  total  RNA  electropherogram  analysis.  A:  Intact  total  RNA 
sample; B: Partially degraded total RNA sample (Reagent Kit Guide; Edition 2003, Agilent 
Technologies). 
 
To prepare the chip and to analyse the RNA samples on the 2100 bioanalzer I 
used the RNA 6000 Nano Assay (Agilent Technologies) and the Reagent Kit 
Guide (Edition 2003) protocol was followed. The RNA Integrity Number (RIN) 
is calculated to give a better quantitative evaluation of the quality of the RNA. 
Values  obtained  were  within  the  range  expected  for  good  quality  RNA. 
However, these results were lost due to a software upgrade done to the system. 
 
When a simple quantification of the RNA sample was required, the Nanodrop 
system was used (  3.1.2.2). 
 
3.1.5  cDNA Synthesis 
For  the  conversion  of  total  RNA  or  mRNA  into  cDNA  anchored  oligo  dT 
primers (Promega) were used, or random nonamers primers (Promega), or a mix 
of both. 
 
For  the  primer  annealing  reaction,  the  following  were  added  to  a  0.5  mL 
microcentrifuge tube: (1) mRNA between 50 ng to 1 µg; (2) 1µL of the primers; 
(3)  RNase  free  water  (Ambion)  up  to  a  total  volume  of  11µl.  The  reaction 
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mixture was incubated at 70 C for 10 min and immediately put on ice to allow 
primers to anneal with mRNA template. For the extension process the following 
were added to the tube: 10X First Strand Reaction, 0.1 M DTT, 50 mM dNTP 
mix and 10 U of SuperScript III Reverse Trancriptase, in a total volume of 20 
µl (All reagents from Invitrogen). These reaction mixtures were incubated at 42 
C  for  1.5  hours  for  the  extension  process.  In  the  end,  cDNA  can  be  used 
immediately or stored at -20 C. 
 
As a negative control in subsequent PCR reactions, Reverse Transcriptase (RT) 
was not added to some of the RNA samples. This means that if any amplification 
occurs during PCR it was due to gDNA contamination.  
 
3.1.6  Primer Design 
Primers  were  generally  15-25  nucleotides  long  for  specific  targeting  and 
amplification and must span the specific region of interest.  
 
Primers  were  designed  using  the  Primer3  software,  developed  by  MIT 
Whitehead Institute (Rozen et al. 2000). It is free software, which is available on 
the internet (http://frodo.wi.mit.edu/). Primer 3 uses algorithms to pick up primer 
sequences, taking in consideration the following parameters:  
(a) sequence specificity; 
(b) avoidance of repetitive sequences; 
(c) forward and reverse primers with similar melting temperatures (Tm);   93 
(d) pairing of primers with a low probability of forming loops (which would 
decrease amplification efficiency).   
 
For sequencing reactions, M13 tails (Table   3.1) were added to the 5’ end of the 
forward  and  reverse  primers.  These  M13  sequences  worked  as  sequencing 
priming binding sites during subsequent sequencing amplification reaction. This 
makes  the  whole  sequencing  procedure  easier,  since  in  all  the  sequencing 
amplification reactions only one pair of M13 primers were used, regardless of the 
region to be sequenced. After adding the M13 tail to the primers 5’ end, the 
entire  primer  sequence  was  checked  to  see  if  secondary  structures  such  as  a 
hairpin  loop  would  inhibit  the  amplification.  This  was  checked  by  using  the 
OligoCalc:  Oligonucleotide  Properties  Calculator  (Kibbe  2007) 
(http://www.basic.northwestern.edu/biotools/oligocalc.html).  For  genotyping 
reactions a similar procedure is followed, but the M13 tail is only added to one of 
the primers. The addition of the M13 tail to the forward or reverse primer will 
depend  on  the  secondary  structure  formation,  which  was  checked  using 
OligoCalc.  
 
Table   3.1 M13 tails sequences. 
M13  M13F CACGACGTTGTAAAACGAC  M13R GGATAACAATTTCACACAGG 
 
 
After being designed, the primers were ordered from Sigma Genosys and diluted 
in TE buffer at a concentration of 100 µM. 
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3.1.7  Polymerase Chain Reaction (PCR) 
3.1.7.1  Mastermix for General Optimization and Amplification 
Newly designed primers need to be optimised to find the optimal master mix 
concentrations and PCR conditions to produce the best results and a successful 
amplification of the targeted region. Optimisation was carried out on a few DNA 
samples  that  have  been  excluded  from  the  study  and  PCR  products  were 
visualised on agarose or polyacrylamide gels.  
 
For optimisation of primers, four common master mixes conditions were used to 
amplify the target region (Table   3.2). These master mixes can be manipulated to 
produce  the  optimal  conditions  by,  for  example,  altering  the  magnesium 
concentration  or  by  the  presence  or  absence  of  betaine.  The  magnesium  ion 
concentration variation influences the specificity of the PCR reaction and also 
acts as a co-enzyme to the Taq polymerase. The presence of 5M betaine can be 
valuable,  since  betaine  helps  to  reduce  the  melting  point  and  it  is  useful  in 
regions of high GC content. The optimisation conditions that provided the best 
results  were  then  used  to  amplify  the  entire  sample.  Where  the  samples  are 
suboptimal further manipulation of the PCR conditions were performed. 
 
All the  master  mix components were  from Bioline with the exception of the 
primers and the betaine that were from Sigma. 
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Table   3.2 Volumes (µl) of reagents in a single 12µl reaction and the common conditions 
used for primer optimisation and amplification. 
  Condition A  Condition B  Condition C  Condition D 
         
  2.0mM MgCl2 + 
Betaine 
2.0mM MgCl2 +  
No Betaine 
2.5mM MgCl2 + 
Betaine 
2.5mM MgCl2 + 
No Betaine 
         
10X Buffer  1.2  1.2  1.2  1.2 
Betaine 5M  2.4  0  2.4  0 
50mM MgCl2  0.48  0.48  0.6  0.6 
25mM dNTP  0.1  0.1  0.1  0.1 
F  primer 
100pmol/µl 
0.036  0.036  0.036  0.036 
R  primer 
100pmol/µl 
0.036  0.036  0.036  0.036 
M13  800 
100pmol/µl 
       
M13  700 
100pmol/µl 
0.036  0.036  0.036  0.036 
Taq 1U/µl  0.19  0.19  0.19  0.19 
DNA 25ng/µl  2.0  2.0  2.0  2.0 
Water  5.52  7.92  5.39  7.79 
         
Total  Volume 
(µl) 
12.0  12.0  12.0  12.0 
 
 
3.1.7.2  PCR Cycling Conditions 
Once the primers are added to the master mix containing all the required reagents 
for DNA amplification (such as dNTPs, Taq, magnesium and buffer and also the 
genomic template) the PCR can begin. The PCR was run on the PCR thermal 
cycler MWG-HT Primus 96. 
 
The PCR runs in a three step cycle of: 
1.  Denaturation: which typically occurs at 93-95
0C 
2.  Reannealing: where the primers bind specifically to their complementary 
sequence.  The  annealing  temperature  usually  depends  on  the  melting 
temperature (Tm) of the expected duplex. This tends to be approximately 
5
0C below the expected Tm.   96 
3.  DNA synthesis: extension of the complementary strand initiated by the 
annealed primer which occurs at 70-75
0C. 
 
This runs for approximately 25-35 cycles and is finished by a final extended hold 
at 72
0C to complete all synthesis and extensions of the targeted region. After 
about 25 cycles approximately 2
26 copies of the targeted region would be made. 
 
Usually, one of the three standard PCR programs was used to amplify a specific 
region successfully. They are Standard 55
0C, Standard 60
0C and Touch Down. 
These programs can be manipulated to adjust the annealing temperature and by 
adding or removing one or two cycles to obtain a clean specific amplification of 
the target region. The cycles are set out in Table   3.3. 
 
Table   3.3 PCR cycling conditions. 
Standard 55
0C  Standard 60
0C  Touch Down 
Lid Heated to 105
0C  Lid Heated to 105
0C  Lid Heated to 105
0C 
Products  are  denatured  at 
94
0C for 5 minutes  
Products  are  denatured  at 
94
0C for 5 minutes  
Products  are  denatured  at 
94
0C for 5 minutes  
     
35 cycles of:-  35 cycles of:-  3 cycles of:- 
94
0C – 30 seconds  94
0C – 30 seconds  94
0C – 30 seconds 
55
0C – 30 seconds  60
0C – 30 seconds  63
0C – 30 seconds 
72
0C – 30 seconds  72
0C – 30 seconds  72
0C – 30 seconds 
     
Hold at 72
0C – 10 minutes  Hold at 72
0C – 10 minutes  3 cycles of 
Store at 4
0C  Store at 4
0C  94
0C – 30 seconds 
    60
0C – 30 seconds 
    72
0C – 30 seconds 
     
    3 cycles of 
    94
0C – 30 seconds 
    57
0C – 30 seconds 
    72
0C – 30 seconds 
     
    3 cycles of 
    94
0C – 30 seconds 
    54
0C – 30 seconds 
    72
0C – 30 seconds 
     
    3 cycles of 
    94
0C – 30 seconds   97 
    51
0C – 30 seconds 
    72
0C – 30 seconds 
     
    20 cycles of 
    94
0C – 30 seconds 
    48
0C – 30 seconds 
    72
0C – 30 seconds 
     
    Hold at 72
0C – 10 minutes 
    Store at 4
0C 
 
3.1.8  Electrophoresis 
Gel electrophoresis was used to separate DNA fragments according to size. The 
nucleic acid on the gel always runs from the cathode (negative pole) to the anode 
(positive pole), because DNA carries a negative charge due to the phosphodiester 
backbone. As the DNA migrates through the gel matrix the fragments separate 
out according to size with the small fragments migrating faster and further than 
bigger sized amplimers. The more concentrated the gel matrix, and the further 
the  product  has  to  migrate,  the  finer  the  resolution  of  fragment  separation 
becomes. 
 
3.1.8.1  Agarose Gels 
Low resolution agarose gels were used to check on the amplification of PCR 
products. The different sized fragments were separated by electrophoresis. A 1 to 
2% agarose gel was created by dissolving agarose powder (Sigma) in 1x TBE 
(the electrolyte used). A molten solution was created by heating the solution in a 
microwave  until  the  agarose  powder  was  fully  dissolved.  Ethidium  bromide 
(Sigma) was then added and mixed with the cooling molten agarose to make a 
final concentration of 0.5µg/ml. The molten agarose was poured into a sealed   98 
casting plate and a comb was inserted to cast wells within the agarose. The gel 
was then allowed to cool to set. 
 
When the gel was set, the comb was removed to form the wells and the gel was 
immersed in the electrolyte (1x TBE). The samples were loaded into the wells 
with a molecular ladder running along side (such as Hyperladder IV, for PCR 
products sized between 100 and 1000 bp or Hyperladder I for amplimers that can 
as  long  as  10000bp,  Bioline).  The  molecular  ladder  allows  the  size  of  the 
amplimer to be estimated and also can be used as rough quantification method. 
The  voltage  was  held  at  a  set  value  (the  higher  the  voltage  the  faster  the 
migration)  for  the  length  of  time  needed  to  the  product  migrate  far  enough 
through the gel to be properly resolved by eye. As the product migrates through 
the  gel  the  ethidium  bromide  intercalates  with  the  DNA.  This  allows  the 
visualisation of the DNA bands under the Ultra Violet light.  
 
3.1.8.2  Polyacrylamide Gels 
Polyacrylamide gels were used to resolve DNA fragments to less than one base 
difference. The gels were prepared using ammonium persulfate (APS, Sigma) to 
polymerise the acrylamide. 800µl of 10% APS was added to every 100ml of 
buffered  SequaGel  XR  solution  (National  Diagnostics).  The  gel  apparatus 
consisted  of  two  glass  plates  separated  using  two  2mm  thick  spacers.  When 
genotyping was carried out the plates were 25 cm length. If the gel was being set 
up for a sequencing run, the plates used were 44 cm length. The gel was then 
poured  and  allowed  to  set  for  two  hours.  Once  the  gel  was  set,  the  surplus   99 
polyacrylamide was cleaned and a shark tooth comb was inserted to form the 
wells that allowed sample loading.  
 
The gel was loaded vertically into the Li-COR 4200 DNA sequencer (Li-COR 
Biosciences).  Both  on  the  top  and  on  the  bottom  of  the  gel  there  are  two 
containers that hold 500ml of electrolyte (1x TBE). This allows a current to be 
applied  through  the  gel  for  electrophoresis  to occur.  A  scanning  laser  at  the 
bottom of the gel continually scans for both 700nm and 800nm wavelengths. The 
signal was then converted into a graphical image to view.  
 
The samples were first mixed with an equal volume of 0.001% fuschin (w/v, 
fuschin dissolved in formaldehyde) loading buffer (Sigma) and denatured at 95
0C 
for approximately three  minutes, to allow the DNA  strands to become single 
stranded. The gel was preheated to 45
0C before loading the gel, to help prevent 
the  formation of secondary structure and  hence  allow the  linear DNA run  in 
proportion to their length. When running a genotyping reaction the molecular 
weight  marker MicroSTEP20a (Microzone Limited) was used. The  molecular 
weight  marker  was  also  mixed  with  loading  buffer  like  the  samples,  and  its 
similarly denatured. The size of the molecular weight markers were as follows:  
70, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 310, 330, 340, 
350, 360, 380 and 400 base pairs. 
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3.1.9  PCR Product Cleaning Method 
Purification  of  the  PCR  products  was  done  using  the  microCLEAN  system 
(Microzone Limited). microCLEAN is a DNA clean-up reagent that is used for 
all DNA including PCR products. It removes the enzymes and reagents from the 
PCR reaction. The microCLEAN protocol (version 2006) was used. 
 
An equal volume of microCLEAN was added to DNA sample. The samples were 
mixed by vortexing and left for 5 minutes at room temperature.  
 
If  the  DNA  was  in  tubes,  the  samples  were  spun  down  at  high  speed  for  5 
minutes. The supernatant was removed and the tube was centrifuged briefly to 
remove drags. The pellet was ressuspended in the volume of ultra pure water 
(Sigma). The samples were left for at least 5 minutes at room temperature to 
allow DNA to rehydrate.  
 
When the samples were in 96 well-plates, the mix microCLEAN-DNA was spun 
at 2000 to 4000 g for 40 minutes. The supernatant was removed by inverting the 
plate onto tissue paper in the centrifuge holder and centrifuged at low speed (<40 
g) for 30 seconds. The pellet was ressuspended in the appropriate volume of ultra 
pure water (Sigma), and left to rehydrate for 5 minutes. 
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3.1.10  Sequencing 
Sequencing  was  used  for  mutation  detection  and  also  to  confirm  clones 
sequences.  
 
To  screen  for  mutations  on  IGF1  that  could  be  associated  to  disease,  DNA 
samples  from  our  UCL  case/control  sample  were  selected  based  on  bipolar 
patients  that  had  inherited  alleles  and  haplotypes  that  had  previously  shown 
association to the disorder. This was carried out using the Big Dye Sequencing 
Method. 
 
Plasmid DNA sequences originated from cloning were screened by PCR before 
being sequenced to ensure it contained the expected ligand. These samples were 
sequenced using both Sanger-Coulson and the Big Dye Sequencing Method.  
 
3.1.10.1 Choice of Samples to Sequence 
 
UCL sample 
U.K.  National  Health  Service  (NHS)  multicentre  and  Local  Research  Ethics 
Committee  approval  was  obtained.  Each  volunteer  was  given  an  information 
sheet and description of the study. All volunteers signed an approved consent 
form. The cases were recruited from London NHS psychiatric services and from 
volunteers who were members of the Manic Depression Fellowship, a support 
organisation  for  sufferers  of  BP.  The  control  subjects  were  recruited  from 
London branches of the National Blood Service, from local NHS family doctor 
clinics and from university student/staff volunteers.   102 
It is crucially important for association studies that the case and control sample 
are derived from the same population. Ancestry criteria for participation in the 
study had been set out at the very start of the study. Volunteers had to be of 
British  or  Irish  ancestry.  This  was  defined  as  having  at  least  three  of  four 
grandparents  of  such  ancestry.  Volunteers  with  a  grandparent of  non-western 
European ancestry were excluded. All volunteers were screened with an ancestry 
questionnaire.  
 
All volunteers were interviewed using the SADS-L (Endicott et al. 1978). This 
information was supplemented by material from case-notes where appropriate. A 
second psychiatrist reviewed the diagnoses. All the bipolar disorder cases were 
rated with the 90 item OPCRIT checklist (McGuffin et al. 1991). Information 
regarding family history of mental disorder and drug treatment response was also 
collected. Phenotypic information was collated in a Microsoft Access database. 
 
620 ‘supernormal’ controls were recruited for the study. Control volunteers had 
no personal history of mental disorder or any family history of bipolar disorder, 
schizophrenia or alcoholism. It has been argued that it is more efficient to use 
such controls (Morton et al. 1998). A further 480 DNA control samples were 
added to our UCL sample. These were ECACC Human Random Control (HRC) 
DNAs from a control population of randomly selected, non-related normal UK 
Caucasian blood donors. The DNA was extracted from lymphoblastoid cell lines 
derived by EBV transformation of peripheral blood lymphocytes.  
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The UCL case/control sample used in this study had a total of 937 cases and 941 
controls.  The  statistical  power  of  the  UCL  sample  was  calculated  using  an 
internet  based  software  (http://www.dssresearch.com).  A  Two-Tail  Test  using 
percentage values was done. If the allele frequency in cases was 50% and in 
controls  was  57%  with  a  significance  of  0.05  the  UCL  case/control  had  a 
statistical power of 86.1%. This means that the sample can detect and replicate 
7% allele frequency differences 86.1% of the time.    
 
3.1.10.2 Chain Termination Sequencing Method (Sanger-Coulson) 
M13 tailed PCR products for mutation detection or plasmid clones containing 
M13 primer sequences (Section   3.1.6) were sequenced simultaneously in both 
directions  using  IRD  700/800  labelled  M13  forward  and  reverse 
oligonucleotides.  The  products  were  visualised  using  a  Li-COR  4200  DNA 
Sequencer. 
 
The M13F/R primer during the PCR reaction binds to the specific template and 
allows extension and synthesis of the complementary strand by the Sequitherm 
DNA  polymerase  (Microzone).  The  advantage  of  using  M13F  IRD700  and 
M13R IRD800 is that both strands can be sequenced at the same time and used 
as a crosscheck for one another to assess whether novel bands were artefacts or 
real polymorphisms. 
 
In  sequencing,  the  usual  dNTPs  are  used  along  with  a  small  amount  of 
dideoxynucleotide (like ddATP) which is incorporated efficiently into a growing 
polynucleotide  strand  but  prevents  further  synthesis.  This  happens  due  to   104 
dideoxynucleotide lacking a hydroxyl group at the 3 prime position of the sugar 
component  and  this  prevents  further  incorporation  into  the  polynucleotide. 
Therefore  chain  termination  occurs  wherever  a  dideoxynucleotide  is 
incorporated. As a result the reaction can run with each individual ddNTP and 
will  result  with  terminations  at  every  base  of  the  sequence  showing  exactly 
where each base belongs in a sequence. 
For the reaction mix, 3µl of the cleaned DNA template was mixed with 6.8µl of 
the sequencing master mix. 2µl of this was mixed with 2µl of each ddNTP as 
shown in Figure   3.2. The sequencing reaction was then PCR amplified by the 
Sequitherm  program,  which  has  a  longer  extension  time  to  allow  the  full 
extension prior to incorporation of the chain terminating nucleotide. The cycling 
conditions are in Table 3.4. This was carried out on a 96 well plate and enables 
one to sequence 16 individuals at a time on a single polyacrylamide gel. All the 
reagents  Reagents  used  were  from  the  SequiTherm  EXCEL™  II  (Microzone 
Limited) kit with the exception of the M13F 700 and M13R 800 that came from 
MWG. 
 
Table   3.4 Sequencing cycling conditions for Sanger-Coulson chain termination method. 
Sequitherm PCR cycle: 
 
Lid Heated to 105
0C 
Products are denatured at 94
0C for 5 minutes  
 
30 cycles of:- 
92
0C – 30 seconds 
60
0C – 30 seconds 
70
0C – 1 minute 
End 
 
Store at 4
0C. 
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Figure   3.2 Layout of the sequencing reaction, showing how the Master Mix and DNA are 
mixed with each ddNTP separately. 
 
 
As  mentioned  before,  after the  sequencing  PCR  an  equal  volume  of  Fuchsin 
loading buffer was added to the PCR products and the samples were ran in a 
polyacrilamide gel that had 44 cm length and 2 mm thick.  
 
3.1.10.3 Big Dye Terminator Method 
The Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems)  is 
based on the Sanger method explained in the previous section. However the dye 
is  not on the M13 forward and reverse primers but on the dideoxynucleotide 
terminators.  This  means  that  each  of  the  four  dideoxynucleotide  will  have  a 
different  wavelengths  emission.  This  kit  has  a  special  formulation  that  gives 
increased robustness, more even peaks and longer read lengths, which will be 
reflected on better and more accurate results. 
As before, the region of interest was amplified with the M13 tailed primers, and 
cleaned with the MicroCLEAN system (section 3.1.9) and were ressuspended in 
5 µL of ultra pure water (Sigma).  
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The cleaned  samples  were amplified with the BigDye Terminator sequencing 
program  (Table    3.5).  This  program  was  optimized  to  work  with  the  BigDye 
Terminator v3.1 master mix (Table   3.6). At this point, two plates with mastermix 
are prepared, one with the forward primer and a second with the reverse primers. 
                                 
                                 Table   3.5 BigDye Sequencing PCR cycles. 
BigDye Terminator kit PCR cycle: 
 
Lid Heated to 105
0C 
Products are denatured at 94
0C for 5 minutes  
 
25 cycles of: 
96
0C – 10 seconds 
50
0C – 5 seconds 
60
0C – 4 minutes 
End 
 
Store at 4
0C. 
 
 
                Table   3.6  MasterMix conditions for the Bigdye sequencing PCR. 
Reagent  Volume per well (µL) 
Terminator Ready Reaction Mix  1 
BigDye Sequencing Buffer 5X  1.5 
10 µM M13 primer F or R  0.32 
Template  1 
Water  6.18 
Total Volume  10 
 
 
Once the amplification reaction was completed, the samples were cleaned again. 
For that an ethanol precipitation was preformed. 2.5 µL of 125 mM EDTA and 
30µL of 100% ethanol were added to each well, and the plates were left at room 
temperature for 10 mins for DNA precipitation. Then, they were spun for 60 min 
at 3870 rpm. The plates were turned upside down on the centrifuge holder, spun 
for 1 min at 1000 rpm and left at room temperature for 15 min.  
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The  plates  were  then  covered  in  a  foil  seal,  they  were  sent to the  Center of 
Comparative Genomics, in the Department of Biology, UCL. The samples were 
run on the 3730xl DNA Analyzer (ABI).  The Applied Biosystems 3730xl DNA 
Analyzer is an automated, high throughput, 96-capillary electrophoresis system 
used  for analyzing  fluorescently  labeled DNA  fragments. First, purified dried 
samples are ressuspended in injection solution. The injections solution used is 
formamide. Then the samples plates were placed on the machine. The run cycle 
is represented on Figure   3.1. 
 
 
 
 
 
 
 
 
 
Figure    3.3  Representation  of  the  Sequencing  Machine  Applied  Biosystems  3730xl  DNA 
Analyzer run cycle (Applied Biosystems 3730xl DNA Analyzer Protocol; Edition 2006). 
 
The results were analysed using the Staden Package Pregap4 and Gap4 (Staden 
1996).  Pregap4  provides  a  graphical  user  interface  to  set  up  the  processing 
required to prepare trace data for assembly or analysis. It also automates these 
processes. The possible processes which can be set up and automated include 
trace format conversion, quality analysis, vector clipping, contaminant screening,   108 
repeat  searching  and  mutation  detection.  Gap4  performs  sequence  assembly, 
contig  ordering  based  on  read  pair  data,  contig  joining  based  on  sequence 
comparisons, assembly checking, repeat searching, experiment suggestion, read 
pair analysis and  contig editing. It has graphical  views of contigs, templates, 
readings  and  traces  which  all  scroll  in  register.  Contig  editor  searches  and 
experiment suggestion routines use confidence values to calculate the confidence 
of the consensus sequence and hence identify only places requiring visual trace 
inspection  or  extra  data.  With  this  software  sequences  were  screened  for 
mutations. If a possible mutation was detected, DNA databases, such as UCSC 
and NCBI, were used to check if it was a new mutation or an already identified 
one. In addition,  mutations  in the promoter regions were examined using the 
Transcription  Element  Search  System  (TESS)  software  (Schug  et  al.  1997). 
TESS  is  a  web  tool  for  predicting  transcription  factor  binding  sites  in  DNA 
sequences.  It  can  identify  binding  sites  using  site  or  consensus  strings  and 
positional weight matrices from the TRANSFAC, JASPAR, IMD, and their own 
CBIL-GibbsMat  database.  Interesting  mutations  present  in  the  32  cases  more 
often than in the 32 controls were genotyped in the UCL case/control sample.  
 
3.1.11  Genotyping 
3.1.11.1 KASPar Method 
Some SNPs were genotyped using the KBiosciences competitive allele specific 
PCR  system  (KASPar).  This  assay  is  a  modified  version  of  the  Amplifluor 
(Myakishev  et  al.  2001)  genotyping  method  from  Millipore.  This  method 
involves the allele specific amplification of SNP alleles using two tailed locus   109 
specific oligonucleotides and a standard locus specific reverse primer (Figure   3.4 
Figure    3.5).  In  addition,  two  tailed  oligonucleotides  labelled  with  different 
fluorescent dyes are used in the reaction. In the early cycles of amplification the 
allele specific oligonucleotides compete with one another for template. The best 
fitting  (matching)  oligonucleotide  binds  the  template  with  high  affinity  and 
thereby creates more of this allele’s template for subsequent amplification. In the 
later  cycles  the  appropriate  tailed  fluorescent  oligonucleotide  is  incorporated. 
The  end  point  fluorescence  is  then  detected  using  a  fluorescent  plate  reader. 
There  are  four  different  possible  outcomes  each  with  different  fluorescent 
intensities:  low  intensity  for  both  fluorescent  dyes  indicating  that  no 
amplification  has  occurred;  high  intensity  for  one  fluorescent  dye  and  low 
intensity for the other indicating a homozygote template for the appropriate SNP 
allele; the opposite scenario; and finally moderate intensities for both fluorescent 
dyes indicating a heterozygous template for the SNP.  
 
                    
Figure   3.4 KASPar method for genotyping a two allele SNP using allele-specific primers 
coupled with two Universal Amplifluor primers (Bengra et al. 2002).   110 
 
 
Figure   3.5 An alternative diagrammatic representation of two-allele SNP detection using 
allele-specific primers coupled with two Universal Amplifluor primer (Bengra et al. 2002). 
 
 
For  more  common  SNPs  the  assay  was  sent to  KBiosciences  for  SNP  assay 
development. The SNPs assays were optimized at KBiosciences and were ran in 
our  laboratory  in  the  Light  Cycler  480  (Roche).  The  Light  Cycler  software 
allows mutation detection and clusters the different genotypes (Figure   3.6). For 
more  rare  SNPs,  the  primers  were  designed  using  the  Primer  Picker 
(KBiosciences) and ordered from Sigma Genosys. These assays were optimized 
in our lab and also run in the Light Cycler480 (Roche). 
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Figure   3.6 Shows of the clusters created by the LightCycler mutation detection software 
based on the genotyping data of an IGF1 SNP.  
 
3.1.11.2 High Resolution Melting Curve Method 
High-resolution melting has proven to be a highly sensitive method for SNPs 
studies. The PCR is performed in the presence of a double-strand DNA binding 
dye.  Samples  are  then  denatured  and  the  nucleic  acid  melting  is  tracked  by 
monitoring the fluorescence of the samples across a defined temperature range, 
generating melting profiles that can be used to identify the presence of sequence 
variation  within  the  amplicon.  Single  point  mutations,  small  insertions,  and 
deletions can all be identified using high-resolution melting. 
 
To genotype the samples using this method the LightCycler 480 High Resolution 
Melting Master (Roche) was used. The protocol followed is stated on the kit’s 
handbook  (February  2008).  The  samples  were  run  in  the  LightCycler  480 
(Roche) and the data analysed on the LightCycler 480 Gene Scanning software 
(Roche).  The  software  analysed  the  different  profiles  of  the  melting  curves.   112 
Heterozygous and homozygous samples will present different melting profiles 
(Figure   3.7). The LightCycler 480 software analyses these differences by first 
normalising  the  data  and  then  temperature  shifting  the  curves  such  that 
differences  in  the  melting  temperatures  between  both  homozygous  and  the 
heterozygous can be noticed. In the end, the software will group the samples 
according to the three possible genotypes (Figure   3.8).     
 
                
Figure   3.7 Representation of the melting curves profiles of an IGF1 SNP. Result obtained 
using the HRM method in the LightCycler 480. In green and blue we have the homozygous 
samples and in red the heterozygous samples. 
 
 
                  
Figure   3.8 Representation of the difference plot of the genotyping data of an IGF1 SNP. The 
plot groups the samples according to their melting temperature. In green and blue there are 
represented the homozygous samples and in red the heterozygous samples.  
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3.1.11.3 Microsatellites 
The microsatellite detected by sequencing was amplified in our bipolar sample 
and matched control sample, along with an M13 forward primer (700 or 800 
wavelengths). The products were then pooled and mixed with an equal volume of 
loading buffer (fuchsin). The sample was loaded on to a vertical polyacrylamide 
gel.  Also,  eight  molecular  weight  (MW)  markers  were  run  along  side  the 
samples.  The  MW  were  evenly  spaced  to  enable  differentiation  between  the 
polymorphic marker alleles and also to check the uniformity of the run to be able 
to call the alleles correctly and give the correct size. The gel was analysed using 
a Li-COR 4200 (Li-COR Biosciences), a dual laser scanning laser. 
 
In addition to analysing the entire case control sample, a minimum of 17% of all 
the samples are repeated in separate microtitre plates as a cross check, to ensure 
the alleles were called correctly and the common allele size was kept constant 
between  gels  to  prevent  any  gel  shifts.  This  helped  to  improve  genotyping 
accuracy and reliability. 
 
SAGA-GT  is  a  software  program  (developed  by  Li-COR)  which  is  used  to 
efficiently genotype gel images produced by the Li-COR. It has the ability to 
load up the sample  identifications, detect the  lanes which they are  in, and to 
identify the location of each marker with the aid of the molecular weights. The 
program  detects  the  uniformity  of  the  gel  with  aid  of  the  spaced  molecular 
weights and produces a “desmile line” to allow correct calling of allele sizes. 
Although SAGA-GT is able to automatically call the genotypes, each individual   114 
genotype was checked by eye and corrected if  necessary  by two independent 
researchers. 
  
Both the entire sample of cases and controls were genotyped with the aid of 
SAGA-GT (Figure 3.9). The genotypes were then read by a second individual 
blind to diagnosis. Any discrepancies between callers resulted in the individual in 
being re-amplified for the marker and re-genotyped, until the discrepancy was 
resolved. 
 
Figure   3.9 Shows a tetranucleotide repeat marker that has been analysed using SAGA-GT 
software. Allele size calls for all the genotypes are shown using coloured “X” symbols. 
 
The genotyping data was then extracted for each marker from SAGA-GT and 
entered into a database in Microsoft Access. This database contains a list of all 
individual identification codes and has a program that checks for conflicts from 
the data of individuals that have been genotyped more than once. Conflicts were 
rechecked on SAGA-GT to determine the reason for the conflict and amended or 
discarded. 
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3.1.11.4 Data analysis 
 
For  all  the  markers  a  repeat  17%  of  samples  in  each  microtitre  plate  were 
reduplicated to detect error and confirm the reproducibility of genotypes.  
The data was analysed to confirm Hardy-Weinberg equilibrium (HWE). Markers 
with lack of HWE were rejected and repeated. Genotypic and allelic associations 
for SNPs were tested using χ
2 tests. Microsatellite data was analyzed for allelic 
association  with  bipolar  disorder  using  CLUMP  which  employs  an  empirical 
Monte  Carlo  test  of  significance  and  which  does  not  require  correction  for 
multiple alleles (Sham et al. 1996). Subtests of the CLUMP programme are: T1 -
 Pearson's 
2 statistic of the  raw  contingency table; T2 - the 
2 statistic of a 
table with rare alleles grouped together to prevent small expected cell counts; 
T3 - the largest of the 
2 statistics of 2 × 2 tables each of which compares one 
allele against the rest grouped together; T4 - the largest of the 
2 statistics of all 
possible 2 × 2 tables comparing any combination of alleles against the rest.  
 
Tests of haplotypic association were carried out using GENECOUNTING, which 
computes  the  maximum  likelihood  estimates  of  haplotypic  frequencies  from 
phase-unknown  data,  and  the  empirical  significance  was  obtained  using 
permutation tests (Zhao et al. 2000; Zhao et al. 2002; Curtis et al. 2006). Since 
running 44 markers on GENECOUNTING for all cases and controls requires a 
lot of processing power and is time consuming, a preliminary analysis of the 
haplotypes  was  done  using  SCANASSOC.  SCANASSOC  is  part  of 
GENECOUNTING’s  software.  SCANASSOC  computes  the  maximum 
likelihood  estimates  of  haplotypic  frequencies  from  phase-unknown  data 
similarly  to  GENECOUNTING,  however  does  not  perform  the  permutation   116 
testing (Zhao et al. 2002; Curtis et al. 2006). This means that SCANASSOC 
gives  a  raw  result  but  does  not  calculate  the  empirical  significance  of  those 
results.  Analysis  of  haplotype  block  structure  was  performed  using 
HAPLOVIEW  (Barrett  et  al.  2005).  GENECOUNTING  was  also  used  to 
calculate  pairwise  linkage  disequilibrium  between  all  markers,  and  their 
relationship was viewed on LocusView 2.0 (Broad Institute) (Petryshen et al. 
2003).  
 
To combine all the markers to implicate association at the level of the whole 
gene  rather  than  just  for  individual  markers  or  haplotypes,  it  was  used 
COMBASSOC. This software combines the p values from all single locus and/or 
multilocus analyses of different markers according to the formula of Fisher, X = 
Σ(−2ln(pi)), and then assesses the empirical significance of this statistic using 
permutation testing (Curtis et al. 2008).  
 
 
 
3.1.12  Cloning 
DNA cloning  is a process where there  is the transfer of a DNA  fragment of 
interest  from  one  organism  to  a  self-replicating  genetic  element  such  as  a 
bacterial plasmid. The DNA of interest can then be propagated in a foreign host 
cell.  This  technology  has  been  used  since  the  1970s,  and  it  has  become  a 
common practice in molecular biology labs.  
Bacterial  plasmids  are  self-replicating  extra-chromosomal  circular  DNA 
molecules, and are often used as they can generate multiple copies of the same 
gene. To clone a gene, a DNA fragment containing the gene of interest is isolated   117 
from chromosomal DNA using restriction enzymes, or from PCR reactions. Then 
the fragment is ligated into a plasmid that has complementary ends to the ones of 
the fragment and transferred into suitable host cells. In these cells, the plasmid 
will replicate and will increase the number of copies of the gene of interest. 
 
3.1.12.1 Cloning Process 
The regions of interest were amplified by standard PCR and the PCR products 
were purified by the microCLEAN system. Then were cloned into the pDrive 
Cloning Vector (Qiagen) using the Qiagen Cloning Kit (Qiagen). 
 
                              
Figure   3.10 Schematic representation of the pDrive Cloning Vector (Qiagen) used in the 
cloning experiments (Cloning Qiagen Kit Handbook ; April 2001).  
 
 
The pDrive Cloning Vector (Figure   3.10) contains antibiotic markers (kanamycin 
and ampicillin). These confer host cell resistance to the antibiotics, if the cells 
where transfected with the vector. Also the vector has the LacZ α peptide, for α-  118 
complementation, disrupted by the MCS (Multiple Cloning Site). If the ligation 
of the insert to the MCS was successful, the bacterial colony will be white, if not, 
the colony will be blue, when grown on the appropriate media. This technique 
allows  for the quick and easy detection of  successful  ligation. The  molecular 
mechanism  for  blue  white  screening  is  based  on  the  Lac  operon,  and  -
galactosidase protein expression. The chemical required for this screen is X-gal, 
which functions as indicator, and Isopropyl -D-1-thiogalactopyranoside (IPTG), 
which functions as the inducer of the Lac operon. The hydrolysis of colourless 
X-gal by the β-galactosidase causes the characteristic blue color in the colonies.  
 
The ligation kit works based on the fact that Taq and other non-proofreading 
Polymerases generate a single A overhanging at each end of PCR products. The 
pDrive Cloning Vector has U overhangs at each end which hybridize to PCR 
products A overhang with high specificity.  
 
For the ligation, a ligation-reaction mixture with: 1X Ligation Master Mix, 50 ng 
of pDrive Cloning Vector DNA, 1 to 4 µl of PCR product and distiled water, all 
in a final volume of 10 µl, was prepared and incubated at 4 to 16°C, for 30 mins. 
Finished the incubation, we proceed with the tranformation of the host cells. The 
followed protocol is on the Cloning Qiagen Kit Handbook (April 2001). 
 
3.1.12.2 Transformation 
For  the  transformation  reaction  was  done  with  MAX  Efficiency
®  DH5α™ 
Competent Cells. These chemically competent cells contain the φ80dlacZΔM15 
marker  for  α-complementation  of  the  β-galactosidase  and  are  not  ampicillin   119 
resistant. These characteristics were essential to get only bacteria transformed 
with the vector and to select the ones that have the insert.  
 
Very  briefly, the competent cells were thawed  on wet ice. Then, the  ligation 
mixture was added to 100 µl of cells and incubated for 30 mins on ice. Cells were 
heat chocked for 45 seconds in a 42°C water bath, and placed on ice for more 2 
mins. After, 0.9mL of SOC medium were added to cells at room temperature, 
and they were incubated for 1 h, at 37°C and 225 rpm. In the end, 25 µL or 100 
µL of cells were spread into LB plates containing 100 µg/ml ampicillin (Sigma), 
50 µM IPTG (Sigma) and 80 µg/ml X-gal (Sigma). Also 50 pg of pUC19 were 
used  to  transform  100  µL  of  competent  cells.  This  control  was  essential  to 
determine the transformation efficiency. 
 
The  transformation  steps  were  followed  as  stated  on  the  Max  Efficiency
® 
DH5α™ Competent Cells protocol (December 2001). 
 
3.1.12.3 Colony Selection 
Once there was growth of the colonies on the plates, the selection was done. 
Since  the  insert  disrupts  the  plasmid  Lac  Z  sequence  white  colonies  were 
expected. The selected colonies were collected with a tip and were dipped into 
water in a PCR plate and  in a  falcon tube with 2 mL YT  medium with 100 
µg/mL of ampicillin. In the PCR plate we checked which clones had the right 
insert. Meanwhile, the cells in the falcon tube were grown overnight at 37 C, at 
200 rpm. From this grown clones the plasmid was extracted and purified. 
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3.1.12.4 Plasmid Extraction and Purification 
For plasmid extraction and purification was used the QIAprep
® Spin Miniprep 
Kit (Qiagen). QIAprep miniprep procedure is based on alkaline lysis of bacterial 
cells followed by adsorption of DNA onto a silica membrane in the presence of 
high salts. The four main steps are the preparation and cleaning of the bacterial 
lysate, the adsorption of DNA onto the silica membrane in the spin column, the 
washing of the samples and the elution of the DNA. The protocol followed was 
on the QIAprep
® Miniprep Handbook (June 2005).  
 
The  yields  of  purified  plasmid  were  estimated  running  the  samples  in  a  1% 
agarose  gel  with  the  ladder  that  corresponds  to  the  size  of  the  DNA,  or the 
samples were quantified using the Nanodrop system.  
 
3.1.13  Northern Blot 
The  Northern  blot  is  a  gel-transfer  hybridization  technique  for  detecting  and 
determining  the  size  of  specific  RNA  molecules.  The  RNA  is  separated  by 
electrophoresis in an agarose gel under denaturing conditions. Then is transferred 
to  a  membrane,  crosslinked  and  hybridized  with  a  specific  radioactive  or 
nonisotopic  probe.  The  blot  can  be  probed  using  labeled  DNA,  in  vitro 
transcribed RNA and oligonucleotides (Sambrook et al. 1989). 
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3.1.13.1 Formaldehyde/Formamide denaturing agarose gel   
The  methodology  used  was  based  on  the  methodology  described  in Maniatis 
(Sambrook et al. 1989) and the Hybond NX leaflet (Amersham Biosciences , 
2003).  
 
To separate the RNA by size a 1.6% (W/V) agarose gel with 0.7 M formaldehyde 
and 1X MOPS was used. Also was included 0.01 µg/mL of ethidium bromide to 
visualize the RNA after the electrophoresis.  
2µg of RNA sample was added to a buffer containing 2.2M formaldehyde, 50% 
(V/V) formamide and 0.5X MOPS. The samples were denatured at 55C for 15 
min and  mixed to 1X loading  buffer.  As a  ladder was used 0.5-10 Kb RNA 
ladder (Invitrogen). RNA samples were separated at 120 V until the front of the 
loading  buffer  was  at  two  thirds  of  the  gel.  1X  MOPS  buffer  was  used  as 
electrophoresis buffer. If the work was with total RNA, the RNA in the gel was 
visualized with UV light to check its integrity. In total RNA was possible to 
observe two bands corresponding to the 28S and 18S ribosomal RNA. When a 
smear is absent and the ratio of 28S and 18S RNA is around 2:1 means that the 
RNA is in good condition.     
 
All of this work was done in the fume hood since formaldehyde vapors are toxic.      
 
3.1.13.2 RNA Transfer to the Nylon Membrane 
The transfer was done trough capillary blotting, where buffer is drawn from a 
reservoir and passes trough the gel into a stack of absorbent paper. The nucleic 
acid  is  eluted  from  the  gel  by  moving  stream  of  buffer  and  is  deposit  on  a   122 
membrane (Sambrook et al. 1989). For this work was used the nylon membrane 
Hybond-NX (Amersham Biosciences). Nylon membranes have the advantage of 
standing up well in several rounds of hybridization, however this can also lead to 
a higher background. 
 
Before the assembling of the transfer apparatus the gel was washed twice with 
10x SSC for 15 minutes with gentle agitation. Since formaldehyde vapors are 
very toxic these washes will remove, or decrease, the levels of formaldehyde in 
the gel.   
 
To prepare the capillary blotting system, first a tray was half-filled with 10X SSC 
(transfer  buffer).  Afterwards  it  was  assembled  as  shown  in  Figure    3.11.  Air 
bubbles must be avoided in the capillary system. They were removed by rolling a 
clean glass rode over the surface. The gel  must also be surrounded by Saran 
Wrap to prevent the transfer buffer being absorbed directly into the paper towels. 
In the end, a weight was applied to the top of the apparatus to ensure a tight 
connection between the layers of material used in the transfer system.  
 
After an overnight transfer, when dismantling the apparatus, the membrane was 
marked to allow identification of the wells, and kept with the sheets of filter 
paper embedded in transfer buffer.    
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  Figure   3.11 Diagrammatic representation of a capillary blotting apparatus (Hybond-NX 
Amersham Biosciences Handbook). 
 
3.1.13.3 Fixation of RNA to Membrane 
After the transfer, the RNA must be fixed to the nylon membrane. That was done 
with the Stratalinker
® UV Crosslinker 2400 (Stratagene). The UV light permits 
the  formation  of  a  covalent  bond  between  the  amino  group  of  the  nylon 
membrane and the uracil of RNA. The crosslinking was done at an UV exposure 
of 70,000 microjoules/cm
2. Blots can be used immediately or stored wrapped in 
Saran wrap under vacuum at -20C. 
 
3.1.13.4 Pre-Made Membranes 
Commercial Northern blots were also used:  
(a) Mouse 12 major tissues polyA
+ RNA Northern Blot (Origene): contained 
RNA samples from brain, heart, kidney, liver, lung, muscle, skin, small 
intestine, spleen, stomach, testis and thymus;    124 
(b) Mouse Brain Northern Blot II (Panomics): included poly A
+ from frontal 
cortex,  back  cortex,  hippocampus,  olfactory  bulb,  thalamus,  striatum, 
cerebellum and whole brain. 
 
Both blots had 2µg of polyA
+ RNA in each lane and were normalized by the 
mRNA amounts. 
 
3.1.13.5 Riboprobe Synthesis 
RNA probes show major advantages when compared with DNA probes. RNA 
probes are highly sensitive and form more stables complexes with both RNA and 
DNA samples. Furthermore, they can be synthesized with high efficiency and 
can be separated from the DNA template just using DNase enzyme. If RNase 
digestion  is  needed to remove  non specific  bounded  RNA probes, this won’t 
affect the RNA:RNA or DNA:RNA complexes (Sambrook et al. 1989). 
 
To synthesize the RNA probe the Strip-EZ RNA T7 Kit (Ambion) was used. 
This kit allows to synthesis of a probe that is stable under conditions used for 
hybridization and washing, but which can be cleaved by a degradation buffer. 
Degradation of the probe happens by cleavage at a modified nucleotide that is 
incorporated during probe synthesis. This allows probe removal without affecting 
the Northern blot membrane.  
 
The probe template was a sequence cloned into the pDrive vector. In the vector, 
the  cloned  sequence  was  flanked  by  two  phage  RNA  polymerases  promoter 
sequences, the T7 and the SP6. The insert orientation was previously checked by   125 
sequencing, which showed that was aligned with the T7 phage RNA promoter. 
The  recombinant  plasmid  was  then  linearized  with  a  restriction  enzyme 
downstream  of  the  insert to  be  transcribed.  The  restriction  enzyme  used  was 
Hind III (Promega), overnight at 37C. Initiation of the transcription is one of the 
limiting steps of the in vitro transcription reactions. Also RNA polymerases are 
very  processive  witch  can  generate  long  heterogeneous  RNA  templates  from 
templates within non linearised vectors. Thus, even a small amount of circular 
plasmid will decrease the probes  synthesis efficiency. Therefore, linearization 
efficiency was checked by electrophoresis in a 1% agarose gel with 0.5 µg/mL of 
ethidium bromide. Following linearization, template was cleaned from restriction 
enzymes and salts. One twentieth volume of 0.5 M EDTA, one tenth volume of 3 
M  sodium  acetate  and  two  volumes  of  ethanol  were  added  to the  restriction 
reaction mixture, and incubated for 15 minutes at -20C. Then DNA was pelleted 
for 15 min in a microcentrifuge at top speed. The supernatant was removed and 
the pellet was re-spun for a few seconds. The residual fluid was removed and the 
pellet was diluted in water in a concentration of 1µg/µL. 
 
For  RNA  probe  synthesis  was  followed  the  Strip-EZ  RNA  Kit  instruction 
manual (Version 401a). The probe was synthesized using the T7 phage RNA 
polymerase,  which  binds  its  promoter  sequence  with  high  affinity.  The 
radiolabeled  nucleotides  [α-
32P]UTP  (Amersham)  were  incorporated  in  the 
probe. After transcription reaction, the probe was DNase I treated to remove 
DNA  template.  To  remove  any  free  nucleotides  that  might  increase  the 
background,  probes  were  cleaned  with  the  Micro  Bio-Spin
®  P-30  Tris 
Chromatography Columns (Bio Rad). These columns were packed with a special   126 
grade Bio-Gel
® P polyacrylamide P-30 gel matrix, which allow non-interactive 
size separation of particles.  
 
To check if the probes were properly labelled, the levels of radioactivity were 
checked using a Geiger counter. 
 
3.1.13.6 Hybridisation 
If the membrane was previously prepared and stored, or, if it was a commercial 
membrane, it was hydrated in 100 mL of 4X (w/v) SSC for 10 minutes, shaking. 
If not, pre-hybridisation would be done immediately. 
 
The  hybridisation  temperature  depends  on  the  type  of  probe  used.  For RNA 
probes, the  pre  and  hybridisation  temperature  used  was  68C,  since  the  high 
temperature  will  decrease  background  and  will  prevent  non  specific  binding.  
The hybridization buffer used was the UltraHyb™ (Ambion). The buffer was 
always  placed  in  the  oven  at  68C,  30  minutes  before  being  used.  For  pre-
hybridisation, the membrane was placed in a hybridisation bottle with 10 mL of 
hybridisation buffer, at 68C for 30 minutes to 1 hour. 
 
When the probe was ready, it was denatured by boiling for 5 minutes and placed 
in  ice  for  2  minutes.  The  probe  was  added  to  the  pre-warmed  hybridisation 
buffer.  Then,  the  previous  pre-hybridisation  buffer  was  replaced  by  the  new 
hybridisation buffer with probe, and incubated overnight at 68C.  
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The washing steps were very important since the probes that didn’t bind were 
removed. The washes were done from high stringent to less stringent conditions. 
Carefully,  the  hybridisation  buffer  with  the  RNA  probe  was  removed  from 
hybridisation bottle. The membrane was washed twice with 2X (w/v) SSC; 0,1% 
(v/v) SDS and twice with 0.25X (w/v) SSC; 0,1% (v/v) SDS, at 68C for 15 
minutes each. Before exposure to X-ray film, the levels of radioactivity were 
checked with the Geiger counter. If the levels were higher than 20 counts per 
minute (cpm), the membrane would be washed again with the second washing 
solution, until the cpm levels were in the expected range.  
 
3.1.13.7 Exposure and Development of the Film 
After the washes the membrane was wrapped in Saran wrap and exposed Kodak 
BioMax MS X-Ray film (Kodak). All the following steps were done in a dark 
room to avoid damaging the film. Membrane and film were kept in a cassette 
film holder at -80C. This cassette not only prevents light to damage the film but 
also it has an emulsion that intensifies the exposure when kept at -80C. The time 
of  exposure  could  vary  depending  on  how  strong  was  the  radioactive  signal. 
Followed by exposure, X-ray film was developed in the Compact X4 Automatic 
X-ray Film Processor (Xograph). 
 
3.1.13.8 Probe Removal 
Northern membranes can be probed more than once. For that, probes that are 
binding the mRNA need to be removed. The riboprobes used were synthesized 
with the Strip-EZ RNA T7 Kit (Ambion). When the RNA probe was being   128 
transcribed, modified nucleotides were incorporated. These modified nucleotides 
were cleaved  by a special  buffer (Degradation  buffer). This allows the probe 
removal without the use of high temperature methods that can affect the RNA 
quality.  The  Strip-EZ  RNA  Kit  instruction  manual  (Version  401a)  was 
followed. If after the first round the membrane still radioactive, the procedure 
was repeated. 
 
3.1.14  Quantitative Real Time PCR (qRT-PCR) 
Quantitative  polymerase  chain  reaction  (qPCR)  is  a  modification  of  the  PCR 
used to rapidly measure the quantity of DNA or cDNA present in a sample. One 
of the most sensitive qPCR methods is the real time PCR (RT-PCR). 
 
The advantage of RT-PCR is the ability to monitor the progress of the PCR as it 
occurs, precisely  measuring the  amount of amplicon  at each and every cycle 
throughout the PCR process. For that, there is the detection and quantification of 
a fluorescent reporter. The signal increases in direct proportion to the amount of 
PCR product in a reaction (Figure   3.12). By plotting fluorescence against the 
cycle number an amplification plot is generated that represents the accumulation 
of  product  over  the  duration  of  the  entire  PCR  reaction.  There  is  a  high 
correlation between the signal and the amount of product present initially. 
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Figure   3.12 Amplification curves of the MAPK1 gene. In red we have the unknown samples, 
in green the non template controls and in dark red the standard curves. 
 
In the present work the qRT-PCR was carried out with the LightCycler
® 480 
(Roche).  
 
3.1.14.1 Detection Systems Used 
One  detection  method  used  was  the  Universal  Probe  Library  (Roche).  This 
system uses hydrolysis probes (Figure   3.13).  The hydrolysis probe relies on the 
5'-3' exonuclease activity of Taq polymerase, which degrades a hybridized non-
extendible  DNA  probe  during  the  extension  step  of  the  PCR.  This  probe  is 
designed to hybridize to a region within the amplicon and is duel labelled with a 
reporter  dye  and  a  quenching  dye.  The  close  proximity  of  the  quencher 
suppresses the fluorescence of the reporter dye. Once the exonuclease activity of 
Taq polymerase degrades the probe, the fluorescence of the reporter increases at 
a rate that is proportional to the amount of template present.   130 
                                     
                Figure    3.13  Diagrammatic  representation  of  the  hydrolysis  probes  detection 
method (http://realtime-pcr.blogspot.com). 
 
 
The other method was the QuantiFast™ SYBR® Green PCR (Qiagen). SYBR 
Green  provides  the  simplest  and  most  economical  format  for  detecting  and 
quantitating PCR products  in real-time reactions. SYBR Green  binds double-
stranded DNA, and upon excitation emits light (Figure 3.14). Thus, as a PCR 
product accumulates, fluorescence increases. 
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Figure    3.14  Diagrammatic  representation  of  the  SYBR  Green  detection  method 
(http://www.cogentech.it/Pcr/methodology.php). 
 
 
The  advantages  of  SYBR  Green  are  that  it  is  inexpensive,  easy  to  use,  and 
sensitive. Since the dye binds double-stranded DNA, there is no need to design a 
probe for any particular target being analyzed. The disadvantage is that SYBR 
Green will bind to any double-stranded DNA in the reaction, including primer-
dimers  and  other  non-specific  reaction  products,  which  results  in  an 
overestimation of the target concentration. Detection by SYBR Green requires 
extensive optimization. Since the dye cannot distinguish between specific and 
non-specific product accumulated during PCR, follow up assays are needed to 
validate results. For single PCR product reactions with well designed primers, 
SYBR Green can work extremely well, with spurious non-specific background 
only  showing  up  in  very  late  cycles. 
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3.1.14.2 Experimental Design 
Primers design  is one of the  first steps of the experimental design. The PCR 
primers should be 18 to 24 bp of length. Should not be complementary of each 
other,  especially  at  the  3’  side  and  should  not  contain  internal  secondary 
structures. Primers  have to contain 40% to 60% of G/C and also a  balanced 
distribution of G/C and A/T domains. The melting temperature (Tm) must allow 
the primers to annealing to the template. 
 
It is also important to choose the detection system. In this work both hydrolysis 
probes and SYBR green were used. For the latter, QuantiFast™ SYBR® Green 
PCR kit (Qiagen) was used. The QuantiFast SYBR Green PCR  Kit provides 
rapid real-time quantification of DNA and cDNA targets. The fluorescent dye 
SYBR Green I in the master mix enables the analysis of many different targets 
without having to synthesize target-specific labeled probes. High specificity and 
sensitivity in PCR are achieved by the use of the hot-start enzyme, HotStarTaq 
Plus DNA Polymerase, together with a specialized fast PCR buffer. The buffer 
also  contains  ROX  dye,  which  allows  fluorescence  normalization  on  certain 
cyclers. For the used Light Cycler 480 (Roche) this  normalization dye  is  not 
needed  since  it  has  a  homogeneous  temperature  distribution  and  also  a 
homogeneous illumination and imaging due to a long object-image distance. It 
also has a large field lens to efficiently collect rays also from lateral wells. 
 
The hydrolysis probes were from the Universal Probe Library (UPL, Roche). The 
combination of the Roche online assay design software and the 165 pre-validated 
real-time  PCR  probes  allows  quantifying  virtually  any  transcript  in  the   133 
transcriptome of a large number of organisms. The almost universal coverage of 
the Universal Probe Library is due to their length of only 8-9 nucleotides. To 
maintain  the  specificity,  Tm,  and  assay  compatibility  that  hybridizing  qPCR 
probes  require  the  duplex-stabilizing  DNA  analogue  LNA  (Locked  Nucleic 
Acid) was included in the sequence of each probe. The Universal Probe Library 
probes are fully compatible with the hydrolysis probe real-time PCR detection 
format. They are labelled 5'-terminal with fluorescein (FAM) and 3'- proximal 
with a dark quencher dye. 
 
The  standard  curve  is  essential  for  the  quantification  analysis.  Thus,  some 
important considerations need to be taken before starting the qRT-PCR run. To 
be used as a standard a sequence must be as homologous to the target as possible 
(same amplicon length; G/C content), to ensure similar amplification efficiency. 
The  standard  sequences  can  be  obtained  from  PCR  (linear  plasmid  DNA; 
purified PCR products; reference genomic DNA) or from a reverse transcription 
reaction (in vitro transcribed RNA; reference cDNA from total RNA or mRNA). 
To  make  a  reliable  standard  curve  a  minimum  of  3  points  must  be  used. 
However,  it  is  more  accurate  to  have  at  least  5  points.  This  curve  points 
correspond  to  serial  dilutions  of  the  standard  sequence.  One  important 
optimization step is to run a wide range of concentrations that can go from 10
1 to 
10
9 copies per µL, in order to make sure that the unknown sample fits into the 
standard curve. 
 
Not only  is the  standard curve  essential,  but the number of replicates is also 
important. In all assays we used a minimum of 3 replicates of both unknown   134 
samples and all the standard points. The higher the number of replicates used, the 
more confident we can  be of our results. The more similar the replicates are 
found to be means then the more efficient the reaction was likely to have been. 
The replicates points will affect the standard curve slope, and that will affect 
efficiency. 
 
The controls are important in any experimental assay. In qRT-PCR both negative 
and positive controls must be used. The non template control (NTC) will indicate 
if the amplification products are specific or due to a contamination or primer 
dimer. The positive control is a control of the PCR runs and conditions. This will 
give us confidence on our results when a negative result is obtained. 
 
3.1.14.3 qRT-PCR Normalization 
Although  real-time  RT-PCR  is  widely  used  to  quantify  biologically  relevant 
changes in mRNA levels, there remain a number of problems associated with its 
use.  These  include  the  inherent  variability  of  RNA,  variability  of  extraction 
protocols that may co-purify inhibitors, and different reverse transcription and 
PCR efficiencies (Bustin et al. 2004). Several strategies have been proposed to 
normalize  real-time  RT-PCR  data.  These  range  from  ensuring  that  a  similar 
sample size is chosen to using an internal housekeeping or reference gene. These 
approaches are not mutually exclusive (Huggett et al. 2005).  
 
One way of reducing experimental error is by ensuring a similar sample size is 
obtained, by sampling similar tissue volume or weight. This can be difficult, but 
will avoid misleading results (Huggett et al. 2005).   135 
 
In the work for this PhD a normalization step using different reference genes was 
used.  For qPCR experiments done in the mouse, the housekeeping genes were: 
cyclophilin;  beta-actin  (ACTB);  glyceraldehyde-3-phosphate  dehydrogenase 
(GAPD);  hypoxanthine-guanine  phosphoribosyltransferase  (HPRT)  and 
glucuronidase  beta (Gus B). For studies done  in human cell  line samples the 
house keeping genes chosen were ACTB, HPRT and phosphoglycerate kinase 1 
(PGK1). 
 
Normalizing to a reference gene is a simple and popular method for internally 
controlling for error in real-time RT-PCR. This strategy targets RNAs encoded 
by genes, which have been collectively called housekeeping genes and benefits 
from the fact that all the steps required to obtain the final PCR measurement are 
controlled for. The procedure is simplified as both the gene of interest and the 
reference gene is measured using real-time RT-PCR. Reference genes can also 
control for different input RNA amounts used in the reverse transcription step; 
however,  because  this  can  vary  with  reverse  transcriptase  type  it  must  be 
validated  (Huggett  et  al.  2005).  The  most  commonly  used  reference  genes 
include  b-actin,  glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH), 
hypoxanthine-guanine  phosphoribosyl  transferase  (HPRT)  and  18S  ribosomal 
RNA. They are historical carry overs and were used as references for many years 
in Northern  blots, RNase protection assays and  conventional RT-PCR assays. 
However,  the  advent  of  real-time  PCR  placed  the  emphasis  on  quantitative 
change, and resulted in a re-evaluation of the use of these “classic” reference 
genes. Nevertheless, studies continue to use arbitrarily chosen reference genes   136 
for this purpose. There are countless examples of published work that have used 
a particular reference gene for normalization without any mention of a validation 
process. More recently, there have been a number of reports that demonstrate that 
the  “classic”  reference  genes  can  vary  extensively  and  are  unsuitable  for 
normalization  purposes  due  to  large  measurement  error  (Dheda  et  al.  2004; 
Huggett et al. 2005).  
 
This occurs when the reference gene is regulated by the experimental conditions. 
One way of solving this problem is the use of multiple reference genes rather 
than relying on a single RNA transcript. This is a robust method for providing 
accurate normalization and is consequently favorable if fine measurements are to 
be made.  
 
For the normalization analysis there are a number of programs based on the excel 
platform that allow the assessment of multiple reference genes. One example is 
geNorm (Vandesompele et al. 2002) that allows the most appropriate reference 
gene to be chosen by using the geometric mean of the expression of the candidate 
cDNA (http://medgen.ugent.be/~jvdesomp/genorm/). This software was used for 
the normalization and validation of the qRT-PCR results. 
 
3.1.14.4 Running Programs 
When hydrolysis probes were used the master mix was prepared as stated on 
Table   3.7. This master mix and the 2 µL of sample were added to each well of 
the 96 well plate. 
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               Table   3.7 Master Mix used for the hydrolysis probes detection method. 
Component  Final concentration 
Water, PCR grade  - 
Universal ProbeLibrary Probe (10 µM)  100nM 
Forward Primer (20 µM)  200nM 
Reverse Primer (20 µM)  200nM 
LightCycler
® 480 Probes Master (2x)  1x 
Total Volume  23 µL 
 
 
The  program  for  the  hydrolysis  probes  run  is  described  on  Table    3.8.  The 
LightCycler  must be  setup  for the detection  format, block type and reactions 
volume. For this specific run, Mono Color Hydrolysis Probe was used as the 
detection format. The 96 well plate was used for the block type and 25 µL was 
used as the reaction volume. 
 
Table   3.8 Running program for the qPCR with hydrolysis probes. 
Target (C) 
Acquisition 
Mode 
Hold 
(hh:mm:ss) 
Ramp Rate 
(C/s) 
Acquisitions 
(per C) 
Pre-Incubation  1 Cycle; Analysis Mode: None 
95  None  00:10:00  4.4  - 
Amplification  45 Cycles; Analysis Mode: Quantification 
95  None  00:00:10  4.4  - 
60  None  00:00:20  2.0  - 
72  Single  00:00:20  4.4  - 
Cooling  1 Cycle; Analysis Mode: None 
40  None  00:00:10  2.0  - 
 
For  QuantiFast  SYBR  Green  (Qiagen)  experiments,  a  master  mix  in  a  total 
volume of 23µL was prepared and then 2µL of sample added to the well. The 
master mix was prepared as described in Table   3.9. 
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                Table   3.9 Master Mix conditions for the qPCR run with SYBR green. 
Components  Final Concentration 
Water, PCR grade  - 
QuantiFast SYBR Green PCR Master Mix (2x)  1x 
Forward Primer (20 µM)  200 nM 
Reverse Primer (20 µM)  200 nM 
Final Volume  23 µL 
 
 
The run programme was not that different from the one used for the hydrolysis 
probes. However, at the end of the SYBR green program, there is the melting 
curve  detection.  The  program  set  up  is  shown  in  Table    3.10.  As  before  the 
machine was set up for Mono Color Hydrolysis Probe as the detection format, 
the 96 well plate as block type and 25 µL as the reaction volume. 
 
Table   3.10 Run programming for the qPCR with the SYBR green method. 
Target (C) 
Acquisition 
Mode 
Hold 
(hh:mm:ss) 
Ramp Rate 
(C/s) 
Acquisitions 
(per C) 
Pre-Incubation  1 Cycle; Analysis Mode: None 
95  None  00:15:00  4.4  - 
Amplification  45 Cycles; Analysis Mode: Quantification 
94  None  00:00:15  2.0  - 
55  None  00:00:20  2.0  - 
72  Single  00:00:20  2.0  - 
Melting Curve  1 Cycle; Analysis Mode: Melting Curves 
95  None  00:00:05  4.4  - 
65  None  00:01:00  2.2  - 
97  Continuous  -  -  5 
Cooling  1 Cycle; Analysis Mode: None 
40  None  00:00:10  1.5  - 
 
 
3.1.14.5 Interpretation of Results 
During  the  early  cycles  of  the  PCR  reaction,  there  is  little  change  in  the 
fluorescence  signal.  As  reaction  progresses,  fluorescence  signal  begins  to 
increase  each  cycle.  A  fluorescence  threshold,  that  is  set  to  decipher 
amplification from background, can be set above the baseline in the exponential   139 
portion of the plot. The cycle threshold (Ct) is defined as the cycle number at 
which the fluorescent signal from each amplification reaction crosses the fixed 
threshold.  The  baseline  must  be  set  up  carefully  to  allow  accurate  Ct 
determination.  
 
Quantification is done by comparing Ct values from unknown samples against its 
standard curve or against another gene that can serve as an internal control. For 
that, a dilution series of known concentration, that must fit the dynamic range of 
the sample, is done to establish a standard curve. The Ct values for these known 
samples are used to generate the standard curve. This curve is useful not only for 
quantification,  but  also  contains  information  about  performance  of  the  qPCR 
reaction. The parameters of the curve provide information about amplification 
efficiency,  replicate  consistency,  and  the  theoretical  detection  limit  of  the 
reaction.  The  detection  limit  was  detected  by  analysis  of  the  correlation 
coefficient  (r
2),  y-intercept  and  the  slope  of  the  standard  curve.  The  r
2  is  a 
measure of the reproducibility, and also indicates how well data fits the standard 
curve. Ideally on a r
2 of 1 should be obtained. The y-intercept corresponds to the 
theoretical  limit  of  detection  of  the  reaction,  or  the Ct  value  expected  if  the 
lowest copy number of target denoted on the X-axis were to be amplified. The 
RT-PCR is theoretically capable of detecting one copy however a number of 10 
is commonly specified as the lowest target level that can be reliably quantified. 
The  slope  of  the  log-linear  phase  reports  the  efficiency  of  the  amplification 
reaction. The efficiency (E) is calculated by: 
E=10
(-1/Slope)  
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Ideally the efficiency of a PCR should be 100%, meaning the amount of template 
doubles every cycle, E=2. 
 
The  LightCycler
®  480  System  software  has  the  following  analysis  modules: 
melting temperature peak calling, absolute quantification, relative quantification 
and  genotyping  analysis.  For  absolute  quantification,  unknown  samples  are 
quantified based on the standard curve. For relative quantification, PCR is done 
on both gene of interest and another standard gene (e.g. housekeeping gene). The 
amount of the gene of interest will be expressed relative to this internal standard. 
The melting curve is the change in fluorescence observed as a double-stranded 
DNA  dissociating  into  single-stranded  DNA,  when  the  temperature  of  the 
reaction increases. The fluorescence is plotted against temperature, and then the 
change  in  fluorescence  over  the  change  in  temperature  is  plotted  against 
temperature. The melting curve analysis is a way to check RT-PCR reactions for 
primer-dimmer  artefacts,  contamination  and  to  ensure  reaction  specificity. 
Because the  melting temperature of  nucleic  acids  is affected  by  length, G+C 
content, and the presence of base mismatches, among other factors, products can 
often be distinguished by their melting characteristics. The melting curve is only 
possible  on  reactions  where  the  fluorophore  remains  associated  with  the 
amplicon, such as the SYBR
® Green system. 
 
3.1.15  cDNA Library Screening 
A cDNA library refers to a complete, or nearly complete, set of the transcriptome 
of a cell, type of tissue or organism. In an attempt to find the clone or clones of 
the  human  Slynar  mouse  homologue,  adult  mouse  brain  cDNA  library  was   141 
screened. Also an adult human brain cDNA was screened to find human Slynar 
and its overlapping full gene clone. 
 
In the work described  here the RapidScreen  Arrayed cDNA Library panels 
(Origene) were used. The cDNA library was in the form of a 96 well plate. At the 
beginning,  a  Master  Plate  that  contains  DNA  for  500,000  cDNA  clones  was 
screened. Each well of the master plate corresponded to a Sub-Plate. The Sub-
Plates were 96 well plates with around 50 clones per well. These plates were 
Escherichia coli glycerol stocks, which meant that positive wells could be plated 
into LB/ampicillin agar plates. The bacterial colonies would grow and would be 
screened in order to find the right clone. These plates were screened using PCR 
methodology with specific primers. Figure   3.15 summarises the procedure.   
 
                              
Figure    3.15    Representation  of  the  cDNA  library  screening  work  flow  (RapidScreen 
Arrayed cDNA Library Handbook, Edition 2007). 
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The mouse cDNA library was screened with the mouse specific set of primers 
using the touch down PCR cycling and the master mix conditions B (Section 
  3.1.7). If any positive wells were detected, the E. coli from the glycerol stocks 
were plated into LB agar plates containing 100 µg/ml ampicillin. From the agar 
plate 96 colonies were picked up and identified. The picked up colonies were 
amplified in a PCR reaction to screen for the presence of our clone of interest. 
When the clone was detected, bacterial colonies were grown in 2 mL of LB and 
100 µg/mL of ampicillin. The clones are in a pCMV6-XL4 vector (Figure   3.16). 
This vector has an ampicilin resistance gene and two sequencing priming sites. 
These sites were used for sequencing, by the Big Dye Terminator v3.1 method 
(  3.1.10.2). A similar procedure was done with the  human cDNA  library. The 
ideal PCR condition was B for both primers and the PCR program used was the 
touch down for SS primers for the human Slynar and touch down with extra 
cycles for BC-1to5 primers for BC069215.  
 
                         
Figure   3.16 Representation of the pCMV6-XL4, the bacterial vector that contains the cDNA 
sequences (RapidScreen Arrayed cDNA Library Handbook, Edition 2007).  
 
   143 
3.1.16  Rapid Amplification of cDNA Ends (RACE) 
3.1.16.1 Principles of RACE 
Rapid Amplification of cDNA Ends (RACE) is a procedure for amplification of 
nucleic  acid  sequences  from  a  messenger  RNA  template  between  a  defined 
internal site and unknown sequences at either the 3' or the 5' -end of the mRNA.  
 
3'  RACE  takes  advantage  of  the  natural  poly(A)  tail  in  mRNA  as  a  generic 
priming site for PCR amplification. In this procedure, mRNAs are converted into 
cDNA using reverse transcriptase (RT) and an oligo-dT adapter primer. Specific 
cDNA is then directly amplified by PCR using a gene-specific primer (GSP) that 
anneals to a region of known exon sequences and an adapter primer that targets 
the  poly(A)  tail  region.  This  permits  the  capture  of  unknown  3'-mRNA 
sequences that lie between the exon and the poly(A) tail. 
 
5' RACE, or “anchored” PCR, is a technique that facilitates the isolation and 
characterization of 5' ends from low-copy messages. First strand cDNA synthesis 
is primed using a gene-specific antisense oligonucleotide (GSP1). This permits 
cDNA conversion of specific mRNA, or related families of mRNAs. Following 
cDNA synthesis, the first strand product is purified from unincorporated dNTPs 
and GSP1. Then, TdT (Terminal deoxynucleotidyl transferase) is used to add 
homopolymeric tails to the 3' ends of the cDNA. In the original protocol, tailed 
cDNA is then amplified by PCR using a mixture of three primers: a nested gene-
specific  primer  (GSP2),  which  anneals  3'  to  GSP1;  and  a  combination  of  a 
complementary  homopolymer-containing  anchor  primer  and  corresponding 
adapter primer which permit amplification  from the homopolymeric tail. This   144 
allows amplification of unknown sequences between the GSP2 and the 5'-end of 
the mRNA. 
 
3.1.16.2 5’RACE 
In this work 5’ RACE was used to isolate and characterize the 5’ prime end of 
specific  transcripts.  The  5’  RACE  System  for Rapid  Amplification  of  cDNA 
Ends (Invitrogen) was used. 
 
The main steps of the 5' RACE System are: (a) synthesis of first strand cDNA, 
(b)  purification  of  first  strand  products,  (c)  homopolymeric  tailing,  (d) 
preparation of target cDNA for subsequent amplification by PCR. Control RNA, 
DNA, and primers are provided for monitoring system performance. 
 
To summarize the procedure (Figure   3.17), first strand cDNA was synthesized 
from total or poly(A)+ RNA using a gene-specific primer (GSP1) and the reverse 
transcriptase  enzyme  SuperScript™  III  (Invitrogen).  After  first  strand  cDNA 
synthesis,  the  original  mRNA  template  was  removed  by  treatment  with  the 
RNase Mix (mixture of RNase H, which is specific for RNA:DNA heteroduplex 
molecules,  and  RNase  T1).  Unincorporated  dNTPs,  GSP1,  and  proteins  were 
separated from cDNA using a S.N.A.P. Column. A homopolymeric tail was then 
added to the 3'-end of the cDNA using TdT and dCTP. Since the tailing reaction 
was performed in a PCR-compatible buffer, the entire contents of the reaction 
were directly amplified by PCR without intermediate organic extractions, ethanol 
precipitations,  or  dilutions.  PCR  amplification  was  accomplished  using 
Elongase® Enzyme Mix (Invitrogen), which consists of a mixture of Taq and   145 
Pyrococcus  species  GB-D  thermostable  DNA  polymerases,  a  nested,  gene-
specific primer (GSP2) that anneals to a site located within the cDNA molecule, 
and a novel deoxyinosine-containing anchor primer provided with the RACE kit. 
Following amplification, 5' RACE products were cloned into the pDrive Cloning 
Vector from the Qiagen Cloning Kit (Qiagen) and sequenced by the Big Dye 
Terminator V3.1 method (  3.1.10.3).  
 
 
Figure   3.17 Diagrammatic representation of the 5’RACE work flow (5’ RACE System for 
Rapid Amplification of cDNA Ends Handbook; Version 2.0). 
 
 
The protocol used is stated on the Invitrogen user manual, 5’ RACE System for 
Rapid Amplification of cDNA Ends, Version 2.0 (2004).  
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3.1.16.3 3’ RACE 
To  run  the  3’  RACE  experiments  we  used  the  3’  RACE  System  for  Rapid 
Amplification of cDNA Ends (Invitrogen). 
 
The procedure is summarized on Figure   3.18.The first step is to anneal a specific 
adapter primer to the RNA that will bind to the oligo-dT tail. Then the extension 
of the new DNA strand is done, using the Superscript II Reverse Polymerase 
(Invitrogen). The RNA template is degraded incubating the DNA:RNA complex 
with RNase H. The newly synthesized cDNA is PCR amplified using a specific 
primer  designed  for  our  gene  and  a  second  primer  that  binds  to  the  adapter 
primer  sequence  used  on  the  reverse  transcription  step.  A  second  PCR 
amplification is done with the same primer for the adaptor primer sequence and a 
second gene specific primer. At this point, the products obtained will be cloned 
a n d   s e q u e n c e d . 
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Figure    3.18  Summary  of  the  3’RACE  experiment  (3’  RACE  System  for  Rapid 
Amplification of cDNA Ends; Version E). 
 
 
The protocol used is stated on the Invitrogen user manual, 3’ RACE System for 
Rapid Amplification of cDNA Ends, Version E (2004).  
   
3.1.17  Animal Cell Culture 
3.1.17.1 Cell Lines 
For this work HeLa and SH-SY5Y neuroblastoma cell lines, both from ECACC, 
were used. 
HeLa  cells  were  the  first  continuously  cultured  human  malignant  cell  line, 
derived  from the cervical  adenocarcinoma of Henrietta Lacks (one of several 
pseudonyms).  These  cells  have  an  epithelial  morphology  and  they  have  an 
adherent growth.    148 
SH-SY5Y is a thrice cloned sub line of the neuroblastoma cell line SK-N-SH 
which was established in 1970 from a metastic bone tumour. The cells came 
from the brain of a 4 year old girl with a neuroblastoma. These cells grow as a 
mixture of floating and adherent cells. The cells grow as clusters of neuroblastic 
cells  with  multiple,  short,  fine  cell  processes  (neurites).  Cells  will  aggregate, 
form clumps and float. SH-SY5Y cells have a 48h doubling time.   
 
3.1.17.2 Growth Conditions 
Both cells lines were grown in 75 cm
2 T-Flasks (Nunc) in 15 mL of Dulbecco 
Modified Eagle’s Medium (DMEM, Sigma) with 1% Pencillin-Streptomycin 10x 
(Sigma) and 10% Fetal Bovine Serum (FBS, Gibco). The cells were kept at 37C 
with 5% CO2. 
 
3.1.17.3 Harvesting of Cells 
When cells reached 80 to 90% confluency, they were harvested and subcultured. 
The medium was removed and cells were rinsed with 10 mL of 1x PBS (Sigma) 
in cell culture water (Sigma). For SH-SY5Y cell line, the removed medium was 
centrifuged  to  recover  floating  cells.  To  harvest  adherent  cells,  5  mL  of  1x 
Trypsin-EDTA Solution (Sigma) was added. They were incubated for a minute at 
37C with 5% CO2 to let cells to detach. After, 10 mL of fresh medium with 
serum was added to deactivate the trypsin. Cells were harvested and centrifuged, 
and cell pellet was ressuspended in 1mL of fresh media. Cells were subcultured 
in a 1:5 to 1:10 ratio. 
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3.1.17.4 Cryogenic Storage of Animal Cell Lines 
To  freeze  cells,  a  freezing  medium  must  be  prepared.  Freezing  medium  is 
complete growth medium supplemented with 5% (v/v) DMSO (Sigma). DMSO 
is a cryoprotective agent that is used to minimize damage to cells during freezing 
process. Cells were harvested using the standard protocol that was routinely used 
for subculturing. However, instead of being resuspended in growth media, cells 
are ressuspended in freezing media in a final cell concentration of 2 to 5 million 
viable  cells  per  mL.  1  mL  of  cell  suspension  is  then  added  to  appropriate 
cryogenic vials (Nunc). For a good recovery of cells the freezing step must be 
done at a slow cooling rate. For that, it was used a freezer container, Nalgene
®, 
Mr.Frosty (Sigma). The freezer container is made of polycarbonate, it has a blue 
high-density polyethylene closure, also a white high-density polyethylene vial 
holder and foam insert. It provides the critical, repeatable, 1 °C/min cooling rate 
that is required for successful cryopreservation of cells. For the freezing step, the 
container was filled with isopropyl alcohol and kept overnight at -80C. Cells 
can be stored at -80C for 6 months or in liquid nitrogen or in its vapor phase up 
to 2 years. 
 
To recover the culture, the vial must be thawed at room temperature for 1 minute 
and, after, in water bath at 37C. To avoid contamination is better to keep the cap 
and the o-ring away from the water. It is important to thaw cells quickly to avoid 
cell membrane damage. The content of the vial was centrifuged and cells were 
ressuspended in 1mL of growth media. Cells were seeded in a 25 mL T-Flask 
and grown in 7.5 mL of full growth media, at 37C with 5% CO2. 
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3.1.17.5 SH-SY5Y Neuroblastoma Cells Differentiation 
Cells were seeded at an initial density of 10
4 cells/ cm
2 in culture dishes. These 
culture dishes were previously coated with 1 mL/cm
2 of 0.01% Poly-L-Lysine 
(Sigma). The plates were left to stand for 1 h at 37 C with the Poly-L-Lysine 
solution, followed by a PBS washing step.  
 
All  trans  Retinoic  Acid  (Sigma)  was  added  the  day  after  plating  at  a  final 
concentration of 10 µM in DMEM with 15% FBS. The cells were kept under 
these conditions for 5 days, changing medium every 2 days. After the 5 days, 
cells were washed 3 times with DMEM and incubated with 50ng/mL of rhBDNF 
(Sigma)  for  another  5  days.  After  these  time  cells  were  checked  on  the 
microscope to check if they acquired neuronal characteristics. 
 
This method was developed based on Encinas et al 2000 and Gimenez-Cassina et 
al 2006 publications (Encinas et al. 2000; Gimenez-Cassina et al. 2006).  
 
3.1.1  siRNA 
 
RNA interference (RNAi) is an evolutionary conserved endogenous biological 
pathway that has been used as an experimental tool to analyse the function of 
mammalian  genes.  A  double-stranded  RNA  (dsRNA)  is  used  to  bind  to  and 
promote  the  degradation  of  target  RNAs,  resulting  in  knockdown  of  the 
expression of specific genes. RNAi can be induced in mammalian cells by the 
introduction of synthetic double-stranded small interfering RNAs (siRNAs) 21–
23 base pairs (bp) in length or by plasmid and viral vector systems that express   151 
double-stranded short hairpin RNAs (shRNAs) that are subsequently processed 
to siRNAs by the cellular machinery (Leung et al. 2005). 
 
The  interfering  method  chosen  was  siRNA.  These  are  small  RNA  molecules 
around 21 to 23 bp long, that present a 19 bp RNA duplex with a 2 nucleotide 
overhang on the 3’ end. This method has the advantage that can elude the cell’s 
stress  response  decreasing  cellular  death  and  interfering  less  on  cells 
homeostasis. The disadvantage could be the fact that provides a transient knock 
down. However, the aim of our studies was to do a simple knock down and 
analyse its effect on cells gene expression, and not to create a stable knock out 
cell line.  
 
For the siRNA assays the cells used were neuroblastoma SH-SY5Y cells and the 
gene to be silenced was Slynar. For this gene four different siRNAs were created 
to increase the probabilities of knocking down the cells. In addition, MAPK1 
siRNA was used as a positive control and a random oligomere, that won’t silence 
any gene, was used to check the effect of the siRNA assay on cells.  All the 
siRNAs  were  designed  by  Qiagen.  The  transfection  reagent  used  was 
Lipofectamine 2000 (Invitrogen) and the kit’s protocol was followed trough out 
the experiments (11 July 2006 version). To check if the knock down assay was 
working the expression level of the genes was quantified by qRT-PCR (  3.1.14). 
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3.1.1.1  Day 1: Seeding the cells 
 
On day one, cells were seeded at an initial density of 10
4 cells/ cm
2 in 6 well 
plate culture dishes. These culture dishes were previously coated with 1 mL/cm
2 
of 0.01% Poly-L-Lysine (  3.1.17.5).  
 
The cells were grown in a DMEM media supplemented with 10% FBS, but with 
no antibiotics. Using media with antibiotics during transfection causes cell death. 
The cells were left overnight at 37C with 5% CO2. 
 
3.1.1.2  Day 2: Transfection   
 
The siRNAs are prepared according to the manufacturer’s instructions (Qiagen) 
and  were  transfected  into  the  cells  using  Lipofectamine  2000  (Invitrogen). 
Lipofectamine  2000  is  a  cationic  liposome  based  reagent  that  provides  high 
transfection  efficiency  and  high  levels  of  transgene  expression  in  a  range  of 
mammalian cell types.  
 
In one tube, 100 pmol of siRNA was diluted in 250 µL of DMEM with no serum 
or antibiotics. In a second tube, 5 µL of Lipofectamine 2000 was diluted in 250 
µL of DMEM, again with  no antibiotics or FBS. The two tubes were gently 
mixed and kept  for 5  minutes at room temperature. After the  incubation, the 
siRNA was combined with the Lipofectamine 2000 and the mix was incubated 
20 minutes at room temperature. Finally, the full contents of the tube were added 
to the well with cells and media, and the cells were incubated for 24h at 37C 
with 5% CO2.   153 
3.1.1.3  Day 3: RNA extraction and quantification by qPCR  
 
After  the  cells  were  incubated  for  24h  with  the  siRNA-Lipofectamine  2000 
complexes,  the  RNA  was  extracted  using  the  method  described  on  section 
(  3.1.3.2)  and  cDNA  was  prepared  as  stated  on  section  (  3.1.5).  The  newly 
prepared  cDNA  was  then  quantified  on  the  LightCycler  480  (Roche).  The 
MAPK1 was quantified using SYBR Green Assay from Roche and the primers 
are from Qiagen. Both Slynar and the housekeeping genes, ACTB, PGK1 and 
HPRT  were  quantified  by  hydrolysis  probe  method,  using  the  Roche  UPL 
system.  Data  was  analysed  using  the  LightCycler  480  absolute  quantification 
software (Roche).  
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4  Slynar Results 
4.1  Slynar Studies in the Mouse 
4.1.1  Slynar Mouse Homologue 
As  it  was  said  in  Section    1.7.1,  not  much  is  known  about  Slynar.  However 
Slynar’s region has been implicated in bipolar disorder, as it was shown by fine 
mapping studies at UCL and in Aarhus (Denmark) (Kalsi et al. 2006). The aim of 
this study was to characterize Slynar gene and try to understand its expression 
and function. Hence, we would like to use the mouse as a model for our studies.  
 
Slynar gene was never identified on the mouse genome. The initial goal was to 
find a Slynar mouse homologue, to enable the gene’s characterization. Analysis 
of  the  UCSC  genome  browser  alignment  between  the  human  and  the  mouse 
genome (Figure   4.1) showed that the mouse genome on chromosome 5, shows a 
better alignment with the human Slynar gene in exons 2, 3 and 4. This specific 
chromosome  5  region  in  the  mouse  has  no  genes  annotated  on  the  browser. 
Figure 4.1 shows uniquely the alignment between human and mouse genomes, 
however does not give homology levels.  
 
Since there was complete alignment between human region of Slynar and the 
mouse in the region of exon 2, 3 and 4 (Figure 4.1), experiments were developed 
in order to detect a possible Slynar mouse homologue. The final goal was to 
carry out expression studies and possibly create a bipolar mouse model of Slynar. 
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 Figure   4.1 Alignment of the human Slynar sequences with the genomic DNA and with the 
mouse genome (figure taken from UCSC genomic database, assembly March 2006). On the 
top,  the  continuous  grey  bar  represents  the  chromosome  band  demarking  the  relative 
location. Below are represented all the human  mRNAs found to be expressed from this 
region. The sequence is represented by small black boxes and thinner line with arrows. The 
black boxes correspond to exons and the thinner line represents the introns. The arrows 
show the direction of the gene’s transcription. The red arrows (on the left of the legend) 
indicate  four  transcripts  correspondent  to  Slynar  and  the  alternative  splicing  products: 
AY070435, BC039096, AK091521 and CR615184. The remaining transcripts do not refer to 
Slynar, as they are transcribed from the antisense strand. In exon 3 and 4 of AY070435 
sequence, the orange bands correspond to a difference in the sequence between the genome 
and the mRNA found. On the bottom, indicated with a light blue arrow (left of legend) is 
the alignment of the mouse genome with the human genome. The sequence may contain a 
box, a single line or a double line. The box represents perfect alignment between the human 
and the mouse genome. The single line indicates that small gaps may exist between the two 
sequences. Double lines indicate that complex gaps in long portions of the sequence do exist. 
The blue circle surrounds the region where the mouse genome better aligns with the human 
genome. This region covers exon 2, 3 and 4 of Slynar (AY070435). 
 
 
4.1.2  Finding Slynar Homologue Transcripts 
Using the conserved regions between mouse and human as templates, primers for 
the mouse homologue were designed.  These primers were covering the most 
conserved region between human Slynar exon 3 and exon 4 (Figure   4.1). Primers 
sequences can be find in Table   8.1.  
 
To  try  to  amplify  a  possible  transcript  from  mouse  brain  RNA,  a  RT-PCR 
reaction was set up. The first step was to produce cDNA from mouse brain total 
RNA. For that, different reactions were done using different primers: reaction 1 – 
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the human 
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RNA with a mix of random primers and oligo dT primers; reaction 2 – random 
primers; reaction 3 – oligo dT primers. The different mixes of primers were used 
to test which pair would produce the best quality cDNA. Also a negative control 
was included, where no reverse transcriptase was added, to check for genomic 
DNA contamination  in the RNA sample (Lane  4, 6, 8 from  Figure    4.2). The 
cDNA was then used in a PCR reaction, set up with primers for the conserved 
region.  
 
The RT-PCR resulted in the amplification of a 220 bp sequence (Figure   4.2). The 
amplification only occurred on lanes 1, 3, 5 and 7, showing that there was no 
gDNA  contamination.  The  amplicon  has  the  same  size  in  both  cDNA  and 
genomic  DNA,  which  indicates  that  the  intron  was  not  spliced  out.  Since  a 
product  was  amplified  from  cDNA  produced  with  oligo-dT  primers,  this 
indicates that it had a poly-A tail. 
 
 
 
 
 
 
 
 
Figure   4.2 Mouse brain cDNA PCR products from the amplification with specific mouse 
primers for the region between end of exon 3 and the middle of exon 4: (1) gDNA; (2) 
water; (3) cDNA produced with a mix of random and oligo dT primers; (4) No RT control 
for  random  and  oligo  dT  primers  produced  cDNA;  (5)  cDNA  produced  with  random 
primers; (6) control for random primers produced cDNA; (7) cDNA produced with oligo-
dT primers; (8) control for oligo-dT primers produced cDNA; arrow, 220 bp PCR product. 
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cDNA  from testis  was also amplified using the same specific  mouse primers 
giving rise to an amplicon of the same size as the one in the brain (data not 
shown).  This  suggests  that  the  gene  is  expressed  in  this  tissue.  This  is  not 
surprising since Slynar’s expression has been detected in human testis. 
   
The PCR product amplified with the mouse specific set of primers was cloned as 
stated in section 3.1.12. A total of 96 clones were screened by PCR, using the 
same primers for region exon 3 to 4 (Table 8.1), to confirm which of these clones 
contained the expected sequence. Among the clones that came positive for the 
presence of the sequence, 16 were plasmid purified and sequenced using the 
LiCor  sequencer.  The  sequences  were  submitted  for  BLAT  (UCSC  genome 
browser)  and  BLAST  (NCBI)  searches  confirming  that  it  was  the  correct 
sequence  and  that  was  localized  to the  correct mouse  chromosome  5  region. 
When comparing the clone sequences to the genome sequence they were 98 to 
100% homologous. The small differences  found between the  mouse genomic 
sequence and the sequences of a small number of clones may be due to errors 
during the sequencing procedure. The sequence of a representative clone can be 
found in section 8.1.1. 
 
4.1.3  Slynar’s Alternative Transcription 
The previous results suggested that transcription was occurring from this specific 
conserved  mouse  region.  However  it  was  not  known  if  there  was  alternative 
transcription happening as for the human Slynar homologue. Additionally, it was 
also  unknown  what  the  size  of  these  transcripts  were  and  where  they  were 
expressed. Hence, mouse tissue mRNA blot and a mouse brain tissue blot were   158 
screened using a specific riboprobe consisting of the end of exon 2, an intron and 
the middle of exon 4 (Section   8.1.5). This probe was produced using the cloned 
amplicon as a template.  
 
 
Figure   4.3 Northern blots carried out with mRNA of different mouse tissues. Northern Blot 
A is a Mouse Tissue mRNA blot: (1) brain; (2) heart; (3) kidney; (4) liver; (5) lung; (6) 
muscle;  (7)  skin;  (8)  small  intestine;  (9)  spleen;  (10)  stomach;  (11)  testis;  (12)  thymus. 
Northern  blot  B  is  a  mouse  brain  mRNA  blot  -  (1)  frontal  cortex,  (2)  back  cortex,  (3) 
hippocampus, (4) olfactory bulb, (5) thalamus, (6) striatum, (7) cerebellum, (8) whole brain. 
Probe labelled with 
32P-αUTP. 
 
 
In both Northern blots a band of 4.5 to 5 kb was detected. This sequence seemed 
to be expressed in several tissues (Figure   4.3 A), and more highly expressed in 
the liver (Figure   4.3 A lane 4). Furthermore, a larger band was detected in the 
heart and kidney (Figure   4.3 A, lanes 2 and 3). In the mouse brain blot a 7,460 bp 
band was detected in many different brain tissues (Figure   4.3 B). Some smaller 
bands  such  as  the  ones  seen  in  lanes  3  and  8  can  be  found  (Figure  4.3  A). 
However, these bands were not considered since they were not present in the 
brain tissue and could be products of degradation.   
   159 
These results suggested that this gene was alternatively spliced in the mouse. 
Moreover, since the transcript was found to be expressed in different tissues, it 
may indicate that Slynar is a complex multifunctional gene.  
 
Even  though  these  results  look  promising,  the  data  needs  to  be  carefully 
analysed. The transcript sizes obtained in the northern blots are in a range of 4.5 
to 7.5 Kb long. The predicted transcript size in the human form of Slynar is 1.4 
Kb long. This difference can be an indication that the northern blot sequences 
may  be  non  specific  and  may  not  represent  a  Slynar  mouse  homologous 
transcript. 
 
4.1.4  The  search  for  the  detected  transcripts  –  getting  the 
cDNA clone  
 
To learn more about Slynar and its function, it was essential to get a full clone 
representative  of  the  detected  transcripts  to  proceed  with  functional  and 
expression studies.  The first step was to screen an arrayed mouse brain cDNA 
Library panel (OriGene) using the set of primers used in   4.1.2. First, a master 
plate (96 well plate) containing 500,000 cDNA clones was screened. Each one of 
the positive wells corresponds to a sub-plate. This sub-plate is an E-coli glycerol 
stock and contains 50 clones per well. Positive clones detected by PCR on the 
sub-plate are then plated on LB/ampicillin agar  and the desired clone can be 
extracted and sequenced.  
 
This master plate and a replica were screened several times and with different 
primers, however no clones were detected. Since Slynar’s expression levels in   160 
the human brain are low we can assume that the same would be expected in the 
mouse. So, there was a chance of the transcript being missed and not included in 
the cDNA  library. The sequence of all the primers used to screen the cDNA 
library can be seen in Table 8.2.  
 
To solve this problem a 5’ RACE was done. For that, RNA from mouse brain 
and liver was extracted. From the Northern blot results the liver sample seems to 
have higher levels of expression than the brain, thus the liver RNA was used to 
increase the chances of detecting a mouse Slynar clone. A positive and a negative 
control were also included in the experiment. For the cDNA synthesis step the 
mouse Slynar specific reverse primer was used (Table   8.3). In this way we would 
have only specific Slynar cDNA.  
 
After  the  RACE  amplification  steps  no  clone  was  detected.  The  RACE  was 
repeated using different brain and liver samples, all freshly extracted. Also the 
specific primers for Slynar were changed, but Slynar was still undetectable. Once 
again this could be due to very low levels of Slynar transcription.   
 
4.1.5  Slynar and Lithium 
 
Lithium is the most widely prescribed and effective mood-stabilizing drug used 
for  the  treatment  of  bipolar  affective  disorder.  McQuillin  et  al,  in  the  UCL, 
studied brain mRNA from 10 mice after treatment with lithium and compared 
them with 10 untreated controls, to understand how lithium produces changes in 
the brain. They used  Affymetrix MOE430E 2.0 microarrays after 2 weeks of 
lithium  treatment  to  detect  expression  changes  and  found  121  genes  with   161 
significant changes (McQuillin et al. 2007). Based on these results, and since 
Slynar  seems  to  be  involved  in  bipolar  disorder,  research  was  carried  out to 
check if Slynar transcripts in the mouse were changed by lithium, by qPCR. Pre-
existing RNA sample extracted from 10 brains from mice treated with lithium 
and 10 from control were used.  
 
These experiments were being run in parallel with the experiments from Section 
  4.1.4, and in accordance to the RACE and cDNA library results, Slynar was not 
detected by qPCR. Negative and positive controls were included in the assay 
which showed that the technique was working. The Roche probe sets and primers 
were  changed  (Table  8.4), to rule  out  a  specificity  problem,  but  this  did  not 
provide any explanation for the results.  
 
4.1.6  Discussion / Conclusion 
 
An unknown transcript, thought to be Slynar’s mouse homologue, was detected 
from  mouse  brain cDNA. This transcript was again detected  in two different 
northern  blots.  In  fact,  the  Northern  blots  seemed  to  show  the  existence  of 
alternative transcripts. However, these results failed to replicate on qPCR. Also, 
all  attempts  to  detect  a  representative  cDNA  clone  from  5’RACE  or  cDNA 
library screening failed.  
 
One possible explanation for the negative results is the fact that Slynar has very 
low levels of expression in the human. Thus its detection in the human would be 
difficult and may explain why it is also so difficult to detect in the mouse. If the   162 
Northern blot results were correct, Slynar is a very long transcript in the mouse, 
which can make it difficult to amplify and detect in techniques such as RACE 
and cDNA libraries.  
 
On the other hand, there is always the possibility that non-specific products were 
being  detected  in  the  Northern  blots  and  in  the  RT-PCR  experiments.  The 
template used for the riboprobe synthesis, was obtained from the RT-PCR and it 
was cloned and sequenced to confirm that it was representative of the correct 
conserved region. Some signs of possible non-specific amplification may have 
been observed from the northern blot results. The obtained sequences are longer 
than  would  be  expected,  since  the  largest  predicted  mRNA  sequence  in  the 
human in 1.48 Kb long. In addition, when the human and mouse sequence were 
compared, some conservation was found but the homology was not strong. It 
may be that a gene is being transcribed in the chromosome 5 mouse region but it 
may not be a Slynar homologue.  
 
As it was stated in Section   1.6, approximately 99% of mouse genes have human 
counterparts and  mouse orthologs can  be  identified  for 99% of  human genes 
(Tecott 2003). There is a possibility that Slynar belongs to the small group of 
genes that do not have a mouse counterpart, suggesting that it is a gene specific 
to higher mammals. This could explain why Slynar could not be detected in the 
mouse.   
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This led to the conclusion that cell line and CNS human experiments were likely 
to be more productive, since all experimental processes in the mouse seemed to 
be exhausted and no conclusive results were obtained.  
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4.2  Slynar Studies in the Human 
4.2.1  Slynar in the human 
 
Everything  that  is  known  about  Slynar  is  from  human  cell  experiments.  The 
alternative splice variants that have been detected were derived from foetal and 
adult human brain tissue, testis, pooled germ cell tumours and kidney tumours 
and are listed in the UCSC genome browser. However, very little is understood. 
The region is not well characterised in terms of transcription, alternative splicing 
and protein translation and no known function has been attributed to the gene. 
The aim of the research was to try to clarify Slynar’s function, using HeLa and 
neuroblastoma SH-SY5Y cell lines as models. Understanding the gene’s function 
would help one to build an understanding of how it may cause bipolar disorder 
and how its dysfunction affects cells and molecular pathways.  
 
 
4.2.2  Detecting Slynar in Cell Lines 
 
As was mentioned before (Section   1.7.1), Slynar’s alternative transcripts were 
found in different human tissues. Slynar transcription variants that were detected 
in  human  mRNAs  from  GeneBank  are  listed  in  the  UCSC  genome  browser 
(Figure    4.4).  Slynar  or  AY070435  is  the  predicted  gene  and  CR615184, 
BC035096  and  AK091521  are  possible  alternative  transcripts.  To  detect  the 
different Slynar variants a pair of primers was designed (Table   8.1). Looking at 
the  alignment  of  the  primer  sequences  to  Slynar  sequence  (Figure  4.4),  it  is 
possible to see that the forward primer is located in the end of exon 3 and the 
reverse primer is in the end of exon 4. The aim was to detect as many transcripts 
as possible in the two cell lines models, HeLa and SH-SY5Y.       165 
 
 
Figure    4.4  Alignment  of  Slynar  (AY070435),  its  alternative  splicing  transcripts  and  the 
primers Human Slynar Exon 3 to 4 forward and reverse, with the genomic DNA (figure 
taken from UCSC genomic database, assembly March 2006). On the top, the continuous 
grey bar represents the chromosome band demarking the relative location. The blue arrow 
shows  the  primers  used  to  amplify  the  region  between  end  of  exon  3  and  exon  4.  The 
primers are represented by two very thin black vertical lines. The two horizontal lines in 
between the forward and reverse primer is the sequence amplified by these pair of primers. 
The region below represents all the human mRNAs known to be expressed. The mRNA 
sequence is represented by small black boxes and thinner line with arrows. The black boxes 
correspond  to  exons  and  the  thinner  line  represents  the  introns.  The  arrows  show  the 
direction of the gene’s transcription. The red arrows (on the left of the legend) indicate four 
transcripts  correspondent  to  Slynar  and  the  alternative  splicing  products:  AY070435, 
BC039096, AK091521 and CR615184. The remaining transcripts do not refer to Slynar, as 
they are transcribed from the antisense strand. In exon 3 and 4 of AY070435 sequence, the 
orange  bands  correspond  to  a  difference  in  the  sequence  between  the  genome  and  the 
mRNA found. 
 
For the RT-PCR experiments, RNA was extracted  from HeLa and SH-SY5Y 
neuroblastoma cells. These were run alongside a sample of human brain RNA, 
acquired  from  Ambion.  cDNA was  synthesised.  A  reaction  with  and  without 
reverse transcriptase was run to check for genome DNA contamination.  
 
                         
Figure   4.5 Human brain cDNA PCR products from the amplification with specific primers 
for the region between exon 3 and exon 4: (A) gDNA; (B) SH-SY5Y cDNA; (C) SH-SY5Y 
cDNA negative control; (D) HeLa cDNA; (E) HeLa cDNA negative control; (F) Human 
Brain cDNA; (G) Human Brain cDNA negative control; (H) water; (I) Molecular weight 
marker HyperLadder IV (Bioline) 
A  B  C  D  E  F  G  H  I 
Human Slynar Exon 3 to 4 primers. The primers are the thin vertical lines. The 
double horizontal lines correspond to the sequence in between the primers   166 
The results of the RT-PCR experiment are shown in Figure   4.5. Three transcripts 
were  detected  in  human  brain  RNA  (Figure    4.5  F).  The  transcripts  were 
approximately 400 bp, 300 bp and 250 bp long. Moreover, there was some level 
of expression in the RNA from HeLa and SH-SY5Y cells (Figure   4.5 B and D). 
In  both  cell  lines  only  one  transcript,  of  around  400  bp,  was  detected.  This 
transcript shares the same size of the genomic band. However, the detection of 
the  bands  was  not  due  to  genomic  DNA  contamination  because  all  negative 
controls are band free (Figure   4.5 C, E, G and H).  
 
The three transcripts obtained from human brain RNA were extracted from gels, 
cloned and  sequenced. The sequences obtained  were compared to the  human 
genome  sequence  with  BLAT  from  the  UCSC  genome  browser.  AK091521 
seems to be a 400 bp band and is a clone obtained from foetal brain. This clone 
shares the same size as the genomic band since the intron is not spliced between 
exon 3 and 4. The 300  bp  band seems to represent AY070435, which  is the 
predicted cDNA. Finally, the 250 bp may be identified as BC039096, an IMAGE 
clone obtained from testis.  
 
These results confirm that Slynar is expressed in the human brain. Furthermore, 
the  presence  of  one  transcript  in  human  cell  lines  mean  that  some  level  of 
transcription  occurs  in  these  cell  models.  However,  given  that  neuroblastoma 
cells are better representatives of the human brain cells and have the capacity of 
being differentiated into mature neurons, these cells were used in the subsequent 
Slynar experiments.  
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4.2.3  Human Slynar’s Clone 
 
To do more experiments on Slynar and try to find its cellular function it was 
essential to find a full clone of the gene. For that we ran a 3’ and 5’ RACE on 
human  brain, non-differentiated SH-SY5Y and differentiated SH-SY5Y RNA. 
Neuroblastoma  cells  were  differentiated  using  the  retinoic  acid  and  BDNF 
protocol  (Encinas  et  al.  2000;  Gimenez-Cassina  et  al.  2006).  All  sequences 
detected from RACE were cloned and 8 clones of each RACE sequence were 
sequenced to confirm that they corresponded to the specific Slynar’s transcripts. 
 
 
Figure    4.6  Clones  obtained  from  3’  and  5’  RACE  aligned  with  the  GeneBank  mRNA 
sequences on the UCSC genome browser and the genomic DNA (figure taken from UCSC 
genomic database, assembly March 2006). On the top, the continuous grey bar represents 
the chromosome band demarking the relative location. The blue arrows shows the aligned 
sequences  of  the  clones.  The  5’  RACE  clones,  which  show  the  5’  side  of  Slynar  are 
5RACE_CloneA, 5RACE_CloneD and 5RACE_CloneE. The 3’ RACE clones, that show the 
3’ end of Slynar, are 3RACE_CloneB and 3RACE_CloneC. The full boxes in the clone 
sequence  are  the  sequence  of  the  clone  that  was  submitted  to  BLAT.  The  thin  line 
represents the genomic sequence that was not represented in the clone, possibily because it 
is  an  intronic  region.  The region  below  represents all the  human  mRNAs  known  to  be 
expressed. The mRNA sequence is represented by small black boxes and thinner line with 
arrows. The black boxes correspond to exons and the thinner line represents the introns. 
The arrows show the direction of the gene’s transcription. The red arrows (on the left of the 
legend)  indicate  four  transcripts  correspondent  to  Slynar  and  the  alternative  splicing 
products: AY070435, BC039096, AK091521 and CR615184. The remaining transcripts do 
not refer to Slynar, as they are transcribed from the antisense strand. In exon 3 and 4 of 
AY070435 sequence and the clones sequences there are coulored bands than corresponds to 
differences between the mRNA or clone sequences and the genome. Red means that genome 
and  query  sequence  have  different  bases  at  this  position;  orange  indicates  that  query 
sequence has an insertion; blue shows when query sequence extends to beyond the end of 
alignment.  
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In all the RACE experiments no Slynar clones were detected from SH-SY5Y 
whether they were differentiated or non-differentiated. These experiments were 
repeated at least 3 times and also alternative primers were used to try to detect as 
many clones as possible. All primers sequences can be found in Table   8.3. 
 
Running 5’ and 3’ RACE on human brain RNA lead to the detection of three 
5’RACE  clones:  5RACE_CloneA,  5RACE_CloneD  and  5RACE_CloneE,  and 
two 3’ RACE clones: 3RACE_CloneB and 3RACE_CloneC (Figure   4.6). The 
5’RACE ends are a representation of the beginning of Slynar transcription and 
the  3’RACE  clones  indicate  where  the  mRNA  stops.  However,  when  these 
clones were aligned with each other and with the gene’s transcripts sequences, 
against the human genome (Figure 4.6), it was not possible to obtain a full clone 
from the 5’ end to the 3’end. This means that a full transcript of Slynar was not 
obtained. Even after repeating the RACE experiment with freshly prepared cells 
and alternative specific primers (sequences of primers  in  section 8.1.3), there 
were no improvements. The RACE technique failed to give a full length Slynar 
clone. 
 
In a further attempt to obtain a full Slynar clone a human brain cDNA library 
panel  (OriGene)  was  used,  using  different  sets  of  primers  (Table  8.2). 
Unfortunately, after screening the library several times with more than one set of 
primers, a Slynar clone was not detected.  
 
Both RACE and cDNA library screening failed to deliver a clone for Slynar. This 
could be explained by the fact that Slynar was present in low abundance, which   169 
means that it could be hard to detect with these techniques. Also, long sequences 
are harder to obtain from RACE, and the predicted cDNA sequences on UCSC 
genome browser (March 2004) ranges from 1300 to 1750 bp. This may explain 
why it was not possible to obtain a full clone from RACE.  
  
4.2.4  Detection of Slynar by qPCR 
 
After the failure of getting a full clone of Slynar it was decided to run a qPCR 
experiment to  further  confirm  that  Slynar  was  being  expressed  in  the  human 
brain and SH-SY5Y non differentiated cell line.  
 
For that, primers and a probe were developed for qPCR using the UPL system 
(Roche).  The  primers  covered  the  exon  3  to  exon  4  region.  The  primer 
sequences, probe reference and housekeeping genes used are described in Table 
8.4  and  Table    8.5.  RNA  from  human  brain  (Ambion)  and  RNA  from  non-
differentiated SH-SY5Y cells were used. Then cDNA was synthesised. A RT and 
no RT control reaction was done to check for genomic DNA contamination. The 
samples were then cycled in the Light Cycler 480 (Roche).  
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Figure   4.7 qPCR plot. Horizontal lines: correspond to water and no RT control; red colored 
lines: human brain RNA sample; green coloured lines: SHSY5Y RNA sample; All the other 
curves: standard curve. Plot acquired from the Roche software.  
 
 
The plot in Figure   4.7 shows that Slynar was detected by qPCR (Figure   4.7 red 
and green curves). The qPCR reaction showed once more that Slynar does exist 
but at a very low level. For reactions with any housekeeping gene, a dilution of 1 
in 100 of the cDNA was used. To detect Slynar it was necessary to use 2µL of 
pure cDNA. As an example, in the experiment exemplified on Figure   4.7, on the 
same SH-SY5Y RNA sample 2.05 copies/µL of Slynar were detected and 8.58 x 
10
4 copies/µL of the house keeping gene PGK1.  
  
4.2.5  Silencing Slynar 
 
The fact that we could not obtain a full clone of Slynar made it difficult to do 
overexpression  experiments  with  the  gene  in  SH-SY5Y  neuroblastoma  cells. 
However, since it was known that some transcription of Slynar was detected in 
SH-SY5Y cells when amplifying the region between exon 3 to 4, it was decided 
to develop 4 different siRNA oligos for this region. The aim was to knock down   171 
Slynar  in  neuroblastoma  cells  and  see  how  it  affects  gene  expression  using 
microarrays. The aim of the microarray experiment was to identify pathways that 
were being altered by Slynar and elucidate potential functions of the gene in the 
human brain. It was also going to be carried out imaging experiments on calcium 
flux  changes  in  SH-SY5Y  cells.  This  experiment  was  based  on  the  fact  that 
recent GWAS studies have implicated ion channel genes such as CACNA1C in 
bipolar disorder (Ferreira et al. 2008; Sklar et al. 2008).  
 
 
Figure   4.8 Plots representing the siRNA results for MAPK1 positive control and Slynar, 
when  the  siRNA  concentration  used  was  50  pmol  and  the  RNA  colected  24h  post-
transfection. (A) MAPK1 silencing results: MAPK1 1 and MAPK 1 2 correspond to two 
different transfection reagents. 1 is Qiagen reagent and 2 is Lipofectamine2000. The two 
first MAPK1 1 and MAPK1 2 results were obtained with generation 15 batch of SH-SY5Y 
cells, and the two second pair of results were obtained using generation 16 batch of cells. (B) 
Slynar silencing results: Sly 1, Sly 2, Sly 3 and Sly 4 correspond to four different siRNA 
oligos.  For  this  experiment,  all  siRNAs  were  transfected  using  Lipofectamine2000.  The 
qPCR quantified data was normalized using PGK1 reference gene. White columns: samples 
knock down, Black columns: samples transfected with a random siRNA that won’t silence 
genes. 
   
 
Unfortunately, after optimizing the technique and achieving a stable knock down 
with  the  positive  control  siRNA  (MAPK1),  the  same  was  not  achieved  for 
Slynar. Slynar control cells had the same level of expression as the knock down 
cells and MAPK1 expression was reduced 70 to 80% when using 50 pmol of 
siRNA and collecting the RNA 24h post-transfection (Figure 4.8). Knock down 
experiments  were  attempted  at  different  times  (24h,  48h  and  72h)  with 
improvements on MAPK1 or Slynar knock down results. In addition different 
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quantities of siRNA were delivered to cells, ranging from 50 pmol to 250 pmol. 
The different concentrations of siRNA had no effect on Slynar silencing levels, 
however  50  pmol  showed  to  be  best  oligo  concentration  to  reduce  MAPK1 
expression  levels.  Finally,  two  different  transfection  agents  were  tested:  the 
siRNA  transfection  reagent  from  Qiagen  and  Lipofectamine  2000  from 
Invitrogen. The transfection reagent had no effect on Slynar silencing, however it 
is possible to see that with Lipofectamine2000 (samples MAPK1 2 from Figure 
4.8 A) higher levels of silencing were achieved than with the Qiagen reagent 
(samples MAPK1 1 from Figure 4.8 A) in silencing MAPK1 gene. This indicates 
that  in  this  experiment  Lipofectamin2000  was  a  more  efficient  than  Qiagen 
transfection reagent. Looking at MAPK1 results, it is also possible to see that in 
the two batches of cells there are differences (Figure 4.8 A), being the generation 
15 batch more efficiently silenced than the generation 16 batch. The two batches 
of SH-SY5Y cells have one splitting step of difference to each other. This shows 
that splitting cells does affect the culture and that ideally replicates must be done 
from the same batch of cells.  
 
To  conclude,  after  optimizing  and  consistently  silencing  the  positive  control 
gene, MAPK1, the same was not obtained for Slynar gene. So, no evidence of 
knock down of Slynar in SH-SY5Y cells was found (Figure   4.8). 
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4.2.6  Discussion/Conclusion 
 
In the Kalsi et al study, Slynar seemed to be the most promising gene in the 300 
Kb  sequence  within  12q24  bipolar  disorder  susceptibility  region (Kalsi  et  al. 
2006). To understand the function of the gene at a cellular level and how it might 
increase risk to bipolar disorder many assays were developed. RT-PCR and q-
PCR confirmed that Slynar is expressed in the human brain RNA, with at least 3 
different transcripts identified in the UCL (Figure   4.5). Also, a transcript that was 
not  spliced  between  exon  3  and  4  was  identified  as  being  homologous  to 
AK091521  was  found  in  SH-SY5Y  cells  (Figure    4.5).  However  it  was  not 
possible to obtain a  full  length clone  by  RACE and cDNA  library screening 
methods. From RACE we identified five clones, three from 5’RACE and two 
from 3’RACE (Figure   4.6). However these clones would not align in a way that 
would deliver a full clone. Hence, it was impossible to overexpress the Slynar 
gene and investigate its effect in cells. Therefore attempts were made to knock 
down  Slynar  in  SH-SY5Y  cells  using  the  siRNA  silencing  method.  This 
technique failed to give clear evidence of silencing which meant that was not 
possible to do further studies on Slynar. 
 
In an attempt to try to predict a possible structure and function for a putative 
Slynar peptide, the Molecular Modeling Database (MMDB) software from the 
National  Centre  for  Biotechnology  Information  (NCBI) 
(http://www.ncbi.nlm.nih.gov/)  was  used.  The  MMDB  contains  3D 
macromolecular structures, including proteins and polynucleotides. The database 
includes over 40,000 structures and is linked to the rest of the NCBI databases, 
including  sequences,  bibliographic  citations,  taxonomic  classifications,  and   174 
sequence  and  structure  neighbours.  When  submitting  the  sequences  found  in 
human brain RNA and also the RACE clone sequences, no known structure was 
detected. It is an indication that Slynar possibly does not encode a protein and 
that it may be a non-protein-coding RNA (npcRNA). 
 
 In  recent  years,  npcRNAs  have  emerged  as  a  major  part  of  the  eukaryotic 
transcriptome  and  are  known  to  play  important  roles  in  cellular  metabolism 
including RNA processing and  mRNA  stability. Indeed, altered expression of 
some  of  these  npcRNAs  has  been  associated  with  cancer,  neurodegenerative 
diseases  such  as  Alzheimer's  disease,  as  well  as  various  types  of  mental 
retardation  and  psychiatric  disorders  (Xie  et  al.  2008).  Its  importance  in 
development  has  also  been  shown  (Amaral  et  al.  2008;  Erson  et  al.  2008). 
Moreover, the progressive  maturation and  functional plasticity of the nervous 
system in health and disease seems to involve a dynamic interplay between the 
transcriptome and the environment. There is increasing evidence that dynamic 
changes to chromatin, chromosomes and nuclear architecture are regulated by 
RNA  signalling.  Although  the  precise  molecular  mechanisms  are  not  well 
understood, they appear to involve the differential recruitment of a hierarchy of 
generic chromatin modifying complexes and DNA methyltransferases to specific 
loci  by  RNAs during differentiation  and development. This process  seems to 
implicate npcRNAs and also RNA editing. RNA editing is a primary means by 
which hardwired genetic information in animals can be altered by environmental 
signals, especially in the brain, indicating a dynamic RNA-mediated interplay 
between  the  transcriptome,  the  environment  and  the  epigenome.  Moreover, 
RNA-directed regulatory processes may also transfer epigenetic information not   175 
only within cells but also between cells and organ systems, as well as across 
generations.  RNA-based  epigenetic  mechanisms  appear  to  be  essential  for 
neurological development and may be the cause of a spectrum of neurological 
diseases (Mehler et al. 2007; Mattick et al. 2009). From a psychiatric disorder 
point of view, epigenetic mechanisms have been implicated in bipolar disorder. 
Epigenomic profiling reveals DNA-methylation changes associated with major 
psychosis (Mill et al. 2008). An epigenetic  aberration  from the  normal DNA 
methylation status of REELIN may confer susceptibility to psychiatric disorders 
(Tamura et al. 2007). In a recent study, genes  of the extended dopaminergic 
(DAergic) system such as membrane-bound catechol-O-methyltransferase (MB-
COMT),  monoamine  oxidase  A  (MAOA),  dopamine  transporter  1  (DAT1), 
tyrosine  hydroxylase (TH), dopamine (DA) receptors 1 and 2 (DRD1/2), and 
related  genes  (e.g.,  reelin  and  BDNF)  are  cited  to  illustrate  the  associations 
between  differential  promoter  DNA  methylations  and  disease  phenotype  in 
schizophrenia  and  bipolar  disorder.  This  study  suggests  that  epigenetic 
alterations of the dopaminergic system do exist in major psychiatric disorders 
(Abdolmaleky et al. 2008).  
 
It is possible that there is a long distance effect from the region of chromosome 
12  encoding  Slynar  on  a  remote  gene,  which  could  be  the  real  cause  of  the 
positive association with bipolar disorder. It has been found that more than 50% 
of genes uses tissue-specific promoters and that can be located in set of exons 
outside the current boundaries of their annotation (Denoeud et al. 2007). For 
some genes the promoters of other neighboring genes are used in specific cells 
and/or  developmental  stages.  Slynar’s  region  may  also  contain  enhancer  and   176 
silencer sequences, which could mean that a mutation in this region may affect a 
gene  in  a  totally  different  location.  Enhancers  and  silencers  are  a  type  of 
regulatory DNA sequences that may be located 5’ or 3’ or within an exon or 
intron of a gene. These regulatory sequences are considered to act via a DNA-
loop.  The  enhancer  or  silencer  and  core  promoter  are  brought  into  close 
proximity by looping out the intervening DNA (Maston et al. 2006). Whereas 
there  are  common  motifs  in  core  and  proximal  promoters,  enhancers  and 
silencers do not contain many distinctive sequence motifs. Therefore they cannot 
easily  be  identified on the basis of their DNA sequence alone (Maston et al. 
2006; de Vooght et al. 2009). 
 
To conclude, we failed to find Slynar’s function in this work. However there is a 
possibility that Slynar is a non protein coding sequence. There is a possibility 
that Slynar may be a regulatory RNA. It may also be a region rich in regulatory 
sequences  for  other  genes.  In  any  of  these  hypotheses  aetiological  base  pair 
change in the 12q24 Slynar region could ultimately result in the disruption of a 
gene or a pathway and be indirectly causative of bipolar disorder.      
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5  IGF1 Results  
 
5.1  IGF1 Sequencing 
From the UCL GWAS sample, 32 cases and 32 controls were selected, according 
to the most representative haplotypes (16 cases that presented rs5742688 allele A 
and 16 cases presenting the haplotype AAG composed by rs5742688, rs35765 
and rs2607983 SNPs).  
The  chosen  samples  were  sequenced  using  29  pairs  of  primers  (Primers 
sequences in Table 8.6) covering a total of approximately 9000 bp. The primers 
were designed to cover 1500 bp of the promoter region, the exons, intron/exon 
junctions and the 3’ UTR of IGF1. The sequencing was done using the Big Dye 
Terminator  v3.1  Cycle  Sequencing  Kit  (Applied  Biosystems)  and  ran  on  the 
3730xl  DNA  Analyzer  (ABI).  The  results  were  analysed  using  the  Staden 
Package Pregap4 and Gap4 (Staden 1996).  
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Figure   5.1 IGF1 sequencing traces. In the center of the traces there are the SNPs found in 
IGF1. (A) Pc, (B) Pd, (C) rs5742612, (D) rs5742620, (E) rs6214, (F) 4k.  Figure obtained 
from the Staden package traces analysis.  
 
 
Analysing the sequences (Figure 5.1), seven new markers were found: three non 
database SNPs (4k, Pc and Pd), three database SNPs (rs6214, rs5742612 and 
rs5742620) and a previously published CA repeat (Rotwein et al. 1986). The 
SNPs  Pc,  Pd,  rs5742612  and  the  microsatellite  are  located  in  the  promoter 
region. The CA repeat is located approximately 750 bp before the start of IGF1. 
Database SNP rs5742620 is in intron 1, approximately 26 bp from beginning of 
exon 2. SNPs rs6214 and 4k are located in the 3’untranslated region (UTR).  
All the markers found from sequencing, that showed to be more represented in 
the 32 cases than controls or not present at all in controls, were genotyped in the 
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full UCL sample of 937 cases and 941 controls. The CA repeat found in the 
promoter region was genotyped by amplifying the sequence using PCR primers 
that were directly labelled with a fluorescent probe. The amplified samples were 
loaded
  manually  and  electrophoresed  on  Li-COR  DNA  4200  sequencers  (Li-
COR
 Biosciences). The SAGA-GT (Li-COR)
 program was used to perform the 
microsatellite analysis. The identified SNPs were genotyped using two different 
methods. SNPs rs5742620, 4k and rs6214 were genotyped in the UCL lab using 
the  KBiosciences  competitive  allele  specific  PCR  system  (KASPar)  and  Pd, 
rs5742612 and Pc were genotyped using High-resolution melting Curve Assay 
from Roche.  
Results of allelic association tests for these markers are shown in Table   5.1 and 
Table 5.2. The association tests for SNPs were done using a simple Chi
2 test. The 
CA  repeat  association  test  was  done  using  CLUMP.  Out  of  the  seven  new 
markers  two  showed  evidence  for  association  (Pd,  p=0.006;  CA  repeat, 
p=0.0132).  
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Table   5.1 Tests of association of SNPs in the IGF1 region that were found by sequencing. 
Association test done using Chi
2. UCSC March 2004 assembly positions. 
Marker  Marker Location  Alleles and Observed Allele Frequencies  χ2  P value 
Ex4k    G    C        
Controls  101295526  1786  0.975  46  0.025  0.299  0.583 
Cases     1793  0.978  41  0.022       
rs6214    G    A       
Controls  101296036  769  0.414  1089  0.586  0.415  0.519 
Cases     785  0.424  1065  0.576       
rs5742620    C    A        
Controls  101372067  51  0.028  1779  0.972  3.724  0.053 
Cases     73  0.04  1783  0.96       
Pd    G    T        
Controls  101377223  1805  0.973  51  0.027  7.490  0.006 
Cases     1825  0.985  27  0.015       
rs5742612    T    C       
Controls  101377331  1781  0.96  75  0.04  0.753  0.385 
Cases     1793  0.965  65  0.035       
Pc     T     G          
Controls  101377396  1785  0.96  75  0.04  0.753  0.385 
Cases     1797  0.965  65  0.035       
 
 
Table    5.2  CLUMP  analysis  of  the  CA  repeat.  UCSC  March  2004  assembly  positions. 
pValues from all CLUMP tests in Table   8.8.* pValue from CLUMP T3 test. 
 
 
 
5.2  IGF1 Haplotypic association 
Linkage desiquilibrium (LD) analysis of all the GWAS data and the new markers 
found  by  sequencing  was  done  using  GENECOUNTING  software  package 
(Zhao et al. 2000; Zhao et al. 2002; Curtis et al. 2006). Linkage disequilibrium 
(LD)  between  pairs  of  markers  after  being  calculated  was  observed  using 
LocusView 2.0 (Petryshen et al. 2003) (Figure 5.2)  
Marker Marker Location χ2 P value
CA Repeat
Controls 101377593 1 0.001 5 0.003 25 0.014 104 0.060 1150 0.664 325 0.188 83 0.048 37 0.021 2 0.001 9.461 0.0132*
Cases 1 0.001 9 0.005 28 0.016 98 0.056 1113 0.632 352 0.200 128 0.073 31 0.018 0.000
310
Alleles and Observed Allele Frequencies
278 284 298 300 302 304 306 308  181 
 
Figure   5.2 LD plot with all markers covering IGF1 region, analysed in the 2000 case/control 
UCL sample. LD representation done using LocusView 2.0 (Broad Institute).  On the top, 
the purple bar represents IGF1 gene. The vertical bands correspond to the exons and the 
horizontal band represents the introns. IGF1 is transcribed from the negative strand of the 
chromosome. Below there is an logarithm plot, plotting IGF1 log values of the 44 markers. 
The full dots correspond to markers that showed association to bipolar disorder. The empty 
dots are from markers that did not show association to bipolar disorder. The black band 
represents the chromosome band demarking the relative location of IGF1. Below, there is a 
representation of the LD block of the 44 IGF1 markers. Strong red equals a D’ of 1. D’ <1 is 
represented with lighter shades of red. The five green arrows are pointing out the SNPs that 
correspond to HAP A and the three orange arrows are indicating HAP B. 
 
Due to the high number of markers used in the haplotypic analysis of IGF1, a 
preliminary  analysis  of  the  haplotypes  was  done  using  SCANASSOC.  This 
Promoter region  Downstream region of IGF1   182 
software,  that  is  part  of  GENECOUNTING  software  package,  computes  the 
maximum  likelihood  estimates  of  haplotypic  frequencies  but  does  not  do the 
permutation  testing  to  calculate  the  empirical  significance.  Analysing 
SCANASSOC’s raw data together it was possible to choose the haplotypes that 
were more represented in cases rather than controls. The chosen haplotypes were 
inputted into GENECOUNTING to test for the significance of the results. 
Haplotypic analysis of the region showed that there are two groups of alleles that 
show empirical association, as  it  is possible to analyse  in table 5.3 empirical 
significances, calculated using GENECOUNTING. HAP A includes five markers 
downstream of the gene (rs11111243, rs10860857, rs4764695, rs10860860 and 
rs2946831)  (Figure  5.2,  green  arrows  indicating  markers).  These  markers,  on 
their own, do not show allelic association as we can see on the dot plot in Figure 
5.2. However, the five SNPs together show an empirical haplotypic association 
of  0.0006  (Table    5.3).  In  addition,  the  haplotype  comprising  the  CA  repeat, 
rs2195243 and rs12309723 (located in the promoter region, Figure 5.2, orange 
arrows indicating markers) gives an empirical pValue of 0.00068 (Table   5.3). 
Looking at the dot plot from Figure 5.2 is possible to see that the three markers 
of  this  haplotype  are  significant  on  their  own.  However,  the  three  markers 
together have a higher level of significance than on their own. It should be noted 
that GENECOUNTING computes significances for all possible haplotypes as a 
global test and does not give significance for individual haplotypes for a given 
set of markers. 
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Table   5.3 Haplotypic association with bipolar disorder and IGF1 markers. Results obtained 
using GENECOUNTING software. The group of alleles of HAP A and HAP B represented 
in the table were the ones showing a higher presence in cases than controls.  
Haplotype name rs11111243 rs10860857 rs4764695 rs10860860 rs2946831 CA repeat rs2195243 rs12309723 Controls Cases Global Empirical Significance
HAP A C C C T A 9.96% 15.85% 0.0006
HAP B 306 G A 3.07% 6.18% 0.00068018
Alleles Frequency
 
 
In addition, a global analysis of the all dataset was done using COMBASSOC 
(Curtis et al. 2008). This indicates the significance of the entire set of markers 
and haplotypes in the gene and gives a ‘gene wide’ analysis of association which 
needs  no  further  correction  for  multiple  markers  within  the  gene.  Two  data 
analysis were done: (a) using the 44 markers data; (b) using the 44 markers and 
the two haplotypes, HAP A and HAP B. COMBASSOC analysis of the entire set 
of markers gave an empirical significance of 0.009. The joined analyses of the 44 
markers, HAP A and HAP B gave an empirical significance of 0.0058.  
 
5.3  Discussion/Conclusion 
IGF1  has  been  implicated  in  many  diseases.  There  is  increasing  evidence  of 
IGF1  having  a  protective  effect  against  metabolic  syndrome,  endothelial 
dysfunction, atherosclerotic plaque development or ischemic myocardial damage 
(Conti et al. 2004). There are studies that indicate that high plasma levels of 
IGF1 may reduce risk of type 2 diabetes and coronary disease (Sandhu 2005). 
Also,  a  2008  review  brought  together  the  findings  that  implicate  the  IGF1 
pathway and IGF1 receptor to the progressive loss of neurogenic capacity of the 
aging brain and to the pathogenesis of Alzheimer's disease (Puglielli 2008). The 
data presented here implicates IGF1 in bipolar disorder.   184 
The GWAS study in the UCL sample highlighted 10 SNPs, five within IGF1 and 
five  in  the  promoter  region  (Table  1.,  Figure  5.2).  These  SNPs  showed 
association  with  bipolar  disorder  (Table  1.),  the  strongest  P-value  being 
P=0.000037.  
 
Sequencing of IGF1 did not identify any potential aetiological base pair changes. 
However, new markers were detected and genotyped in an extended UCL sample 
of  937  cases  and  941  controls.  Database  SNP  rs5742620  showed  a  trend  to 
association (Table 5.2) is located in an intronic region, between exon 1 and 2. 
Due to the close proximity to exon 2 (around 24 bp from the beginning of exon 
2,  Figure  5.2), this  SNP  could  change  the  splicing  patterns  of  this  particular 
intron. To analyse this possibility the sequence of this region, with both SNP 
alleles,  was  analysed  using  the  Splice  Site  Prediction  by  Neural  Network 
(http://www.fruitfly.org/index.html). The software uses training and tested sets of 
human and Drosophila melanogaster splice sites, for testing splice site predictors 
other human or Drosophila DNA sequences (Reese et al. 1997). The base pair 
changes due to the presence of the SNP rs5742620 do not seem to affect the 
predicted splicing site. Nevertheless, there is always the possibility that a change 
so close to the exon may affect the transcription, for example, by the changing 
folding structure of the DNA chain in that region decreasing the efficiency of 
transcription.  
 
The two significantly associated markers found by sequencing were Pd, a non 
database SNP and a CA repeat. The two markers show association with bipolar 
disorder, respectively, with significance values of 0.006 and 0.0132 (Table   5.1   185 
and Table 5.3). Both markers are between 750 to 1000 bp from IGF1 (Figure 
5.2).  It  is  known  that  the  promoter  is  a  regulatory  region  of  DNA  located 
upstream  of  a  gene  and  plays  an  important  role  in  transcriptional  regulation. 
Some 1% of single base-pair substitutions causing human genetic disease occur 
within gene promoter regions, where they disrupt the normal processes of gene 
activation  and  transcriptional  initiation  and  usually  decrease  or  increase  the 
amount  of  mRNA  and  thus  protein  (Cooper  2002).  Examples  of  promoter 
mutations  causing  disease  include  β-thalassemia,  Bernard-  Soulier  syndrome, 
pyruvate  kinase  deficiency,  familial  hypercholesterolemia,  and  hemophilia 
(Maston et al. 2006).  Hence, the importance of the finding of the five GWAS 
positive markers in IGF1 and the two additional markers found by sequencing. 
Changes in the promoter region could disrupt expression of IGF1 which could be 
causative of disease.  
 
The haplotypic analysis of the CA repeat with other two SNPs (Table   5.3) further 
implicate the promoter region and the microsatellite in bipolar disorder, with a 
pValue of 0.0006. This microsatellite has been published in the past due to its 
possible involvement in many diseases. It has been shown to be associated with 
left ventricular hypertrophy (LVH) (Bleumink et al. 2005). The absence of the 
common  allele  seems  to  show  higher  susceptibility  to (LVH).  Vaessen et  al, 
reported that individuals not carrying the commonest allele of the dinucleotide 
repeat showed lower body weight, lower birth weight and increased relative risk 
of type 2 diabetes and myocardial infarction (Vaessen et al. 2001; Vaessen et al. 
2002). The CA repeat’s common allele has also been implicated in increased 
levels of fasting serum trygliceride in glucose-tolerant subjects (Nielsen et al.   186 
2004). The muscle strength response to strength training was studied in a set of 
67 adults and replicated in a bigger sample of 128 individuals. The data suggests 
that the presence of the IGF1 promoter polymorphism may influence strength 
response  to  strength  training  (Kostek  et  al.  2005;  Hand  et  al.  2007).  IGF1’s 
promoter dinucleotide has also been linked and associated (p-value = 0.0002) 
with obesity risk traits in a study of 190 parents and 312 adult offspring (Sun et 
al. 1999). It may be relevant that this microsatellite has been conserved among 
species, being found in mice, rats, pigs, sheep, cattle and equids (Shimatsu et al. 
1987; Dickson et al. 1991; Kirkpatrick 1992; Caetano et al. 1998; Andrade et al. 
2008). 
 
The COMBASSOC global analysis shows that IGF1 region is associated with 
bipolar disorder.  
 
The  positive  results  are  further  confirmed  by  examination  of  data  from 
UCL/STEP-BD (Sklar et al. 2008), WTCCC GWAS (WTCCC 2007) and the 
Ferreira  data  (Ferreira  et  al.  2008).  The  IGF1  region  was  covered  by  SNPs 
included  in  the  chips  and  show  positive  association  in  all  the  three  samples 
(Table 5.4).  In both WTCCC and Ferreira et al samples rs7955640 was the SNP 
most strongly associated with bipolar disorder (0.0132 and 0.0053, respectively). 
This  SNP  is  located  upstream  the  IGF1  gene.  In  the  STEP-BD  sample, 
rs7955640 shows no association, but there are three SNPs, all with pValues of 
0.0301 also upstream IGF1. In the WTCCC sample we can also observe that 
three  SNPs  with  pValues  ranging  from  0.03  and  0.04  show  association 
downstream of the IGF1 gene.    187 
 
Table   5.4 Association analysis of IGF1 region in STEP-BD (Ferreira et al. 2008), Wellcome 
Trust (Lopez et al. 2007) and Ferreira et al (Ferreira et al. 2008) data. 
SNPs Position WTCCC STEPBD Ferreira et al
rs7313075 101154809 >0.05 >0.05 >0.05
rs12426318 101159651 0.0317 >0.05 >0.05
rs17439974 101192963 >0.05 >0.05 >0.05
rs10745938 101213386 0.0362 >0.05 >0.05
rs4764695 101281243 0.0426 >0.05 >0.05
rs5742688 101336656 >0.05 >0.05 >0.05
rs2072592 101337762 >0.05 >0.05 >0.05
rs12423791 101382958 >0.05 >0.05 >0.05
rs4764698 101384190 >0.05 >0.05 >0.05
rs5742615 101394931 >0.05 >0.05 >0.05
rs35765 101405826 >0.05 >0.05 >0.05
rs860598 101422576 >0.05 0.0309 >0.05
rs2607983 101423834 >0.05 0.0310 >0.05
rs12309723 101447643 >0.05 >0.05 >0.05
rs703542 101465208 >0.05 >0.05 >0.05
rs703548 101468803 >0.05 >0.05 >0.05
rs7955640 101492429 0.0132 >0.05 0.0053
rs10778179 101495406 >0.05 >0.05 >0.05
rs4609653 101496200 >0.05 >0.05 0.0443
rs1457602 101498898 0.0468 >0.05 0.0082
rs10745943 101504886 >0.05 >0.05 >0.05
rs2100635 101515117 >0.05 >0.05 0.0343
rs7977073 101515601 >0.05 >0.05 0.0239
rs17032879 101517463 >0.05 0.0301 >0.05  
 
Differences between the results of the different population samples are likely to 
be  due  to  allelic  and  locus  heterogeneity.  The  three  samples  are  based  on 
different populations. The STEP-BD (Sklar et al. 2008) study uses a population 
sample from America, the WTCCC (WTCCC 2007) uses individuals that were 
living  within  England,  Scotland  and  Wales  (‘Great  Britain’)  and  identified 
themselves has white Europeans and the UCL sample (Sklar et al. 2008) had 
bipolar  disorder  subjects  who  had  both  parents  of  English,  Irish,  Welsh  or 
Scottish  descent  and  three  out  of  four  grandparents  of  the  same  descent.  In 
addition, there is the possibility that bipolar disorder follows a polygenic model 
where interaction of modest effects from many genetic variants in each affected 
individual may be the cause of disease.    188 
In conclusion, the new data seems to suggest the involvement of IGF1 in bipolar 
disorder.  
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6  Future Work 
6.1  Slynar 
 
Unfortunately, during the time of PhD it was not possible to unravel the truth 
about Slynar. This project focused on Slynar, however there are other unknown 
transcripts in the implicated 300 Kb region. This region has been implicated as a 
susceptibility region for bipolar disorder in two different populations (UCL and 
Denmark) (Kalsi et al. 2006). The  next step would  be to carry out a project 
where the surrounding genes are characterized. They could be expressed in the 
mouse and they too could be studied for expression patterns in different tissues. 
 
The  idea  that  Slynar  may  be  a  ncpRNA  or  even  a  region  rich  in  critical 
regulatory  sequences  for  other  genes  should  not  be  discarded.  With  the 
development of new techniques it should become easier to study Slynar and its 
possible regulatory functions further.  
 
It is also  important that more replication studies are done  in bipolar disorder 
studies. It is important to note that the Slynar region is not represented on the 
chips used for the latest GWAS (WTCCC 2007; Baum et al. 2008; Ferreira et al. 
2008; Sklar et al. 2008). So, the lack of results implicating Slynar in the latest 
GWAS is due to lack coverage and not to a failure of finding association.  
 
Slynar  has  been  previously  sequenced  by  members  of  our team,  however  no 
aetiological base pair changes were found. The gene should now be resequenced, 
to include the surrounding areas. It is known that regulatory regions can be in   190 
found as far as 14 Kb (Ho et al. 2006) and 5’ untranslated regions have been 
shown  to  contain  critical  regulatory  elements  (Zimmermann  et  al.  2005;  de 
Vooght et al. 2008). The intronic regions should also not be overlooked. There 
are examples of mutations in intronic regions that can cause disease. An example 
is  myotonic  dystrophy  (type  2),  which  is  caused  by  a  CGTG  expansion,  of 
approximately 5000 repeats, located in the zinc finger protein 9 (ZNF9) gene 
(Liquori et al. 2001). The three SNP haplotype, located in intron 1 of OCA2 
(Oculocutaneous Albinism type 2), is thought to influence eye colour variation 
(Duffy et al. 2007).  
 
 
6.2  IGF1 
 
Similarly  to  what  was  described  in  Section    6.1  for  Slynar,  IGF1  association 
ought to be replicated in further samples to confirm association. IGF1 can also be 
subjected to more sequencing covering further 5’ and 3’ non translated areas and 
introns. It has been discussed on the previous section that the gene surrounding 
areas and introns may carry important regulatory sequences (Liquori et al. 2001; 
Zimmermann et al. 2005; Ho et al. 2006; Duffy et al. 2007; de Vooght et al. 
2008).  A  base  pair  change  in  these  regions  could  hold  the  answer  to 
understanding how IGF1 may cause bipolar disorder.  
 
IGF1  is  a  very  well  known  gene.  However,  until  now  it  has  never  been 
implicated in bipolar disorder. The next step it to understand how IGF1 may be a 
risk factor to bipolar disorder. For that, knock out studies with cell lines and 
animal models should be done. A subsequent expression analysis of other genes 
implicated in bipolar in the presence and absence of the knock out, could give an   191 
insight in how IGF1 may interact with other genes to cause bipolar disorder. An 
example of sets of genes to be used in this study could be BDNF and serotonin 
related genes. BDNF has been implicated in the past on bipolar disorder (Neves-
Pereira et al. 2002; Sklar et al. 2002) and association with the disease has been 
found on the short allele of serotonin transporter gene (5-HTT) (Collier et al. 
1996). More recently, studies have shown that the central administration of  IGF1 
and BDNF in rats lead to a long lasting antidepressant-like effect (Hoshaw et al. 
2005). The authors discuss that the BDNF and IGF1 antidepressant-like effect 
may  be  mediated  through  serotonergic  pathways  or  receptors.  This  theory  is 
supported by data indicating that administration of BDNF  increases serotonin 
tissue content and the mRNA of tryptophan hydroxaylase (the limiting step in 
serotonin production), in the rat brain (Siuciak et al. 1996; Siuciak et al. 1998). 
In addition, a more recent study where IGF1 was centrally administered to rats 
led to the hypothesis that IGF1 initiates a long lasting cascade of neurochemical 
effects  involving  increased  serotonin  levels  that  results  in  antidepressant-like 
behavioural effects (Hoshaw et al. 2008). It has been shown that the downstream 
signalling pathways of IGF1, BDNF and 5-HT demonstrate a high degree of 
overlap (Mattson et al. 2004). Malberg et al in a review paper discuss that the 
functional effects of these three signalling pathways might be a combination of 
increasing cell proliferation and neurogenic pathways, all with the objective of 
increasing synaptic strength and plasticity (Malberg et al. 2005).   
 
Another interesting study could be to overexpress IGF1 in an animal model. As 
far as I could find in the literature, attempts have only been made to create a 
depressive  behaviour  in  animals  by  blocking  IGF1,  followed  by  IGF1   192 
administration to confirm IGF1’s antidepressant-like effect. However it would be 
interesting to see what the effect of having too much IGF1 and to check if this 
resembled the bipolar phenotype of mania.  
 
Another obvious  experiment  could  be  the  use  of  sequences  with  the  positive 
SNPs  that  are  located  on  the  promoter  region  and  to  do  an  electrophoretic 
mobility shift assay (EMSA), to observe if they affect the binding of a possible 
regulatory protein. If it had a real effect, the mutation could be used to create a 
transgenic mouse and see how the animal behaviour would be affected.  
 
If further replications of association are successful, IGF1 pathways may become 
a target for new drug treatments of affective disorder. If mutations can be found 
than predictive testing and  studies of treatment outcome can  be envisaged. It 
seems likely that the current phase of genetic research with GWAS is analogous 
to  the  days  of  linkage  analysis.  At  that  time  the  complication  was  locus 
heterogeneity and only when many studies were completed could a consensus be 
reached. For association studies the problem is haplotypic diversity with different 
disease haplotype frequencies being present even within UK. 
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8   Appendix  
 
8.1  Primers  and  Probes  Sequences  for  Slynar 
Experiments  
8.1.1  RT-PCR 
 
Primers  sequences  used  for  both  mouse  and  human  cell  lines  RT-PCR 
experiments.  
Table   8.1 Slynar primer sequences for RT-PCR 
Forward Primers Reverse Primers
Slynar Mouse Exon 3 to 4 CTGCCAGATCTGATTTTCTGC GGATGGGAAAGAACAGAAGG
Slynar Human Exon 3 to 4 ATGGAGCCTGTTGAGCCACAG GCTGCTAAGGAACTCAGTCTG
  
The clone sequence of the 220 bp band found in the mouse was: 
 
CGGCCGCGAGCTCGGGCCCACACGTGTGGTCTAGAGCTAGCCTAGGC
TCGAGAAGCTTGTCGACGAATTCAGATTGGATGGGAAAGAACAGAAG
GCAATAGGAATGTCAGTCACTGCCCATGGACTGGGAGGACAGCAAAA
CAAAAATCCAGCAGCTGACATGGTATCTATAAGATGATGTCCAACAC
AACCCTCTGGCTACCCTGGGCCTCATCAGCAGTGAGAAGTCATGGAT
CATGCATTCTCAATGACCTTCCAGAAGACCAGGCAGAGGGCAGAAAA
TCAGATCTGCAGAATCACGAATTCTGGATCCATACGTAACGCGTCTGC
AGCATGCGTGG 
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8.1.2  cDNA Library Screening 
 
Primers sequences used for Slynar’s detection on the cDNA library. The table 
shows the primers used for both mouse and human cDNA library screenings. 
 
Table   8.2 Slynar primers used for cDNA library screening 
Forward Primers Reverse Primers
Slynar Mouse Exon 3 to 4 CTGCCAGATCTGATTTTCTGC GGATGGGAAAGAACAGAAGG
Slynar Human Exon 3 to 4 ATGGAGCCTGTTGAGCCACAG GCTGCTAAGGAACTCAGTCTG
Slynar_AK Human Exon 1 to 3 TCTCTGTGCCTGAGTCGTTG AGGGAGAAGTCGATTCAGCA
Slynar_DA7 Human Exon 1 to 2 CGGTTCAGAAAAGTTGTCAGG AAGCCAACACCTCTCTCCTT
   
8.1.3  RACE 
 
The table lists the sequences for the gene specific primers used for 3’ and 5’ 
RACE experiments, for both human and mouse. 
 
Table   8.3 Slynar primers used for RACE 
                   
5' RACE Gene Specific Primers
Slynar Mouse Exon 4 GGATGGGAAAGAACAGAAGG
Slynar Mouse Exon 3a GCAGAGGGCAGAAAATCAGA
Slynar Mouse Exon 3b TTCCAGAAGACCAGGCAGAG
Slynar Mouse Exon 2 AAGGTATAATGTGCAGGCTTTTT
Slynar Human Exon 4a  GCTGCTAAGGAACTCAGTCTG
Slynar Human Exon 4b  TTCCCCAACAGTGAAAATTCGTG
Slynar Human Exon 3  AGGGAGAAGTCGATTCAGCA
3'RACE Gene Specific Primers
Slynar Human Exon 1a GGAGTTTCCGTGCCAGAG
Slynar Human Exon 1b CGGTTCAGAAAAGTTGTCAGG
Slynar_AK Human Exon 1a  CACACGGCTACATTTCGGTA
Slynar_AK Human Exon 1b TCTCTGTGCCTGAGTCGTTG  
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Sequences from the clones obtained from human 3’ and 5’ RACE: 
Human 3’ RACE clone B 
TTTTTTTTTTTTTTTTTTTAGAATGCAGGATTTTAATTCTAAGGGAAAG
GAAAATTCTCCATGTATCTAATCTAAAAAAAACATGGAAGTCATCAT
GAGTTTGTTTCTGGGGGATGATATCAGATGAAAATGGGCCCTTAGGT
AGTAGGAGGTGGCAGGTCTCAGTTCAGTGTTTACACATGGCTCCACG
CAGAGCTACAGACTGAGTTCCTTAGCAGCTTCCGTAGGAGGTCCTTTG
AAGAAGGGCTGCTCTGCATTCGATATGTAGAAACTTGTGGAGAAGAT
GAGGAAACTGAGGAAAACCACCAATGCAATCCACAATCCAATCCCTT
GACTCTCTGTTTTCCCCAACAGTGAAAATTCGTGTACAGAGTATTCCC
CAATGACTTCTCTCAGGCAATGTAGAAAGGGAGAAGTCGATTCAGCA
TTGACTAGTTGGTACTGTGGCTCAACAGGCTCCATCTCTGAAAGTGTT
GTTTCTTCCTTTTCCGGAGCTGGAACTGCCTGTCCGCGTGGACCCTCTC
CTCTGGCACGGAAACTCC 
 
Human 3’ RACE clone B 
TGGAGTTTCCGTGCCAGAGGAGCGGGTCCACGCGGACAGGCAGTTCC
AGCTCCGGAGAGTCAAGGGATTGGATTGTGGATTGCATTGGTGGTTTT
CCTCAGTTTCCTCATCTTCTCCACAAGTTTCTACATATCGAATGCAGA
GCAGCCCTTCTTCAAAGGACCTCCTACGGAAGCTGCTAAGGAACTCA
GTCTGTAGCTCTGCGTGGAGCCATGTGTAAACACTGAACTGAGACCT
GCCACCTCCTACTACCTAAGGGCCCATTTTCATCTGATATCATCCCCC
AGAAACAAACTCATGATGACTTCCATGTTTTTTTTAGATTAGATACAT
GGAGAATTTTCCTTTCCCTTAGAATTAAAATCCTGCATTCTAATTTTCA
AAAAAAAAAAAAAAA 
 
Human 5’ RACE clone A 
CGAGGTTAGGGGTTATGTGTGAGATAGTATGCCAGCCTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTGTCCAGCGCGAGCGTTCGTATCGGATCCGAA
TTGTGATTGGCCACGCGGCGACTAGTACGGGGGGGGGGGGGCACAAA
GGGCTGAACTTGCAGGAGCCCCGCTTCTCAACCTCCATCGCTTTATGA
ATGAATTCACTAGAAAGAAAAGGAAGAATCAACACTTTCAAAGATGG
AGCCTGTTGAGCCACAGTACCAACTAGTCAATGCTGAATCGACTTCTC
CCTTTCTACATTGCCTGAAAAAAGTCATTGGGGAATACTTTGTACTAG
TCGACGCGTGGCCA 
 
Human 5’ RACE clone D 
CCTCCTCGGGCTCGCTATCTGTTTGTTTTAGATGCAAAGCCAAAAATT
TTTTTTTTTTTTTTTTTTTATTTTTTTCTCTTACTCTAATGTTCTTATCTG
ATCCAGAATTCCTGATTGGTAGATTGCAACAAAATATTCTTGAATTTA
GACATATATATTGAATTTTATAAAGCCACAAATATATGTCTTGAGGAA
TACATGGTAGTTTGACAAGCCAACACCTCTCTCCTTAATCCAAAATTC  267 
AAAAGGTAGTATAATTCTTTCTTTCCCAGCAGCAGAGGAAGTGACTAT
TGCAACCCACATTCTGAGTGTGAAATGAGGCCTCATTCAGTTTCCTAA
TTTCCAAGATTCTTTTTCAGCACCCAGCTGAATAAAGTATGTCCCGGA
GCTGGAACTGCCTGTCCGCGTGGACCCTCTCCTCTGGCACGGAAACTC
CGTGTCTGCAGACTGCCTCAGCCCTGGAGACTTCTGCCGGGAACCCG
GGACACCGAGAGGGGCCCAGCCCTTCCCCATCTCTCTCCTGACCGTTA
CTCCGGACAGGTAGGGTCTGCGCTCCTCTCCCCCCCCCCCCCCGTACT
AGTCTACGCGTGGCCA 
 
Human 5’ RACE clone E 
CTCCCCAAGGAAAATTTCCGTCGATTTGGCTAAGATTGCAACAAAAT
ATCCTTTAGAATGTTAGACATATATATTGAATTTTATAAAGCCACAAA
AATATGTCTTGAGGAATACATGGTAGTTTGACAAGCCAACACCTCTCT
CCTTAATCCAAAATTCAAAAGGTAGTATAATTCTTTCTTTCCCAGCAG
CAGAGGAAGTGACTATTGCAACCCACATTCTGAGTGTGAAATGAGGC
CTCATTCAGTTTCCTAATTTCCAAGATTCTTTTTCAGCACCCAGCTGAA
TAAAGTATGTCCTGTGCCGGGGAAGGCGCCAAGCACCCGCCCCAGCG
CGCCGCACCTGCCGGGGCCGCGATCTCCCAGCTCATCGAGTCCCTCGC
GCCCGTGGCCCTTTGACCCCCCCCCC 
 
8.1.4  qPCR  
 
The first table shows the sequences for the primers used on qPCR and also the 
specific UPL Roche probe for the region.  
 
Table   8.4 Slynar primers and UPL probes used for qPCR 
Forward Primers Reverse Primers UPL probes
Slynar Mouse Exon 3 to 4 (a) aaggcaataggaatgtcagtcac tgtcagctgctggatttttg 56
Slynar Mouse Exon 3 to 4 (b) tccatgacttctcactgctga ggtatctataagatgatgtccaacaca 106
Slynar Human Exon 3 to 4  cctgttgagccacagtacca caatgacttctctcaggcaatg 7  
 
The  second  table  contains  the  list  of  reference  genes  used  on  the  qPCR 
experiments for the mouse and the human cell lines. These set of primers were 
obtained from Roche or Qiagen and were ready to use optimised mixes. MAPK1 
was not used as a reference gene for qPCR but was a positive control for siRNA. 
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Table   8.5 List of house keeping genes used in human and mouse qPCR experiments 
Genes Source Mouse Human Function
ACTB Roche   Reference
HPRT Roche   Reference
Gus B Qiagen  Reference
GAPD Roche  Reference
Cyclophilin Qiagen  Reference
PGK1 Roche  Reference
MAPK1 Qiagen  siRNA positive control  
 
8.1.5  Northern Blot 
 
The riboprobe used was  based on  an amplified  sequence  from Slynar Mouse 
Exon 3 to 4 (  8.1.1). The sequence had to be cloned and sequenced to confirm that 
was specific for the region of interest. 
 
The riboprobe sequence: 
CTGCCAGATCTGATTTTCTGCCCTCTGCCTGGTCTTCTGGAAGGTCATT
GAGAATGCATGATCCATGACTTCTCACTGCTGATGAGGCCCAGGGTA
GCCAGAGAGTTGTGTTGGACATCATCTTATAGATACCATGTCAGCTGC
TGGATTTTTGTTTTGCTGTCCTCCCAGTCCATGGGCAGTGACTGACATT
CCTATTGCCTTCTGTTCTTTCCCATCC 
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8.1.6  siRNA  
 
The four siRNA oligos sequences are unknown. A sequence of the region of 
Slynar exon 3 to exon 4 was sent to Qiagen, for the siRNA to be designed. Due 
to the company terms and conditions, we unaware of which regions of Slynar’s 
sequence were used to design the oligos. Nonetheless, we do know that exon 3 
and exon 4 are targets.  
 
Slynar exon 3 and 4 target sequence: 
CAGAGAGTCAAGGGATTGGATTGTGGATTGCATTGGTGGTTTTCCTCA
GTTTCCTCATCTTCTCCACAAGTTTCTACATATCGAATGCAGAGCAGC
CCTTCTTCAAAGGACCTCCTACGGAAGCTGCTAAGGAACTCAGTCTGT
AGCTCTGCGTGGAGCCATGTGTAAACACTGAACTGAGACCTGCCACC
TCCTACTACCTAAGGGCCCATTTTCATCTGATATCATCCCCCAGAAAC
AAACTCATGATGACTTCCATGTTTTTTTTAGATTAGATACATGGAGAA 
TTTTCCTTTCCCTTAGAATTAAAATCCTGCATTCT 
 
8.2  IGF1 Sequencing primers 
 
The table represents the list of primers used to sequence IGF1. The primers cover 
a part of the 5’ and 3’untraslated regions, exons and intron/exon junctions. To 
these sequences was also added a M13 tail (Table   3.1 M13 tails sequences.). 
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Table   8.6 Primers used for IGF1 sequencing 
IGF1 region Forward Primer Reverse Primer
IGF1_Ex1a GCAGCACTTAAATAATTGGGTTGGAA TCATGCCCAGCAGAAAGTTAATCA
IGF1_Ex1b CGGAAGCCCTGCAGAAGTGG GAGGGAGAGAGAGAGAAGGCAAATG
IGF1_Ex2 GGCCTAGGATGGCTGCCAGA CCGAGACACGCTCCATCCAC
IGF1_Ex3 CATCGTCCATAGCGGTGGGA CCGGGAGACATACTGGCATTCA
IGF1_Ex4a GACAAGGTTGCTGAATGAATGGC ACCAAGGTTCAAGCTCTCTATTAGCTC
IGF1_Ex4b AGGAGGCCAAATTCGGCAAA CGCAAGTAGAGGGAGTGCAGGA
IGF1_Ex4c TCTTTGGCTCCAGGCTTCCC GCACTTCTTTCTACACAACTCGGGC
IGF1_Ex4d CGCCAGTCCAATTTGCATCA GCCGAATTTGGCCTCCTCAA
IGF1_Ex4e TTGGCCAGTTATTTGGATAGCTTCA GGGAAGCCTGGAGCCAAAGA
IGF1_Ex4f CCCTTTCACTGGTAGAAATCTCTTTG GACTGGCGAGTCCAGAGAGGAA
IGF1_Ex4g CTTTCAACTGGAAACTCTAGTCAAGCA GGGCGCTTGAGTTGCTGAGA
IGF1_Ex4h TGCATGAAATAATCAAGCCTGGG CAAAGAGATTTCTACCAGTGAAAGGG
IGF1_Ex4i CCATCTTGGGAAGAGGAGTCCA CATGCCTGCTCAGAAGGGTAGC
IGF1_Ex4j TTGGTTGCTCCTTTCTATGAAATCTGA TCCAACATTATTTGAATTGAGCACCTC
IGF1_Ex4k GAGTGGATTCTGATGGAGAGCTGC GGAAAGCTGAAAGATGCACTGCC
IGF1_Ex4l GGATTCTCAAGGGTGGACAGGC TTGATGCAAACCCTGGAAGTCA
IGF1_Ex4m GTTGAAAGGTGGTGGTGGCTAGA TGCAGCTCTCCATCAGAATCCA
IGF1_Ex4n TCACAGATTGTTAGCCATCTCTTTCA GCCACCACCACCTTTCAACTTT
IGF1_Ex4o TTTATGGTCTTTGCAAGGGAGGG TCTCCCTTCACCCAGACATCTCA
IGF1_Ex4p GAGTTTCAGCTTGGTCAGCCCTC GCAGAACCTGTTTGGCTCTCCTC
IGF1_Ex4q CTGAGGCGGGCAAATCACAA AACCAATTCCTATCTGGAACAATGCTT
IGF1_Ex4r CAGCTCCGGTTATTAGGAGAAACTCTG GAGGGCTGACCAAGCTGAAACTC
IGF1_Ex4s TGCAGTGTGTTTAGCAGCGGG TGGATCTTAAACATGATCCTTCTCTCC
IGF1_In3a CATCATCATCTAGCTCCAGCAGGC CAGGTGACCCAGCGCCTCTT
IGF1_In3b GGGAATCTGGGAACTTCTATGACACA GCCAAAGACACATCCAGGAGGG
IGF1_Pa TCTCCTGCGATGAGGCAAAGA CCACCACTCCTGGGAAACCA
IGF1_Pb CCCTTGTCCCAGTTGCCAAG AAACCAAAGGGAAATAGGTACAAACTG
IGF1_Pc TGTGTTAGTGACAGGGTTCGCAGA CCCTTCTCCCAGAGTGGTGGG
IGF1_Pd TCTCTCTCTCTCCCTCTTCTGGCA TCTTTGCCTCATCGCAGGAGAA  
 
8.3  IGF1 Association Table 
 
On chapter   5, I include the table of the positive GWAS SNPs (Table 1.) and the 
SNPs found by sequencing IGF1 (Table   5.1). This additional table contains all 
the  43  SNPs  (from  GWAS  and  sequencing)  used  for  allelic  and  haplotypic 
associations and COMBASSOC analysis. In bold are highlighted P<0.05. 
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Table   8.7 List of markers used for IGF1 association tests. Includes markers form GWAS 
and from sequencing. 
Marker  Marker Location  Alleles and Observed AlleleFrequencies  χ2  P value 
rs11111243    C    G       
Controls  101232831  691  0.68  325  0.32  1.713  0.191 
Cases    714  0.707  296  0.293     
rs10860857     C     A          
Controls  101252032  604  0.608  390  0.392  2.899  0.089 
Cases     642  0.645  354  0.355       
rs4764695    T    C       
Controls  101259580  496  0.486  524  0.514  1.331  0.249 
Cases    517  0.512  493  0.488     
rs10860860     T     A          
Controls  101283300  692  0.678  328  0.322  1.385  0.239 
Cases     711  0.703  301  0.297       
rs2946831    A    C       
Controls  101289247  52  0.051  968  0.949  1.419  0.234 
Cases     64  0.063  948  0.937       
Ex4k*    G    C        
Controls  101295526  1786  0.975  46  0.025  0.299  0.583 
Cases     1793  0.978  41  0.022       
rs6214*    G    A       
Controls  101296036  769  0.414  1089  0.586  0.415  0.519 
Cases     785  0.424  1065  0.576       
rs10745940    C    T       
Controls  101299663  281  0.275  739  0.725  0.008  0.930 
Cases     280  0.277  730  0.723       
rs978458    G    A       
Controls  101304706  256  0.251  764  0.749  0.011  0.918 
Cases     256  0.253  756  0.747       
rs9308315    T    A       
Controls  101306360  250  0.247  762  0.753  0.016  0.899 
Cases     248  0.249  746  0.751       
rs17727841               
Controls  101312097  179  0.175  841  0.825  0.039  0.843 
Cases     181  0.179  831  0.821       
rs5742688    G    A       
Controls  101314993  13  0.013  1001  0.987  7.637  0.006 
Cases     31  0.031  977  0.969       
rs2072592    G    A       
Controls  101316099  992  0.973  28  0.027  11.152  0.001 
Cases     1004  0.992  8  0.008       
rs5742678    C    G       
Controls  101316799  256  0.251  764  0.749  0.011  0.918 
Cases     256  0.253  756  0.747       
rs10860864    C    T       
Controls  101325329  175  0.173  835  0.827  0.184  0.668 
Cases     182  0.181  826  0.819       
rs2373721    G    C       
Controls  101329512  228  0.224  792  0.776  1.308  0.253 
Cases     247  0.245  761  0.755       
rs11111272    G    C       
Controls  101329908  282  0.278  734  0.722  0.014  0.907   272 
Cases     281  0.28  723  0.72       
rs5742652    C    T       
Controls  101338533  23  0.023  995  0.977  0.098  0.754 
Cases     25  0.025  987  0.975       
rs5742632    A    G       
Controls  101358941  763  0.751  253  0.249  1.577  0.209 
Cases     784  0.775  228  0.225       
rs12423791    C    G       
Controls  101361295  989  0.973  27  0.027  13.334  3.000E-04 
Cases     998  0.994  6  0.006       
rs4764698    G    C       
Controls  101362527  987  0.973  27  0.027  13.375  3.000E-04 
Cases     998  0.994  6  0.006       
rs1019731    G    T       
Controls  101366892  856  0.844  158  0.156  0.008  0.929 
Cases     849  0.846  155  0.154       
rs10860869    A    T       
Controls  101367519  726  0.716  288  0.284  0.375  0.540 
Cases     734  0.728  274  0.272       
rs12821878    G    A        
Controls  101370134  745  0.738  265  0.262  1.585  0.208 
Cases     768  0.762  240  0.238       
rs5742620*    C    A        
Controls  101372067  51  0.028  1779  0.972  3.724  0.053 
Cases     73  0.04  1783  0.96       
rs5742615**    G    T        
Controls  101373268  1002  0.969  31  0.031  17.006  3.726E-05 
Cases     1002  0.994  6  0.006       
Pd*    G    T        
Controls  101377223  1805  0.973  51  0.027  7.490  0.006 
Cases     1825  0.985  27  0.015       
rs5742612*    T    C       
Controls  101377331  1781  0.96  75  0.04  0.753  0.385 
Cases     1793  0.965  65  0.035       
Pc*    T    G        
Controls  101377396  1785  0.96  75  0.04  0.753  0.385 
Cases     1797  0.965  65  0.035       
rs35765     C     A          
Controls  101384163  85  0.083  935  0.917  5.257  0.022 
Cases     115  0.114  897  0.886       
rs860598    G    C       
Controls  101400913  145  0.148  837  0.852  1.292  0.256 
Cases     163  0.166  817  0.834       
rs2607983    A    G        
Controls  101402171  114  0.112  904  0.888  7.153  0.008 
Cases     154  0.152  858  0.848      
rs2607986    T     G         
Controls  101404245  136  0.136  862  0.864  2.228  0.136 
Cases     160  0.16  840  0.84       
rs7978777    C    A        
Controls  101421787  20  0.02  986  0.98  0.110  0.740 
Cases     22  0.022  978  0.978       
rs11829367    G    A        
Controls  101422834  20  0.02  1000  0.98  0.239  0.625   273 
Cases     23  0.023  989  0.977       
rs2195243    G    C        
Controls  101425453  227  0.223  793  0.777  0.065  0.799 
Cases     230  0.227  782  0.773       
rs12309723    A    C       
Controls  101425980  975  0.956  45  0.044  3.969  0.046 
Cases     984  0.972  28  0.028       
rs2114913    A    G        
Controls  101431171  983  0.964  37  0.036  3.253  0.071 
Cases     989  0.977  23  0.023       
rs855288    C    G       
Controls  101441098  140  0.137  880  0.863  3.710  0.054 
Cases     170  0.168  842  0.832       
rs703542    G    C        
Controls  101443545  135  0.133  881  0.867  4.975  0.026 
Cases     170  0.168  840  0.832       
rs703548    G    A       
Controls  101447140  139  0.137  879  0.863  4.040  0.044 
Cases     170  0.169  838  0.831       
rs35762    G    A        
Controls  101452114  154  0.152  862  0.848  2.020  0.155 
Cases    177  0.175  835  0.825     
rs753479     A     G          
Controls  101461029  154  0.151  866  0.849  1.803  0.179 
Cases     175  0.173  837  0.827       
 
UCSC March 2004 assembly positions 
* Newly found SNPs by sequencing 
** SNP out of Hardy-Weinberg 
 
 
 
8.4 CLUMP test results for CA the repeat 
 
Table   8.8 CLUMP p-values for the four CLUMP tests. 
CLUMP test X2 Pvalue
T1 15.161 0.041
T2 12.24 0.053
T3 9.567 0.013
T4 10.698 0.021  
 
 
 
 